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ABSTRACT
Post-traumatic stress disorder (PTSD) is a psychiatric disorder caused by
environmental and genetic factors resulting from alterations in genetic variation,
epigenetic changes and neuroimaging characteristics. There is a pressing need to
identify reliable molecular and physiological biomarkers for accurate diagnosis,
prognosis, and treatment, as well to deepen the understanding of PTSD
pathophysiology. Machine learning methods are widely used to infer patterns
from biological data, identify biomarkers, and make predictions. The objective of
this research is to apply machine learning methods for the accurate classification
of human diseases from genome-scale datasets, focusing primarily on PTSD.
The DoD-funded Systems Biology of PTSD Consortium has recruited
combat veterans with and without PTSD for measurement of molecular and
physiological data from blood or urine samples with the goal of identifying
accurate and specific PTSD biomarkers. As a member of the Consortium with
access to these PTSD multiple omics datasets, we first completed a project titled
“Clinical Subgroup-Specific PTSD Classification and Biomarker Discovery”. We
applied machine learning approaches to these data to build classification models
consisting of molecular and clinical features to predict PTSD status. We also
identified candidate biomarkers for diagnosis, which improves our understanding
of PTSD pathogenesis. In a second project, entitled “Multi-Omic PTSD
Subgroup Identification and Clinical Characterization”, we applied methods for
integrating multiple omics datasets to investigate the complex, multivariate
nature of the biological systems underlying PTSD. We identified an optimal 2
PTSD subgroups using two different machine learning approaches from 82 PTSD
positive samples, and we found that the subgroups exhibited different remitting
behavior as inferred from subjects recalled at a later time point. The results from
our association, differential expression, and classification analyses demonstrated
the distinct clinical and molecular features characterizing these subgroups.
Taken together, our work has advanced our understanding of PTSD
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biomarkers and subgroups through the use of machine learning approaches.
Results from our work should strongly contribute to the precise diagnosis and
eventual treatment of PTSD, as well as other diseases. Future work will involve
continuing to leverage these results to enable precision medicine for PTSD.
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Chapter 1
Introduction
1.1
1.1.1

Post-Traumatic Stress Disorder (PTSD)
PTSD Epidemiology
Post-Traumatic stress disorder (PTSD) is a mental disorder that can

develop after exposure to serious traumatic events, such as combat, violence,
warfare, traffic collisions, or other life-threatening threats. PTSD symptoms may
appear within a month or longer after the traumatic events. From the mayo
clinic website (“Post-Traumatic Stress Disorder (PTSD) - Symptoms and
Causes” 2018), the symptoms can be generally grouped into four types: intrusive
memories, avoidance, negative changes in thinking and mood, and changes in
physical and emotional reactions. Intrusive memories include recurrent,
unwanted distressing memories of the traumatic events. Avoidance means to
avoid thinking or talking about the traumatic event. Negative changes in
thinking and mood result in problems such as negative thoughts, hopelessness,
detachment from family and friends and emotional numbness. Changes in
physical and emotional reactions may include irritability, hypervigilance,
self-destructive behaviors and trouble sleeping and concentrating. These
symptoms cause serious problems in work and life, including significant problems
in social or work situations and in relationships. Their frequency interferes with
being able to perform normal daily tasks. PTSD severity is often associated with
co-occurring conditions such as anxiety disorders.
The current diagnosis of PTSD is from the Clinician Administered PTSD
Scale (CAPS - 5) from the Diagnostic and Statistical Manual of Mental Disorders
(DSM-V), published in 2013 by the American Psychiatric Association. CAPS - 5
queries PTSD symptoms using 7 criteria and scores are added up to the final
assessment. The detailed descriptions and the differences compared with the
previous version DSM-IV are shown in the Figure 1.1, as summarized [1].
One of the first large epidemiological analyses of PTSD was performed on
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Fig. 1.1: DSM-5 criteria for PTSD, referred from [1] and [2]
Vietnam War veterans in the United States. Results from this study show that
28% of veterans who had experienced combat developed PTSD, though 11% are
still experiencing PTSD 40 years after the combat [3]. Another longitudinal
epidemiological study on war fighters serving in Iraq or Afghanistan concluded a
13% PTSD occurrence rate in combat-exposed infantry units while 6% in the
general population [4]. According to NIMH statistics (“NIMH » Post-Traumatic
Stress Disorder (PTSD)” n.d.) for the whole prevalence, about 6.8% adults in
the US experience PTSD at some point in their lives while 3.5% have 12-month
prevalence as seen in Figure 1.2.
Across different populations and cultures, the prevalence of PTSD varies
significantly.
1.1.2

PTSD Pathophysiology
It has been widely recognized that PTSD is the result of genetic and

environmental interaction [5] [6]. In a study of PTSD etiology, Keane et al [7]

2

Fig. 1.2: PTSD Prevalence and Demographics across US From NIMH
proposed the triggering model of PTSD and analyzed potential PTSD risk
factors divided into three major categories: (a) pre-existing factors specific to the
individual, (b) factors related to the traumatic event, including one’s immediate
response during the trauma, and (c) events that occur following the trauma.
Pre-existing Factors include familial psychology, demographic factors (gender,
age, race, marital status), prior trauma and life adversity and psychopathology
prior to the trauma. A conditional model of PTSD etiology illustrated the
processes of PTSD development in the consideration of the three category
factors (Figure 1.3).
Systems biology is an approach in biomedical research to integrate
information from different scales and gain the benefit of data integration to
understand complicated biological systems [8] [9]. These scales consist of
measurements in the “omics” level including molecular data–Genomic,
Transcriptomic, Epigenetic, Proteomic and Metabolic–and non-molecular
data–biological Images and Clinical and Physiological measurements. Given the
known pathogenesis spanning neural biology to genomics and genetics discovered
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Fig. 1.3: A conditioning model of the etiology of Post-Traumatic stress disorder
(PTSD), referred from [7]
in previous PTSD studies, systems biology has been applied to evaluate these
discoveries and obtain new biological insights.
PTSD is a psychiatric disorder caused by genetic and environmental
interactions, involving a series of biological changes from stress and fear to
PTSD [1] [10] [9]. Biological understanding of PTSD has progressed in
deciphering the interplay between environmental stimulation, stress
responses/reactions, and pathology in light of alterations in brain circuitry and
neurochemistry and cellular, immune, endocrine, metabolic, and genetic factors.
Characteristic changes in brain regions including hippocampus, amygdala and
prefrontal cortex (PFC) have been identified in patients with PTSD. These areas
relate to abnormal responses of fear, stress and cognitive deficits, which help to
explain the development of PTSD [11]. The hypothalamic-pituitary-adrenal
(HPA) axis constitutes the central coordinator of the mammalian
neuroendocrine stress response systems and exhibits low cortisol levels in PTSD
cases [12]. Molecular-level studies on glucocorticoid signalling confirmed
alterations of the HPA axis that reflect exaggerated responses. The increased
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secretion of corticotropin-releasing hormone from the hypothalamus results in
activated glucocorticoid receptors (GRs). The complex of GRs and cortisols,
bound by chaperone proteins including FK506-binding protein 5 (FKBP5),
translocates to the nucleus and binds to glucocorticoid response elements (GRE)
to ultimately affect transcription of a number of genes [13][1]. The
neurochemical features of PTSD found in brain circuits that regulate/integrate
stress and fear responses include catecholamine, serotonin, amino acids, peptides,
and opioid neurotransmitters. Neuropeptide Y (NPY), which encodes a
neuropeptide that is widely expressed in the central nervous system and
influences many physiological processes, has been shown to be protective against
the development of PTSD. Decreased NPY levels from combat veterans suggests
resilience to PTSD by contributing to noradrenergic hyperactivity [14] [15].
In PTSD candidate gene research, previously reported genes confirmed
the alterations in PTSD neurobiology, as well as expanded to other biological
systems [16] [17] [18]. FKBP5, an important regulator of the stress system by
altering GR sensitivity, was reported to have polymorphisms associated with
PTSD through interactions with child abuse severity [19] [20] and gene
expression modulation by DNA methylation [21]. Catechol-O-methyltransferase
(COMT), a critical enzyme involved in the breakdown of the catecholamine
neurotransmitters, was reported to play an important role in fear processing, and
a genotype change (SNP rs4680) led to impaired fear inhibition in PTSD [22].
Brain-derived neurotrophic factor (BDNF), involved in the neural plasticity
underlying the extinction of fear and stress, was identified in relation to anxiety
and PTSD [23].Using a hypothesis-free approach, genome-wide association
studies (GWAS) have discovered that genes such as retinoid-related orphan
receptor alpha (RORA), Cordon-Bleu WH2 Repeat Protein (COBL),
Phosphoribosyl Transferase Domain Containing 1 (PRTFDC1) and lincRNA
AC068718.1 are associated with PTSD ([24] [25] [26] [27]).
Beyond standard genetics analyses, DNA methylation studies have
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identified methylation levels changed due to PTSD in genes Solute Carrier
Family 6 Member 4 (SLC6A4), Solute Carrier Family 6 Member 3 (SLC6A3),
FKBP Prolyl Isomerase 5 (FKBP5), Nuclear Receptor Subfamily 3 Group C
Member 1 (NR3C1) [28]. Neuroimaging genetics studies have also helped
identify intermediate phenotypes of PTSD that clarify the functional link
between genes and disease phenotype by characterizing gene-specific
neurobiological traits associated with PTSD [29]. However, variations in sample
size and research methods in these studies have made conclusive identification of
PTSD candidate genes difficult. In particular, most of the identified candidate
genes lack validation in other independent studies.
Although survey-based PTSD diagnosis is well established using DSM-5
based on criteria from seven specific aspects of the disorder, the accuracy of such
diagnoses is influenced by many factors. For instance, some PTSD symptoms are
not easily uncovered via survey, which leads to potential cases going undetected.
Also, some cases may not wish to be identified and thus do not volunteer
information, making it difficult for clinicians to make a correct assessment. For a
more objective assessment of PTSD, researchers have worked to identify
molecular diagnostic biomarkers for clinical evaluation and treatment as well as
to elucidate pathophysiology from these biomarkers ([30] [31] ). Candidate
biomarkers can be derived from neurobiological, molecular, behavioral, and
clinical data and phenotypes associated with PTSD, including neuroendocrine
data, brain region changes, genetic and epigenetic molecules and
psychophysiological measurements. Comorbidities between PTSD, physical
illness and inflammation also directs biomarker investigation to inflammatory
systems, such as elevated expression of pro-inflammatory cytokines and
C-reactive protein (CRP) [31] [32]. A previous review provided schematic
overview of potential biomarkers of PTSD as seen in Figure 1.4.
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Fig. 1.4: Schematic Overview of PTSD Biomarkers from [30]
1.1.3

PTSD Subgroups
The heterogeneity in the triggering and development of PTSD poses

challenges in the diagnosis and treatment of the disorder, and patient diversity
makes it difficult for treatment to be equally beneficial to all individuals.
Therefore, identification of patient subgroups by inferring patterns underlying
groups is a step toward precision medicine and the development of responsive
treatment [33]. Multiple studies have worked to discover PTSD subgroups and
identify unique biological signatures for the groups. The discovery of subgroups
requires techniques from data mining, statistics, and machine learning to learn
interesting variables to represent and classify groups [34]. In a study uncovering
heterogeneities in the progression of early PTSD symptoms, three
trajectories–rapid remitting, slow remitting and non-remitting were proposed
based on longitudinal data from the Jerusalem Trauma Outreach and Prevention
Study [35]. Using the same cohort of 957 trauma survivors, Galatzer-Levy et al.
[36] later applied a support vector machine (SVM) approach to predict the
non-remitting PTSD group from information collected within 10 days of a
traumatic event. Using a number of psychophysiological features, the authors
obtained a mean Area Under Receiver Operating Characteristics Curve (AUC)
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of 0.78. They also found that the non-remitting phenotype was attributed to
features including nightmares, age, and pulse. In a subsequent study of the same
cohort, Galatzer-Levy et al. applied SVMs with feature engineering to build
prediction models for trajectories, reaching an AUC of 0.82 using combined
demographic, psychophysiological, neuroendocrine and clinical information
([37]). In a recent study, Maron-Katz et al. identified two PTSD subgroups
using resting-state functional MRI data from 87 veterans, and these subgroups
showed differences between visual and sensorimotor network connection ([16]).
Despite these findings, there is a lack of studies discovering PTSD subgroups
using multiple scales of biological systems and represented by unique biological
signatures.
1.1.4

PTSD Consortium and Data
In 2012, the Department of Defense initiated a multi-site “PTSD Systems

Biology Consortium” encompassing researchers from more than 10 institutions,
including New York University (NYU), Icahn School of Medicine at Mount Sinai
(ISMMS), University of California at San Francisco (UCSF) and at Santa
Barbara (UCSB), U.S. Army Center for Environmental Health Research
(USACEHR), Emory University, Institute for Systems Biology (ISB), and
Harvard University. The primary goals of the PTSD Systems Biology
Consortium included identifying a panel of sensitive and specific biomarkers from
molecular, physiological, and/or demographic data for PTSD diagnosis,
especially in warzone-related cases.
For subject recruitment, PTSD-positive and PTSD-negative participants
were selected using the following criteria: 1) male veteran between 20 and 60
years old, 2) deployment in Operation Enduring Freedom and/or Operation Iraqi
Freedom, 3) PTSD positive participants with at least 40 CAPS score, 4) PTSD
negative participants with less than 20 CAPS score. For consistency, all study
participants were evaluated using the DSM-IV PTSD assessment upon
recruitment.
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For research purposes, there are three sequential cohorts, a Training
cohort also called the discovery cohort (82 positive and 82 negative samples), a
Test cohort also called the validation cohort (28 positive and 39 negative
samples) and a Recall cohort (14 positive, 10 subthreshold positive and 29
negative samples). In the recall cohort, the samples were recalled from the
samples existing in the training cohort.
For each of the recruited subjects, blood and urine samples were taken
and used to isolate DNA, RNA, protein, metabolites, and endocrine markers for
downstream analyses. Physiological measures (e.g., pulse, blood pressure, body
mass index) were also collected. Molecular and physiological data from the
Training cohort were initially designated for hypothesis generation regarding
potential diagnostic biomarkers and underlying biological mechanisms of PTSD,
while data from the Test cohort were designated for hypothesis testing and
attempted replication of the training sample findings. These subject groups were
designed to be age- and ethnicity-matched to minimize biases within and
confounding covariates between case and control groups. In total, the
genome-wide “omics” measurements include DNA-level methylation of CpG sites,
single nucleotide polymorphisms, expression of miRNA-Plasma, miRNA-Deplete
and miRNA-Exosome fractions, metabolites, proteins and selected endocrine
markers. The miRNA-Plasma fraction measures total miRNA, while
miRNA-Exosome and miRNA-Deplete measure miRNA enriched and depleted in
exosomes, respectively. These rich omics data sets from the PTSD Systems
Biology Consortium were utilized for the following analyses.
1.2

Machine Learning Approaches
High-throughput technologies of molecular biology have advanced to

allow examination of associations between omics data—DNA, RNA, metabolites,
miRNAs, proteins—and biological conditions, particularly human diseases. Here,
omics data refers to the plethora of molecules associated with each “ome” (e.g.,
genome, transcriptome, proteome) such as DNA or RNA. Next-generation

9

sequencing technologies have revolutionized the biological sciences by providing
an ultra-high throughput way to profile DNA and RNA and thus allow omics
data to be generated quickly and economically. Mass spectrometry [38] [39]
allows us to efficiently identify and quantify proteins, metabolites and lipids in
cells, capturing underlying cellular variations in response to physiological and
pathological changes. Although these powerful advances have enabled
examination of hundreds of thousands of molecules at the same time, the
large-scale nature of data from genomes, transcriptomes, and proteomes have
created challenges for data analysis. Machine learning approaches have been
developed and applied to elucidate complex biological systems, identify
molecular signatures and predict clinical outcomes from such large biomedical
datasets ([40] [41]).
Machine learning encompasses algorithms and statistical models applied
by computer systems to perform specific tasks based on patterns in data and
without using explicit instructions. With more computational resources and
elegant algorithms, machine learning has enhanced many real-life experiences
including human visual perception. Machine learning has also become an
integral part of an ever-growing number of healthcare systems and industries. It
has been applied to predict pharmaceutical properties of molecular compounds
and targets for drug discovery, perform pattern recognition and segmentation on
medical images to enable faster diagnoses and tracking of disease progression,
design generative algorithms for computational augmentation of existing clinical
and imaging data sets, and develop deep learning techniques for multimodal data
sources such as genomic and clinical data that can be combined to make new
predictive models [42]. Machine learning mainly uses two types of learning
algorithms, supervised and unsupervised learning (Figure 1.5).
In biomedical applications, high-dimensional sets of molecules (variables
or features) and small sample sizes are particularly challenging in integrative
analysis where multiple omics data are combined to identify unique signatures.
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Fig. 1.5: Machine Learning Introduction
This is called the ”curse of dimensionality,” where the number of features is
substantially higher than the number of samples, making most machine learning
algorithms vulnerable to overfitting [43]. Dimension reduction is the process of
reducing the number of variables under consideration by obtaining a set of
principal variables. Therefore, dimension reduction is quite useful in machine
learning applications for biomedical big data research.
Feature engineering is the process of transforming raw data into fewer
features that better represent the underlying problem for predictive models,
avoiding overfitting as well as resulting in improved model accuracy on unseen
data. Feature engineering generally consists of feature extraction and feature
selection approaches to reduce dimensions. Feature extraction is a process of
dimensionality reduction by which an initial set of raw data is reduced to more
manageable groups for processing. Principal component analysis (PCA) is a
widely-used feature extraction approach where principal components are
extracted to represent the raw data. Feature selection is the process where
features which contribute most to predictive performance or output of interest
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are automatically or manually selected. Feature selection techniques are widely
used to simplify models for interpretation, provide shorter training time, help
avoid the curse of dimensionality and enable enhanced generalization by
reducing overfitting. The removal of irrelevant features is also beneficial to
reduce noise and increase model accuracy. Unlike feature extraction methods
such as PCA, which creates new features from functions of the original features,
feature selection returns a subset of the features. Three main categories of
feature selection algorithms include filters, wrappers and embedded methods.
Both feature engineering and feature selection have been successfully used in
medical applications, where they can not only reduce dimensionality but also
help us understand the causes of a disease ([44]).
PCA is a statistical procedure that uses an orthogonal transformation to
convert a set of observations of possibly correlated variables into a set of values
of linearly uncorrelated variables called principal components. Principal
components summarize a large set of correlated variables with a smaller number
of variables explaining most of the variability in the data, providing a
low-dimensional representation that can be used to produce derived variables for
use in supervised learning problems and visualization of observations or variables.
1.2.1

Supervised Learning
Supervised learning algorithms build a mathematical model from a set of

data that contains both the inputs and the desired outputs. The data consists of
a set of training examples, and each example is a pair consisting of an input
object (typically a vector) and a desired output value. Through iterative
optimization, an algorithm learns patterns relating the input to the output and
improves the performance of predicting output from input. An optimal scenario
will allow for the algorithm to correctly determine the outputs for unseen
instances. Once the model is trained successfully, it can be applied for prediction
in new data (Figure 1.6). One example of supervised learning in biomedicine is
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Fig. 1.6: Supervised learning workflow
to train a model using demographic and anthropometric features such as gender,
height, education and career to predict a patient’s clinical outcome.
Based on the nature of outputs, supervised learning algorithms are
further categorized into tasks of regression, where outputs are continuous, and
classification, where outputs are binary or categorical. Classification is the task
of identifying to which class a new observation belongs, while regression
estimates the quantitative relationship between input features and outputs.
Examples of supervised classification include building a model to predict
whether or not a patient has liver cancer, or building a model to predict whether
a patient with liver cancer will get better or worse. Regression examples include
building a model to estimate gene expression using gene mutation and copy
number variation data. When applied to high-dimensional data such as gene
expression for diagnosis prediction, feature engineering is recommended to
reduce the problem dimension as well to avoid overfitting.
The procedure of efficient supervised learning consists of the following
steps: 1) Determine the type of training examples, 2) Gather a training set, 3)
Determine the input feature representation of the learning function, 4) Determine
the structure of the learned function and corresponding learning algorithm, 5)
Complete the design, 6) Evaluate the accuracy of the learned function.
Logistic Regression is a frequently used supervised classification
approach which models the probability of samples falling into a certain group or
class (Generalized Linear Models 1989). A binary logistic regression model
13

estimates the probability of belonging to one or the other group for each sample.
Typically, a group probability above 0.5 is treated as a prediction for
membership in that group, while a probability below 0.5 predicts membership in
the other group. The regression coefficients are estimated for either univariate or
multivariate input features, and training can be optimized using gradient descent
which maximizes the log-likelihood. Evaluation metrics for logistic regression
include Accuracy, Receiver Operating Characteristic (ROC) curve, and area
under the ROC curve (AUC). Accuracy refers to the rate of correct group
predictions over all samples. ROC curves are created by plotting the true positive
rate (TPR, sensitivity) against the false positive rate (FPR, 1 - specificity) at
various group probability thresholds. AUC is interpreted as the probability that
the classifier will assign a higher group probability to a randomly chosen member
of that group than to a randomly chosen member of the other group. Logistic
regression has the advantages that it uses a probabilistic framework and can
predict binary outcome variables. However, this technique generally assumes
independence between input features and is suitable for predicting either discrete
(group membership) or continuous (group probability) outcomes.
Two regularization approaches–Lasso (least absolute shrinkage and
selection operator) and Ridge regression–can be applied to logistic regression to
avoid model overfitting. Lasso involves adding an L1 penalty which refers to an
absolute value of magnitude of coefficients to the loss function which represents
methods of evaluating model learning for the given data. and in the end can
perform both variable selection and regularization to enhance prediction
accuracy and model interpretability. Ridge adds an L2-form penalty which refers
to the squared magnitude of coefficients and can shrink the regression coefficients
toward zero to reduce model complexity and multi-collinearity of input features.
Support Vector Machines (SVMs) are supervised learning models
with associated learning algorithms used for classification and regression
analyses. SVM constructs a hyperplane or set of hyperplanes in a high- or
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infinite-dimensional space. Intuitively, a good separation is achieved by the
hyperplane that has the largest distance to the nearest training-data point of any
class. SVMs use hinge loss for optimization, and as mentioned above, Recursive
Feature Elimination is often applied to reduce the number of features. Besides
binary classification, SVM can also be applied to classification problems with
more than two classes.
An important feature of SVMs is the use of kernel functions that enable
operation in a high-dimensional, implicit feature space without requiring
computation of the coordinates of data in that space. Kernels provide a mapping
of the problem from the input space to this higher-dimensional space (called the
feature space) by performing a nonlinear transformation. SVMs then use a linear
model in this new high-dimensional feature space, which corresponds to a
nonlinear model in the input space.
SVMs have the following advantages: 1) SVM hyperplane is robust to
outliers, 2) use of a regularization parameter helps to prevent overfitting, 3) a
variety of kernel functions are supported, 4) classifier training is equivalent to
solving a convex optimization problem, which is algorithmically efficient.
Disadvantages include: 1) optimization of the regularisation and kernel
parameters and choice of kernel must be conducted separately from training, 2)
some kernel methods can be quite sensitive to overfitting, 4) the hinge loss used
in SVM optimization results in sparse sets of important features.
SVM has proven to be successful in classifying high-dimensional cancer
samples such as ovarian cancer tissues, normal ovarian tissues and other normal
tissues ([45]).
Cross Validation is a model validation technique for assessing how the
results of a statistical analysis will generalize to an independent data set. In the
case of supervised classification, all samples are randomly divided into training
and validation sets. The classification model is then fit using the training set,
and its performance is quantified by assessing errors made in predicting
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Fig. 1.7: Unsupervised learning workflow
responses for the validation set. In Leave-One-Out (LOO) Cross-Validation, all
data is split into n-1 sample training and 1 sample validation sets, followed by
model training and validation as described above. The process repeats n times
and the average performance of the model is computed over all splits. A more
general form of LOO, K-fold Cross-Validation, randomly splits all samples into k
folds with k-1 folds used for training and 1 fold for validation. The model is
trained and evaluated k times, and average performance is quantified over the k
splits. In supervised learning, cross-validation is commonly used to perform
model evaluation while avoiding overfitting.
1.2.2

Unsupervised Learning and Data Clustering
In contrast to supervised learning, unsupervised learning is the task of

inferring a function to describe a hidden structure in data that is missing output
values (e.g., classes or labels). Goals of unsupervised learning include
understanding relationships between observations, visualizing data in an
informative way and discovering subgroups among the variables or observations
(Figure 1.7). One downside to this approach is that, without label information,
evaluation of predicted structure in the data is not straightforward. Specific
applications of unsupervised learning include clustering, PCA, anomaly
detection, and latent variable identification. A number of studies have applied
unsupervised clustering in prostate cancer subtype identification [46], novel
breast cancer subgroups [47] [48], glioma subtype discovery [49].
Clustering is the task of grouping a set of objects in such a way that
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objects in the same group (called a cluster) are more similar to each other than
to those in other groups (clusters). Since the notion of a cluster is not precisely
defined, many different clustering algorithms have been developed to discover
clusters. Examples of clustering methods include: Connectivity models (e.g.,
hierarchical clustering), which builds clusters based on distance connectivity
where samples are more related to nearby samples than samples far away;
Centroid models (e.g., K-means), which represents each cluster by a single mean
vector; Graph models (e.g., clique-based), which represent a cluster by a subset of
nodes connected by edges; Biologically-inspired models (e.g., unsupervised neural
networks). Clustering can be categorized as either hard(each object belongs to a
single cluster) or soft (each object belongs to every cluster to a certain degree).
As mentioned above, one disadvantage of clustering is the difficulty in evaluating
predicted clusters, particularly in independent test data sets. Thus, these
methods are commonly performed as part of exploratory data analysis.
K-means clustering is a method of vector quantization, originally from
signal processing, that is popular for cluster analysis in data mining. For a given
value of K (number of clusters), the goal of K-means is to partition all training
data samples into K distinct, non-overlapping clusters by identifying clusters for
which within-cluster variation is as small as possible.
The K-means algorithm involves the steps below. Randomly assign a
number, from 1 to K, to each of the observations. These serve as initial cluster
assignments. 1. Iterate until the cluster assignments stop changing: 2. For each
of the clusters, compute the cluster centroid. This is a vector of the feature
means for the observations in the cluster. 3. Assign each observation to the
cluster whose centroid is closest in terms of Euclidean distance.
This algorithm is guaranteed to decrease the sum of within-cluster
variations at each step. However, it is not guaranteed to reach the global
minimum, because results depend on the initial, random cluster assignments of
each observation in Step 1 and individual runs may terminate at suboptimal

17

local minima. In practice, the K-means algorithm is run multiple times from
different random initial configurations, and the best clustering result (smallest
sum of within-cluster variations) is selected.
The K-means algorithm involves repeatedly assigning points to the closest
cluster centroid. To do so, K-Means requires computing of pairwise Euclidean
distances between data points, because the sum of squared deviations from a
centroid is equal to the sum of pairwise squared Euclidean distances between
points divided by the number of points. The term "centroid", which derives from
Euclidean geometry, refers to a multivariate mean calculated in euclidean space.
A second clustering approach, spectral clustering ([50]), uses the
eigenvectors (spectrum) and eigenvalues of a matrix to define cluster
membership. These eigenvectors function as indicators of cluster membership.
Importantly, although small perturbations such as adding a few edges linking
clusters or removing edges from inside the clusters will increase eigenvalues and
change the corresponding eigenvectors, this does not generally cause the
underlying cluster structure to be lost. Like K-means, spectral clustering
technique requires the number of desired clusters to be specified ([51]).
As previously mentioned, it is particularly challenging to evaluate
unsupervised clustering results. Popular approaches consider both internal and
external evaluation. Internal evaluation is typically summarized by a quality
score, although it is not always clear which metric should be used to compute
this score. Examples of popular metrics include the following:
Silhouette coefficient: average distance within the cluster against average
distance outside the cluster. It is calculated using the mean intra-cluster
distance (a) and the mean nearest-cluster distance (b) for each sample with the
formula (b - a) / max(a, b) of each sample. The score ranges from -1 to 1, with a
negative value indicating that the average distance within the cluster is greater
than the distance outside the cluster.
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1.2.3

Deep Learning
Deep learning is a class of machine learning algorithms based on artificial

neural networks (ANNs) and representation learning. It utilizes a cascade of
multi-layered deep neural networks (DNNs) for feature extraction and data
transformation. Deep learning attempts to generate abstractions from large-scale
data including images and texts. Deep learning can be applied for supervised or
unsupervised tasks. An advantage of deep learning architectures is that they
automatically perform multiple levels of nonlinear data transformation and
supervised or unsupervised learning of feature representations. Deep learning
architectures such as autoencoders, recurrent neural networks and convolutional
neural networks have been applied to fields in computer vision, natural language
processing and biomedical data science ([52] [53]). A summary of deep learning
architectures is shown in the neural network zoo [54].
ANNs were originally inspired by the complex neurobiological systems in
the brain which learn to perform tasks by generating representations without
task-specific programming [55]. An ANN is based on a collection of connected
units called artificial neurons, analogous to biological neurons in a biological
brain. Each connection between neurons can transmit a signal in a manner
similar to a synapse. The receiving neuron can process incoming signals and
then signal downstream neurons connected to it. Neurons in ANNs may have a
state, generally represented by real numbers, typically between 0 and 1. Neurons
and synapses may also have weights that vary as learning proceeds, which can
increase or decrease the strength of signals that are sent downstream. Typically,
neurons are organized in layers, with each layer potentially performing different
transformations to their inputs. Signals travel from the first (input) to the last
(output) layer, possibly after traversing inner layers multiple times. The original
goal of the neural network approach was to solve problems in the same way that
a human brain would. However, attention has shifted over time to matching
specific cognitive tasks which led to deviations from biology such as the
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backpropagation optimization technique, in which information is passed from
output to input layers while adjusting the network weights to reflect that
information.
DNNs are ANNs with multiple internal layers between the input and
output layers. Like other ANNs, a DNN learns the correct mathematical
operations to transform the network input into the output. Although there
exists a variety of DNN architectures, most DNNs rely on similar techniques for
feature extraction and training, such as feedforward and backpropagation passes.
In the feedforward pass, the network is activated by an input to the first layer,
which then spreads the activation to the final layer along the weighted
connections and generates the prediction or reconstruction results. In the
backpropagation pass, the weights of connections are tuned by minimizing the
difference between the predicted output and the real output. By combining these
techniques with activation functions, optimization objectives and optimization
methods, deep learning models can be implemented and applied to specific tasks.
Activation functions make up the nonlinear layers in all deep learning
models, and their combination with other layers enable nonlinear
transformations from the input to the output. An optimization objective is
typically composed of a loss function and a regularization term, with the former
measuring the discrepancy between predicted and actual network output and the
latter used to reduce test set error and avoid overfitting. Optimization methods
are strategies used to achieve minima of the objective function by selecting
appropriate hyperparameters which means a number of parameters before the
training processes and their combination set can be optimized based on the
performance in the evaluation data. Stochastic gradient descent (SGD) [56] and
its variants are commonly-used optimization methods which update network
weights (parameters) by a step corresponding to the Jacobian matrix which as a
matrix calculates partial derivatives of a vector function for weight updates. For
example, the Adaptive Gradient Algorithm (AdaGrad) [57] technique updates
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weights according to the accumulation of squared gradients, which can converge
rapidly when applied to convex functions. RMSProp, an AdaGrad algorithm,
has been an effective and popular method for parameter optimization.
Tensorflow (TF) is a widely used end-to-end open source deep learning
platform implemented in the Python language. Keras is a highly wrapped deep
learning framework running on top of TF or other deep learning platforms.
These two deep learning frameworks have implementations on various deep
learning architectures.
An autoencoder (AE) is one class of deep learning architectures used to
learn input data representations in an unsupervised manner [58]. The purposes
of this representation include dimensionality reduction and reconstruction of the
input with the removal of noise. An AE is constituted by two main parts: an
encoder that maps the input into a code, and a decoder that maps the code to a
reconstruction of the original input. In terms of architecture, AEs are
feedforward, non-recurrent neural networks very similar to the multilayer
perceptron (MLP)–they have an input layer, an output layer and one or more
hidden layers connecting them, with the output layer having the same number of
nodes as the input layer. Additional applications of AEs include feature learning
and learning generative models which indicate the architectures can estimate
training data distribution and generate new samples from the same distribution.
Various AE variants exist to prevent autoencoders from simply learning the
identity function and to improve their ability to capture important information
and learn richer representations. Examples include denoising AE, sparse AE and
variational AE, as shown in Figure 1.8.
Variational autoencoder (VAE) models inherit the general autoencoder
architecture of both an encoder and a decoder and are trained to reduce the
reconstruction error between input and output. However, VAEs make strong
assumptions of the input distribution over the latent space which refers to the
middle hidden layer with the fewest neurons in AEs. In practice, encoded
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Fig. 1.8: Architectures for AE, VAE, DAE and SAE
distributions are chosen to be normal so the encoder can be trained to return the
mean and covariance matrix of a multivariate gaussian distribution. The
distributions returned by the encoder are then enforced to be close to a standard
normal distribution. The loss function of VAEs is composed of a reconstruction
loss and Kullback-Leibler divergence. The reconstruction loss measures the
distance between input and output, while the Kullback-Leibler divergence
measures the similarity between the distribution of the encoder and a standard
normal distribution. This loss function has a closed form that can be directly
expressed in terms of the means and covariance matrices of the encoded
distributions. The VAE model is trained in the following steps: 1) the input is
encoded as a distribution over the latent space, 2) a point from the latent space
is sampled from that distribution, 3) the sampled point is decoded and the
reconstruction error computed, 4) the reconstruction error is backpropagated
through the network. An important application of VAEs includes learning deep
generative models to generate new data using the learned distribution. One such
study in biomedical research trained a VAE on cancer gene expression data and
identified biological patterns in the encoded features [59].
1.3

Research Objectives
Given the great promise of machine learning approaches for biomarker

discovery and precision medicine, our research aims to apply these techniques for
subgroup discovery and classification of human diseases such as PTSD or cancer
using genome scale datasets. With multiple omics data sets from the PTSD
Systems Biology Consortium, the first of our projects involved implementing
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clinical subgroup-specific PTSD classification and biomarker discovery.
Specifically, we applied machine learning approaches to classify PTSD positive
patients in three molecular datasets–miRNA-Exosome, miRNA-Deplete and
Metabolomics–and select discriminative features as potential biomarkers. Our
second project aimed to identify PTSD subgroups through multiple omics data
integration via statistical and deep learning approaches. For biological
interpretation, we performed clinical characterization and differential expression
analysis based on the identified subgroups. We also utilized subgroup labels to
improve diagnostic classification. Finally, we worked on two supplementary
projects involving the development of a novel feature selection technique and
histopathological image feature extraction for classification using pre-trained
convolutional neural networks. Taken together, our research aims to explore
applications of machine learning in biomedicine and contribute to the precise
diagnosis and eventual treatment of PTSD, as well as other diseases.
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Chapter 2
Clinical Subgroup-Specific PTSD Classification and Biomarker
Discovery
2.1

Abstract
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder caused

by environmental and genetic factors resulting from alterations in genetic
variation, epigenetic changes and neuroimaging characteristics. There is a
pressing need to identify reliable molecular and physiological biomarkers for
accurate diagnosis, prognosis, and treatment, as well to deep the underpinning of
pathophysiology.
Using a cohort of 234 samples with 166 in training and 68 in validation,
applied machine learning approaches to classify PTSD patients in three
molecular datasets miRNA-Exosome, miRNA-Deplete and Metabolomics. We
first divided patients into multiple sets of two subgroups based on the values of
112 clinical and endocrine measurements. We then performed supervised
classification across all samples and within each subgroup using two feature
selection strategies (Recursive Feature Elimination (RFE) and ANOVA), four
classifiers (logistic regression (LR), support vector machines (SVM), random
forests (RF), and extra trees (ET)), and 10-fold nested cross validation. We
evaluated each subgroup for significantly improved classification performance by
computing empirical false discovery rates (FDRs) based on accuracy and AUC
values. Finally, we combined those significant clinical features with molecular
measurements and constructed an overall PTSD classifier. We fit all data in the
best classification model in training and selected features as biomarkers.
In total, 85 clinical subgroups from 72/112 clinical and endocrine features
lead improved classification performance compared to the baseline from all
samples in training, with 38 yielding improved performance in more than one
method. Tree-based models yielded the greatest number of improved subgroups
in the metabolomics and miRNA from exosomes datasets, while Logistic
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Regression showed the greatest improvement in the miRNA depleted of exosomes
dataset. Using our overall PTSD classifier with molecular and clinical features,
we observed that the majority of classification models show improved accuracy
in both training and testing. In metabolomics, the overall model achieved the
best AUC 0.79 ± 0.13 and ACC 0.722 ± 0.078 at ANOVA-SVM, significantly
better than the baseline models at ACC with only molecular or clinical features.
In miRNA-Exosome, ANOVA-LR model reached the best AUC 0.758 ± 0.097
and ACC 0.701 ± 0.116 with ACC significance compared to the clinical model
baseline. In miRNA-Deplete, RFE-SVM model reached the best AUC 0.677 ±
0.134 and ACC 0.605 ± 0.128. These best models have fair performance in
validation as well. We also selected the features in these models and listed as
potential biomarkers consisting of molecular and clinical features.
We applied machine learning approaches in multiple types of PTSD data
and built classification models consisting of molecular and clinical features to
predict PTSD patients. We also provide candidate biomarkers for the
diagnostics, which improves the pathogenesis understanding of PTSD. Hopefully,
our work contribute to the precise diagnostics and treatment at PTSD.
2.2
2.2.1

Materials and Methods
Study Samples
The Department of Defense-funded Systems Biology of PTSD Consortium

has recruited over 200 male combat veterans with and without PTSD for the
purposes of identifying diagnostics biomarkers. Whole blood samples taken from
each subject have been used to isolate DNA, RNA, protein, metabolites, and
endocrine markers for subsequent study. In the first stage, two cohorts were
collected–a discovery cohort of 166 samples: 83 PTSD positive and 83 PTSD
negative, followed by a validation cohort of 68 samples: 29 PTSD positive and 39
PTSD negative. For this study, we analyzed three molecular datasets from these
two cohorts–two measuring miRNA derived from plasma either enriched
(miRNA-Exosome) or depleted (miRNA-Deplete) in exosomes, and one
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measuring metabolomics. We also included clinical characteristics from four
categories including PTSD scales, demographic information, biochemical and
anthropometric body measurements, and endocrine measurements from blood
and urine. After filtering these clinical characteristics for numeric measurements
with less than 10% missing values in the discovery cohort, we were left with 112
features, among which 24 are binary and 88 are continuous. The datasets used in
this study were collected and preprocessed in or before January 2017.
2.2.2

Clinical Feature Association Analysis
For the 112 clinical features, we first performed statistical association

analysis between those measurements and PTSD labels. In both training and
validation cohorts, we used Fisher’s Exact test for binary features and t-test for
continuous features. We obtained p-values and used the threshold 0.05 to
determine significant associations.
2.2.3

Clinical Subgroups
For each clinical feature, we split samples from the training cohort into

two subgroups based on their feature values. For binary features, subgroups were
created based on which of the two values each sample held. For continuous
features, subgroups were based on the median measurement: a higher expression
subgroup contains samples whose measurements were greater than or equal to
the median, with the remaining samples belonging to a lower expression
subgroup. We used the same criteria to split samples and obtain subgroups in the
validation cohort. After clinical subgroup creation, we split the corresponding
measurements from each of the three omics datasets–miRNA-Exosome,
miRNA-Depleted and metabolomics–accordingly. In the following analyses, we
only considered clinical subgroups with at least 10 samples each from the
training cohort and at least two samples each from the validation cohort.
2.2.4

Missing Value Imputation
Although we kept clinical features with less than 10% missing

measurements, any missing values still prohibited the direct use of many
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supervised machine learning methods. Thus, we first used the method Imputer
to generate missing values based on mean values of nearest neighbors [60]. We
then fed the input data to machine learning algorithms for classification.
2.2.5

Supervised Classification
Feature selection is a common preprocessing step in machine learning,

especially when applied to high-dimensional biological data, as it is effective in
reducing dimensionality, removing irrelevant information, decreasing model
variability and increasing learning accuracy [61]. We applied two types of feature
selection in supervised classification. The first is a filtering approach, which
selects the most relevant features manually or automatically before classification.
We chose Analysis of variance (ANOVA) as a commonly-used filtering feature
selection method. The second is an embedding approach, which considers feature
selection and classification simultaneously as part of an analysis pipeline. For
this approach, we chose recursive feature elimination (RFE), which has the
potential to yield better performance [62].
For performing supervised classification, we included four classifiers:
Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF)
and Extra Tree (ET). LR builds a linear boundary between classes and predicts
the maximum probability for being in one class. SVM builds a hyperplane
between classes and uses kernel tricks to perform linear or nonlinear
classification. Both RF and ET are tree-based classifiers differing in the setup of
randomized trees. For each classifier, we evaluated a series of hyperparameters
including the following: l1 and l2 regularization (LR), linear, polynomial, and
radial basis function kernels (SVM), cost penalty (10−4,4 and 2−4,4 ) and gamma
(10−4,−1 ) (SVM), tree numbers and max features (RF and ET).
When using ANOVA feature selection, we selected the best model for
each classifier using a grid search across a range of 10% to 100% top-scoring
features. When performing RFE-based feature selection and classification, the
lowest-scoring 10% of features were eliminated at each iteration and the best
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model selected across all iterations. To evaluate classification performance, we
computed metrics including AUC (Area under ROC curve) and accuracy (ACC).
To avoid overfitting, we applied 10-fold nested cross validation (NCV) to obtain
the average performance of each classifier. Specifically, we divided all samples
into 10 folds, in which nine folds were used for training with one left for external
testing. In those nine folds, 9/10 were used for tuning classifier hyperparameters,
followed by internal testing in the remaining fold. For both ANOVA- and
RFE-based classification, we computed average model performance based on
10-fold NCV.
2.2.6

Classification Performance Comparison
For the clinical subgroup comparison, we used a paired t-test to detect

mean differences in AUC and ACC between each subgroup and the baseline
where all samples were used for classification. We used a p-value threshold of
0.05 to select significant differences. When performing comparisons between
models composed of molecular data, clinical data and mixed data, we also
applied paired t-tests to detect significant differences in performance.
2.2.7

Biomarker Discovery
We first selected the best overall models from the three omics datasets,

considering both ANOVA- and RFE-based feature selection methods. We then
fit models of all molecular and clinical data together using the same
hyperparameter tuning strategy as above. All selected features were considered
to be candidate PTSD biomarkers. For the tree-based classifiers, the rankings of
these biomarkers were calculated using variable importance, while for LR or
SVM classifiers the rankings were computed from the feature coefficients.
2.3

Results
In this study, we applied machine learning approaches to multiple PTSD

omics datasets and built classification models to predict PTSD status as well as
identify candidate biomarkers. Using the clinical and molecular data described

28

above, we built classification models composed of integrated clinical and
molecular features and identified diagnostic biomarkers from both data types.
2.3.1

Association Analysis of Clinical and Endocrine Features With
PTSD
We first applied statistical tests (t-tests for continuous features and

Fisher’s Exact test for binary features) to detect associations between PTSD
status and clinical and endocrine characteristics. Given the 112 clinical and
endocrine features (24 binary and 88 continuous) passing the filters described
above, we identified 29 (26%) that are significantly associated with PTSD
(Figure 2.1). Of these 29, three consist of physiological measurements (Figure
??-A), two of demographic information (Figure 2.1-B), 17 of biochemical
measurements (Figure 2.1-C), three of blood endocrine measurements (Figure
2.1-D), and four of PTSD scales. The majority of these features show significant
associations in the training cohort but not in the validation cohort. Only
three–pulse, glucose (fasting glucose) and rbc (red blood cell count)–are
significantly associated with PTSD in both cohorts, where PTSD patients have
higher levels of these features.
2.3.2

Clinical Subgroup Classification Performance
Despite the heterogeneity of PTSD pathology, there is currently no

staging approach for suggesting distinct therapeutic treatments depending on
the degree of biological progression of the disorder [63]. Inspired by findings that
subtypes of PTSD vary in time to recovery and disorder severity, we worked to
determine whether clinical subgroups within each omic dataset could enable
improved classification performance compared to a baseline considering all
samples. The analysis flow of such clinical subgroup classification is sketched in
Figure 2.2. For each of three omics datasets–miRNA-exosome, miRNA-deplete
and metabolomics–we split all samples to obtain two clinical subgroups for each
of 112 clinical measurements. We then built classification models for all
subgroups individually as well as for a baseline consisting of all samples for
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Fig. 2.1: Bar Plots of Clinical Characteristics Significantly Associated With
PTSD, x axis indicates clinical or endocrine features, y axis indicates the log
transform p values, red color indicates the significance in training dataset while
blue color indicates in validation dataset, A) in physiological measurements, B)
in clinical biological background, C) in biochemical measurements, D) in
endocrine from blood.
performance comparison. We evaluated two feature selection
approaches–ANOVA and Recursive Feature Elimination (RFE)–and four
classifiers–Logistic Regression (LR), Support Vector Machine (SVM), Random
Forest (RF) and Extra Tree (ET). We utilized 10-fold cross validation to
evaluate model performance using the criteria Area Under ROC Curve (AUC)
and Accuracy (ACC). Additional details about clinical subgroups and
classification models can be seen in the Materials and Methods section above.
Overall, 85 clinical subgroups from 72 clinical and endocrine features
show improved classification performance with significantly improved training
AUC or ACC compared to the baseline. We also listed a list of top clinical
subgroups which showed AUC improvement in the validation (Vad) data in
Table 2.1. Across the eight classification methods tested (two feature selection
approaches times four classifiers), we found that use of the tree-based classifiers
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Fig. 2.2: PTSD Clinical Subgroup Classification Workflow, A) In the analysis
flow from subgrouping to the biomarker discovery, each omic dataset is split
based on each clinical or endocrine measurement and ends up with two clinical
subgroups consisting of PTSD and control samples individually. For each
subgroup, a machine learning approach is used to build classification models and
compared to the baseline from all samples. A set of subgroups with improved
classification performance are selected for each omic dataset. With the combined
molecular and clinical features, machine learning is used to build classification
models. Then best models are selected for three datasets and biomarkers are
discovered from the selected features. B) A machine learning approach is used to
build classification models for datasets in A part. For each dataset with samples
and features, two types of feature selection methods ANOVA and Recursive
Feature Elimination (RFE) and 4 classifiers Logistic Regression, Support Vector
Machine, Random Forest and Extra tree are pipelined and implemented.
RF and ET led to the greatest number of subgroups with improved performance
in Metabolomics and miRNA-Exosome data, while use of LR resulted in the
most improvements in miRNA-Deplete data. In Metabolomics, use of the top
two models–ANOVA-RF and RFE-RF–led to 19 and 16 improved subgroups,
respectively, in training, and 17 and 13 improved subgroups, respectively, in
validation. In the miRNA-Exosome dataset, the top three methods–ANOVA-ET,
ANOVA-RF and RFE-ET–led to 13, 9 and 9 improved subgroups, respectively,
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Fig. 2.3: Heatmaps Showing Improved Performance in Three Datasets
miRNA-Exosome, miRNA-Deplete and Metabolomics, rows indicate different
methods from feature selections and classifiers while columns indicate the clinical
or endocrine subgroups, A) in Metabolomics, b) in miRNA-Deplete, C) in
miRNA-Exosome, red color indicates detected improvement while grey indicates
no improvement.
in training and 4, 9 and 4 improved subgroups, respectively, in validation.
Finally, in the miRNA-Deplete dataset, the top two methods–ANOVA-LR and
RFE-LR–led to 26 and 22 improved subgroups, respectively, in training and 9
and 17 improved subgroups, respectively, in validation. Overall, 38 subgroups
showed significant improvement for more than one classification method using
the same feature selection approach. Of these, 11 are from miRNA-Exosome
data, 12 from miRNA-Deplete data and 15 from Metabolomics data as seen in
Figure 2.3(A-C). We also found that 4 subgroups showed improvements in more
than one dataset: ALBDown (albumin), Army0 (Military Service),
elisa.cordifUP (cortisol1 - cortisol2) and ProTotDown (total serum
protein) as seen in Figure 2.4. Taken together, the improved classification
performance for particular subgroups suggests that inclusion of the
corresponding clinical measurements in classification would improve overall
PTSD status prediction.
2.3.3

Classification From Clinical and Molecular Features
The complex network of clinical and molecular interactions shows promise

for enabling our understanding of the biological dysregulation responsive to
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Table 2.1: Performance Improved Clinical Subgroups
Data Sets
Metabolomics
Metabolomics
Metabolomics
miRNAExosome
Metabolomics
Metabolomics
Metabolomics
Metabolomics
Metabolomics
Metabolomics
Metabolomics
miRNAExosome
Metabolomics
Metabolomics

Methods Clinical Sub- Classigroups
fier
ANOVA monos.ET
Down
RFE
monos.RF
Down
RFE
baso-Down LR
ANOVA etof-Down SVM
RFE
RFE

baso-Down
BILITOTUP
RFE
monos.Down
ANOVA rdw-Down
ANOVA ldl-Down
ANOVA rdw-Down
RFE
rdw-Down
RFE
ABM3B-UP

ANOVA ABM6-UP
ANOVA BILITOTUP
Metabolomics RFE
alkphosDown
Metabolomics RFE
elisa.cordifUP
miRNA-Deplete RFE
Army-0
Metabolomics RFE
ic50-UP
Metabolomics RFE
rdw-Down
Metabolomics RFE
baso-Down
Metabolomics RFE
bthftof-UP
Metabolomics ANOVA baso-Down

0.883 ± 0.172

VadAUC AUC
p
value
0.762
0.0253

0.821 ± 0.148

0.721

0.034

0.831 ± 0.145
0.907 ± 0.161

0.685
0.679

0.0116
0.0278

RF
RF

0.822 ± 0.114
0.782 ± 0.087

0.658
0.653

0.0111
0.0392

LR

0.842 ± 0.217

0.646

0.04

ET
SVM
RF
RF
LR

0.858
0.839
0.869
0.855
0.818

±
±
±
±
±
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0.0244
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0.007
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0.0254
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RF
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0.708 ± 0.186
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0.604
0.602
0.593
0.59
0.59
0.59

0.359
0.0483
0.0203
0.0031
0.0061
0.0339
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AUC

PTSD triggers [64] [?]. After obtaining the clinical and endocrine features
contributing to improved subgroup classification, we combined the top 15 clinical
features with each molecular omics dataset to build overall classification models.
Our working hypothesis is that the complementary information provided by
molecular data and clinical features can contribute to better classification
performance. For comparison, we also built baseline classifiers using only
molecular or clinical data (with the same 15 clinical features). We applied a
one-sided paired t-test to compare training performance between the
mixed-feature model and two baselines. In total, we evaluated eight combined
classification models for each dataset and compared performance with eight
molecular baseline and eight clinical baseline models. From our results, the
majority of combined models outperformed the baselines with a higher AUC in
the validation data set; specifically, we saw improvement in 23/24 combined
model-dataset pairs compared to molecular data and 18/24 pairs compared to
clinical data. Of these improvements, 5 were statistically significantly different
from the molecular baseline and 10 were significantly different from the clinical
baseline.
In the metabolomics data, all of the combined models showed improved
performance relative to the two sets of baseline models (16/16 comparisons
total) in the training data, and 14/16 comparisons showed improvement in the
validation data. In particular, the ANOVA-based linear SVM model with clinical
and molecular features achieved AUC 0.79 ± 0.13 and ACC 0.722 ± 0.078,
which is significantly better than the performance of the clinical data-only model
(p-values: 0.04 and 0.002) or the molecular data-only model (p-values: 0.091 and
0.005). This suggests that the complementation between metabolites and clinical
features yields a better distinction between PTSD case and control. Using
RFE-based models, the best performance observed is from ET with AUC 0.769
± 0.081 and ACC 0.681 ± 0.088 (training data), along with improved
performance in the validation data.
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In the miRNA-Deplete dataset, the best ANOVA- and RFE-based models
both use ET, with AUC 0.725 ± 0.139 and ACC 0.72 ± 0.097 (ANOVA) and
AUC 0.724 ± 0.134 and ACC 0.64 ± 0.154 (RFE). In the miRNA-Exosome
dataset, the best models are ANOVA-LR and RFE-ET, with AUC 0.758 ± 0.097
and ACC 0.701 ± 0.116 for the former and AUC 0.766 ± 0.154 and ACC 0.705
± 0.139 for the latter. The results in the miRNA-Deplete and miRNA-Exosome
datasets suggest more consistent performance using ANOVA- rather than
RFE-based feature selection, which may be due to overfitting when using RFE
with a small sample size. Given these best-performing classification models, we
next selected subsets of features as candidate biomarkers for each dataset.
2.3.4

Biomarker Discovery
Given the best-performing combined clinical and molecular models for

each dataset (Figure B.5), we selected the most relevant features as candidate
biomarkers. To do so, we ranked features by coefficients (LR and SVM) or
variable importance (RF and ET). Our result obtained all of the candidate
biomarkers, while Table 2.2 shows the top 10 candidate biomarkers from each
dataset using ANOVA. We selected the best models from each dataset using each
of the two feature selection approaches in an attempt to identify general relevant
features rather than model-specific features. Interestingly, the top 10 features
from the ANOVA-SVM and RFE-ET combined clinical-metabolomics models
have 8 features in common, including the 2 clinical features ProTot and monos..
In the miRNA-Deplete dataset, the top 10 features (6 clinical and 4 molecular)
were selected from the ANOVA-ET and RFE-ET models, with 5 of the clinical
features (DemoChi, Pulse, ALB, elisa.npy and ProTot) in common between the
models. In the miRNA-Exosome data, the top 10 features for the ANOVA-LR
and RFE-ET models were molecular, with only one molecule (hsa-miR-200b-3p)
in common between the models. These results confirmed our hypothesis about
the complementary nature of the information contained in the clinical and
molecular data. Our results also suggest that the contribution from clinical
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features may be redundant in the miRNA-Exosome dataset (no clinical features
were in the top 10), while clinical features appear to play an important role in
accurate classification using the miRNA-Deplete dataset.
Table 2.2: Top10 Candidate Biomarkers of the ANOVA Approach
miRNA-Exosome
ANOVA
hsa-miR-7-1-5p (M)
hsa-miR-200b-3p (M)
hsa-miR-3613-5p (M)
hsa-miR-376c-3p (M)
hsa-miR-29c-5p (M)
hsa-miR-486-2-5p (M)

miRNA-Deplete
ANOVA
DemoChi (C)
ProTot (C)
ALB (C)
ggt (C)
hsa-miR-185-5p (M)
ABM10 (C)

Metabolomics ANOVA

5-oxoproline (M)
ProTot (C)
lactate (M)
monos. (C)
hypoxanthine (M)
docosapentaenoate
(n3-DPA; 22:5n3) (M)
hsa-miR-941-1-3p (M) hsa-miR-3940-3p (M) tyrosine (M)
hsa-miR-590-5p (M) elisa.npy (C)
2-hydroxypalmitate
(M)
hsa-miR-4454-5p (M) hsa-miR-1304-5p (M) glutamine (M)
hsa-miR-502-3p (M) hsa-miR-574-3p (M) docosahexaenoate
(DHA; 22:6n3) (M)
*C: Clinical features, M: Molecular features

2.4

Discussion
In this study, we built classification models for clinical subgroups, then

combined the clinical features leading to significant improvement with molecular
features to build predictive models of PTSD status. We then selected important
features as candidate diagnostic biomarkers. Specifically, 72 clinical
measurements demonstrated improved classification performance through
subgroup splitting, among which 21 are significantly associated with PTSD. In
the top 10 clinical biomarkers, 8 are both significantly associated with PTSD
status in the training data and contribute significantly to subgroup-specific
classification improvements. The combination of association with PTSD as well
as improvement in PTSD prediction leads to more easily interpretable
biomarkers. Knowledge of these biomarkers may also suggest PTSD candidate
genes or biological pathways related to PTSD pathogenesis. We note that
inconsistencies in performance observed between training and validation datasets
may be due to population differences between the cohorts as well as the smaller
number of validation samples.
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PTSD has the characteristics of hyperarousal and exaggerated startle
responses. It was previously reported that PTSD patients have a high risk of
developing cardiovascular issues, such as increased heart rate and blood pressure
[65] and increased BMI and weight [66] as a result of traumas. Associations of
relationship status (being single) and having children with PTSD may suggest
that the symptoms lead to (or result from) issues with trust, closeness and
communication in relationships and/or with family. Three blood endocrine
biomarker–elisa.npy (plasma neuropeptide Y), elisa.cordif (plasma cortisol
dexamethasone suppression test 1 - plasma cortisol dexamethasone suppression
test 2), and ic50 (Peripheral Blood Mononuclear Cell (PBMC) Lysozyme
IC50-DEX)–showed association with PTSD, which demonstrates a consistency
with known neuroendocrine alterations resulting from PTSD. PTSD is also
associated with enhanced pro-inflammatory cytokines in PBMC [67]. Counts of
monocytes, which secrete chemokines during inflammation, are useful biomarkers
along with ProTot (total serum protein) in metabolomics data, although they do
not appear to be as informative when combined with miRNA data. The lactate,
one of our top metabolite biomarkers, has also been reported as a candidate
biomarker for PTSD diagnosis [68]. Although our discoveries may be limited by
the sample size, to our knowledge this study is the first to use clinical and
endocrine features to define PTSD subgroups for improved diagnostic
performance.
Data integration enables understanding of complex biological systems in
multiple dimensions [69][70]. In our work, we evaluated the classification
performance of models integrating clinical and molecular data in both training
and validation cohorts. For machine learning approaches, we applied two feature
selection techniques and four classifiers in order to find the most suitable model
for each PTSD dataset. In clinical subgroup classification, we found that
tree-based models yielded the largest number of improved groups in
miRNA-Exosome and metabolomics data, while LR yields the most in
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miRNA-Deplete data. In an overall classification with clinical and molecular
features, we observed good performance using ET, LR or SVM. Despite our
success, our best classification performance observed (0.79 AUC) highlights the
ongoing challenges in accurately predicting PTSD status.
As survey-based PTSD diagnoses used to determine PTSD status have
several important limitations, use of molecular biomarkers have the potential to
more objectively predict PTSD status. In this study, we identified candidate
biomarkers for each omics dataset comprising both molecular and clinical
features. Importantly, the molecular candidate biomarkers enabled accurate
PTSD prediction and also provided novel insights for understanding the
pathophysiology of PTSD. Since the dataset used in this study is from combat
veterans, it is likely that our findings are most relevant for patients with a
similar background.
Several other limitations exist in the current study. First, the PTSD
Systems Biology Consortium continually improves sample collection and
experimental assays used to generate data. The work described here is based on
data collected in or before January 2017. A study of the most recent data from
the Consortium would require repeating all steps of our analysis on the latest
data. Second, the relatively small sample sizes of study cohorts pose challenges
in the application of machine learning approaches. The working sample sizes
become even smaller when splitting samples into clinical subgroups. We
presented our statistical test results using raw p-values. However, given the
number of clinical variables used for subgroup generation, a more robust analysis
would require controlling for multiple testing by adjusting the original p-values.
Future work using datasets with larger sample sizes will include this additional
step.
2.5

Conclusions
We applied machine learning approaches to multiple types of PTSD data

to explore the diagnostic potential of clinical subgroups and build classification
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models consisting of molecular and clinical features to predict PTSD status. We
also provided candidate diagnostic biomarkers, knowledge of which improves our
understanding of PTSD pathogenesis. We expect that our work will contribute
to more precise diagnosis and treatment of PTSD.
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Chapter 3
Multi-omic data integration to discover subgroups of PTSD
3.1

Abstract
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder caused

by environmental and genetic factors resulting from alterations to gene
expression, DNA methylation, and neuroimaging characteristics. There is a
pressing need to identify reliable molecular and physiological biomarkers for
accurate diagnosis, prognosis, and treatment of PTSD, as well as to deepen our
understanding of its pathophysiology. Multiple omic data integration enables
investigation of the complex, multivariate nature of the biological systems
underlying PTSD and is essential for identifying molecular subgroups of the
disorder.
Given 284 total samples (124 PTSD positives) from four omics data sets
(miRNA enriched in exosomes, miRNA depleted for exosomes, total miRNA,
and Metabolomics) in cohorts of Training, Validation and Recall, we used two
methods–Similarity Network Fusion (SNF) and Variational Autoencoder
(VAE)–to integrate the data sets and identify subgroups. SNF performs
integration by efficiently fusing sample similarity matrices from each data set
into one network representing the full spectrum of underlying data. Spectral
clustering can then be used to identify subgroups from this network. The VAE
method uses a symmetric deep neural network to reconstruct multiple omics
input data sets by estimating data distributions and identifying representative
hidden variables. K-means clustering is then used to identify subgroups from the
lower dimensional hidden variables. In order to interpret the subgroups, we
tested the associations between identified subgroups and clinical characteristics.
We also calculated differentially expressed molecules between subgroups in each
omics dataset. We then built supervised classification models for PTSD
diagnosis with/without subgroups and compared the accuracy of predicting
PTSD status in the context of subgroups to the accuracy of predicting PTSD
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status without any knowledge of subgroups. Finally, we built a classification
model to predict subgroups in PTSD positive samples.
Our results suggest the presence of two PTSD subgroups in 82 training
PTSD positive samples, both SNF- and VAE-based methods. These subgroups
show significant differences in recalled sample PTSD status (p-value 0.0213). We
also found that a majority of samples associated with the same subgroups when
comparing results from the two methods. Upon statistical testing for association
of the subgroups with over 600 clinical features, we found a significant
association with features including heart rate and insulin. The two identified
subgroups also exhibit a number of differentially expressed molecules from each
omics data set. For diagnostic classification, we observed improved performance
for subgroup-aware PTSD status prediction in total miRNA and Metabolomics
data sets using SNF-based subgroups and in all four omics data sets using
VAE-based subgroups. Finally, using our classification model for subgroup
prediction, we found that identified subgroups in the validation cohort were
significantly associated with many of the same clinical features associated with
subgroups from the training cohort.
We integrated four omics datasets and discovered two clinically-plausible
PTSD subgroups. These subgroups showed significant association with clinical
features and a collection of differentially expressed molecules between them.
Supervised classification using a subgroup-aware classifier suggested improved
PTSD diagnostic potential. Future work will involve leveraging knowledge of
these subgroups to enable precision medicine for PTSD.
3.2

Introduction
Single “omics” data sets have helped explain diagnosis and progression for

complex disorders, but the information contained is limited to one modality. As
different layers of biological systems are often relevant and interdependent,
multiple omics data integration using mRNA expression, miRNA expression,
protein, DNA methylation and metabolomics can utilize complementary
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information and hidden coherent biological signatures to discover biomarkers for
diagnosis, progression and treatment in human diseases [71] [72]. Several studies
have summarized the variety of approaches, challenges and the potential benefits
of using data integration to understand biological systems [70] [73] [74] [75]. Of
these approaches, use of deep neural networks and deep learning is particularly
promising.
Deep learning, a class of machine learning techniques, utilizes a cascade of
multi-layered artificial neural networks for automatic feature extraction and
representation learning. Deep learning architectures such as autoencoders,
recurrent neural networks and convolutional neural networks have been applied
to fields in computer vision, natural language processing and biomedical data
science [52] [53]. Autoencoders (AEs), a type of deep learning model consisting
of an encoder and decoder, learns data reconstruction and efficient representative
features in an unsupervised manner. Specific variants of AEs include Denoising
Autoencoders [76], Adversarial Autoencoders [77], and Variational Autoencoders.
AEs have been successfully applied in biomedical research to solve tasks such as
subgroup discovery in liver cancer [78], neuroblastoma cancer subtype discovery
[79], unsupervised cancer detection using Adversarial AEs [80] and feature
construction and knowledge extraction using a Denoising AE [81]. A number of
studies have applied AEs for multiple omics data integration to enable
neuroblastoma clinical endpoint prediction [82], high-risk neuroblastoma subtype
prediction [79], risk stratification of bladder cancer [83], liver cancer survival
prediction [84] and evaluation of colorectal cancer subtypes and cell lines [85].
However, few studies have made use of multiple omics data integration to
discover subgroups of PTSD.
In this study, we integrated four omics data sets from 82 PTSD positive
samples using two different approaches–Similarity Network Fusion (SNF) and
Variational Autoencoder (VAE). Using these approaches, we identified subgroups
of PTSD which showed significant differences in recalled sample PTSD status. In
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order to interpret the subgroups biologically, we performed differential expression
and clinical characteristic association analyses. We also built a subgroup-aware
PTSD diagnostic model and a PTSD subgroup prediction model which showed
good performance in multiple sample cohorts. These models and our associated
findings regarding PTSD subgroups should contribute to a better understanding
of PTSD pathogenesis and improved clinical applications for PTSD patient
stratification.
3.3
3.3.1

Materials & Methods
Study Samples
The DoD-funded Systems Biology of PTSD Consortium has recruited

over 200 male combat veterans with and without PTSD for the purposes of
identifying diagnostic biomarkers. For subject recruitment, PTSD-positive and
PTSD-negative participants were selected using the following criteria: 1) male
veteran between 20 and 60 years old, 2) deployment in Operation Enduring
Freedom and/or Operation Iraqi Freedom, 3) PTSD positive participants with at
least 40 CAPS score, 4) PTSD negative participants with less than 20 CAPS
score. For consistency, all study participants were evaluated using the DSM-IV
PTSD assessment upon recruitment. For research purposes, there are three
cohorts: a Training cohort also called the discovery cohort (82 PTSD positive
cases and 82 PTSD negative controls), a Test cohort also called the validation
cohort (28 positive and 39 negative samples) and a Recall cohort (14 positive, 10
subthreshold positive and 29 negative samples). In the recall cohort, a subset of
samples from the training cohort were recalled and reassessed an average of three
years later.
For each of the recruited subjects, blood and urine samples were taken
and used to isolate DNA, RNA, protein, metabolites, and endocrine markers for
downstream analyses. Physiological measures (e.g., pulse, blood pressure, body
mass index) were also collected. Molecular and physiological data from the
Training cohort were initially designated for hypothesis generation regarding
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potential diagnostic biomarkers and underlying biological mechanisms of PTSD,
while data from the Test cohort were designated for hypothesis testing and
attempted replication of the training sample findings. For this study, we
analyzed four molecular datasets from these cohorts–three measuring miRNA
derived from either total plasma (miRNA-Plasma), plasma enriched in exosomes
(miRNA-Exosome), or plasma depleted in exosomes (miRNA-Deplete), and one
measuring metabolomics–with the goal of identifying and clinically
characterizing multi-omic PTSD subgroups.
In addition to molecular features, 613 clinical and physiological features
(hereafter referred to as clinical features) belonging to four categories including
demographic information, PTSD diagnostic assessment scores, biochemical and
anthropometric body measurements, and endocrine measurements from blood
and urine, were collected for each subject in the three cohorts. In our analysis,
we first removed clinical features with missing values in the training or validation
cohorts, which left 602 features remaining. We then assigned each clinical feature
to one of three categories based on which of the following criteria were satisfied
for both training and validation cohorts: 1) “Binary” if two unique values exist,
2) “Categorical” if at most five unique values exist, 3) “Continuous” if more than
five unique values exist. In total, we identified 101 binary, 427 categorical and 74
continuous features. To perform statistical association analyses, we used Fisher’s
Exact Test for binary and categorical features and t-test for continuous features.
We adjusted p-values for multiple testing using the Benjamini-Hochberg (BH)
[86] method and considered any feature with adjusted p ≤ 0.05 as significantly
associated.
3.3.2

Principal Component Analysis
Principal component analysis (PCA) is a statistical procedure that uses

an orthogonal transformation to convert a set of observations of possibly
correlated variables into a set of values of linearly uncorrelated variables called
principal components. We applied PCA on the concatenation of all four omics
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data sets from the 82 PTSD positive samples of the Training cohort and used
the maximum number (82) of extracted components to represent the input data.
We then used K-means clustering as described below to discover the optimal
PTSD subgroups.
3.3.3

Similarity Network Fusion Data Integration
Similarity Network Fusion (SNF) is a computational approach for

performing data integration of multiple omics data sets [87]. SNF first calculates
a sample similarity matrix individually for each data set, which may include
mRNA expression, DNA methylation and miRNA expression, among others.
Next, SNF iteratively integrates these similarity matrices into an overall sample
similarity matrix using graph fusion. This approach helps reduce data
set-specific noise and bias to capture complementary information from omics
datasets of different modalities. We used the R library “snftools” to integrate our
four study datasets–miRNA-Exosome, miRNA-Deplete, miRNA-Plasma and
metabolomics–from the PTSD positive samples in the Training cohort. We then
discovered optimal subgroups from the overall sample similarity matrix using the
spectral clustering approach implemented in the snftools library and described
below.
3.3.4

Variational Autoencoder Model
As described above, an Autoencoder (AE) is one class of deep learning

architectures used to learn input data representations in an unsupervised
manner. The purposes of this representation include dimensionality reduction
and reconstruction of the input with the removal of noise. An AE is constituted
by two main parts: an encoder that maps the input into a code, and a decoder
that maps the code to a reconstruction of the original input. The encoder and
decoder are symmetric in terms of layer structure. The simplest AE model is one
hidden layer which refers to the input layer, one hidden layer in the encoder, the
symmetric hidden layer in the decoder and the output layer. The output of the
last encoder hidden layer is also called latent space, which usually has reduced
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dimensions of features compared to the input and the features are also called
latent variables or latent vectors. The output of the decoder is the
reconstruction which is trained to be close to the input. A Variational
Autoencoder (VAE) is an AE variant which inherits the general autoencoder
architecture of both an encoder and a decoder and is trained to reduce the
reconstruction error between input and output. Moreover, VAEs learn the
distribution of samples by estimating a mean and standard deviation vectors
which are used to sample a latent space to be fed to the decoder. VAEs also add
a Kullback-Leibler divergence term to the reconstruction loss which measures the
difference between a standard Gaussian and the estimated distribution.
In our work, we implemented a one-hidden layer VAE to reconstruct the
input data, which in this case is the concatenation of four omics data sets from
the 82 PTSD positive samples of the Training cohort. For model training, we
tuned hyperparameters including learning rate (ranging from 0.0001 to 0.1) and
dropout rate (ranging from 0.1 to 0.5). For each hyperparameter combination,
we trained the corresponding VAE for 500 epochs, at which point the training
process has converged. We then selected nodes from the hidden layer as a
reduced dimensional representation of the input data. Using this representation,
we applied K-means clustering as described below to select the optimal PTSD
subgroups.
3.3.5

Unsupervised Clustering
Spectral clustering [50] [88] is a technique that uses the eigenvectors

(spectrum) and eigenvalues of a matrix to define cluster membership.
This approach is based on the fact that if a graph (network defined by
sample similarity matrix) is formed by k disjoint cliques (clusters), then the
samples are projected into a lower dimensional space to have more obvious
clusters where Graph Laplacian Matrix, a matrix representation of a graph, is
used to calculate eigenvalues and eigenvectors. The eigenvectors of the sample
similarity matrix function as indicators of cluster membership. The eigengap
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refers to the difference between consecutive eigenvalues. Importantly, although
small perturbations such as adding a few edges linking clusters or removing
edges from inside the clusters will increase eigenvalues and change the
corresponding eigenvectors, this does not generally cause the underlying
structure to be lost. This clustering technique requires the number of desired
clusters to be specified [51]. We applied spectral clustering to the integrated
sample similarity matrix from SNF and calculated the eigengaps for numbers of
clusters ranging from 2 to 10. We then selected the optimal number of subgroups
based on the maximum eigengap value.
K-means is another method of unsupervised clustering, originating from
signal processing, that is popular for cluster analysis in data mining. For a given
value of K (number of clusters), the goal of K-means is to partition all training
data samples into K distinct, non-overlapping clusters by identifying clusters for
which within-cluster variation is as small as possible. For our work, we used the
K-means implementation from the Python Scikit-learn library. As with spectral
clustering, we evaluated numbers of clusters ranging from 2 to 10 and calculated
the Silhouette score to determine the optimal number. The Silhouette score
indicates the separation distance between a given set of clusters, with a large
score (close to 1) corresponding to good separation and a small score (close to 0)
corresponding to poor separation. We thus chose the optimal number of
subgroups based on the maximum Silhouette score.
3.3.6

Subgroup Recall Status Test
Among 59 total samples in the recall cohort, the 29 PTSD cases were

recalled from PTSD positive samples in the training cohort. Upon reassessment
on average three years later, these 29 samples were diagnosed as either “Positive”,
“Negative” or “Positive Subthreshold.” For the identified PTSD subgroups, we
compared recalled PTSD status between the groups and used Fisher’s Exact test
to test for differences. We used a p-value threshold of 0.05 to determine if the
subgroups showed significantly different recall statuses.
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3.3.7

Differential Expression Analysis
For the PTSD subgroups, we also identified differentially expressed (DE)

molecules between groups in each of the four omics data sets. In addition, we
identified DE molecules between PTSD positive and PTSD negative samples in
the Training and Validation cohorts. We used the R package “Limma” for DE
analysis and applied a Benjamini-Hochberg adjusted p-value threshold of 0.05 to
determine significantly DE molecules. For the three group (Control vs Subgroup
1 vs Subgroup 2) test, we compared each pair, then selected intersected
significantly DE molecules.
3.3.8

Supervised Diagnosis Classification
Support Vector Machines (SVMs) are supervised learning models with

associated learning algorithms used for classification and regression analyses.
SVM constructs a hyperplane or set of hyperplanes in a high- or
infinite-dimensional space. An important feature of SVMs is the use of kernel
functions that enable operation in a high-dimensional, implicit feature space
without requiring computation of the coordinates of data in that space. Kernels
provide a mapping of the problem from the input space to this
higher-dimensional space (called the feature space) by performing a nonlinear
transformation. We first used SVM with a linear kernel to train diagnostic
classifiers based on PTSD positive and negative labels for each of the four omics
data sets in the Training cohort. We then validated these classifiers using data
from the Validation cohort. We then used SVM to train a PTSD subgroup-aware
classifier based on labels of the identified subgroups as well as PTSD negative
labels. To assess accuracy, we considered any sample classified into one of the
predicted subgroups as a PTSD positive sample and PTSD negative otherwise.
During classifier training, we applied recursive feature elimination and
cross-validation for feature selection and accuracy evaluation, respectively.
Specifically for the latter, we used 10-fold nested cross-validation to perform
training and testing as well as optimize classifier hyperparameters. For the linear
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SVM, we evaluated values for the cost hyperparameter (C) in a series of
10( − 4, 3) and 2( − 4, 4). We selected the optimal hyperparameter based on the
highest average accuracy achieved in the training data and used the
corresponding trained classifier for subsequent evaluation.
3.3.9

Subgroup Prediction
We also used a linear SVM to construct a PTSD subgroup prediction

model. Here, the training labels are the predicted subgroups from the Training
cohort, and we use the resulting classifier to predict subgroups for the Validation
cohort. We used AUC as the evaluation metric for predictions based on the
training data, and we applied the same hyperparameter tuning and
cross-validation schemes as above. The best-performing hyperparameter was
selected based on the average AUC from cross-validation, and the corresponding
trained classifier was used to predict subgroup labels in the validation data. If all
subgroup predictions for the testing data set happen to be the same, we instead
chose the trained classifier using the next-best hyperparameter value as
determined by average AUC.
3.4

Results
In this work, we aimed to integrate multiple omics data sets to discover

PTSD subgroups and their associated clinical characteristics. Specifically, we
integrated three miRNA data sets and 1 metabolomics data set, and we applied
three different approaches–SNF, VAE and PCA–to perform data integration and
unsupervised subgroup discovery. We used the criteria of cluster separation and
differences in recall sample PTSD status to guide hyperparameter tuning and
select the optimal PTSD subgroups. For the subgroups identified using SNF and
VAE, we performed the following downstream analyses: 1) Differential
expression analysis between subgroups, 2) Subgroup clinical association analysis,
3) Subgroup-aware diagnostic model creation and evaluation, 4) Subgroup
prediction model construction and evaluation. Figure 3.1 shows our overall
workflow.
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Fig. 3.1: Workflow for PTSD subgroup identification and associated clinical
characterization. From the left side, we utilized PTSD multiple omic data sets
and applied methods PCA, SNF and VAE to discover subgroups in parallel as
seen in the middle. For the identified PSTD subgroups, we analyzed the status
change for the recalled samples, followed by differential expression, clinical
association and diagnosis model. We also built classification models to predict
PTSD subgroups.
3.4.1

PTSD Subgroup Identification
As described above, we utilized four omics data sets for our

analyses–miRNA-Exosome, miRNA-Deplete, miRNA-Plasma and
metabolomics–from three patient cohorts–Training (discovery), Test (validation)
and Recall. Across all cohorts, miRNA-Exosome contains 209 molecular features,
miRNA-Deplete contains 310 features, miRNA-Plasma contains 284 features and
metabolomics contains 168 features. The counts of samples and features can be
seen in Table 3.1.
Table 3.1: PTSD Multiple Omic Data Sets and Cohorts
Data Sets

Feature Counts

Cohorts

Samples
P:(SP):N
82:82
28:39
14:10:29
124:10:150

miRNA-Exosome 209
Training
miRNA-Deplete
310
Validation
miRNA-Plasma
284
Recall
Metabolomics
168
All
All
971
*P: PTSD positive; SP: Subthreshold PTSD positive; N: PTSD negative

We first removed a known batch effect for location of sample recruitment
from the four omics datasets using the function “removeBatchEffect” from the R
Limma package. We performed this batch correction on data from all cohorts.
We also removed one feature (EDTA) from the metabolomics data set, as
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changes in its levels were known to reflect this batch effect. The above
procedures left us with a concatenated training data set of 82 PTSD positive
samples measured for 971 total molecular features. We applied data integration
and unsupervised clustering to this dataset to discover PTSD subgroups.
As described above, Similarity Network Fusion (SNF) performs omics
data integration through the construction and fusion of sample similarity
matrices from each data set [87]. To begin, we computed normalized pairwise
squared euclidean distances for each data set and then applied SNF to integrate
the data sets and obtain an overall 82 x 82 sample similarity matrix. We next
used spectral clustering to determine the optimal number of clusters within the
matrix. We selected the optimal number of subgroups based on the maximum
value of the eigengap, which reflects the degree of separation between clusters.
We then tuned SNF hyperparameters and tested for significant associations
between candidate subgroups and recall PTSD status. We identified an optimal
2 subgroups, consisting of 48 and 34 samples, respectively, with an eigengap of
0.166 and recall status p-value of 0.0213. We visualized a lower-dimensional
representation of the subgroup assignments using the t-SNE approach. Figure
3.2 A-C displays the numbers of subgroups versus their eigengaps and recall
status p-values, the overall sample similarity matrix and the t-SNE visualization.
Variational autoencoders (VAEs) provide an alternative means for data
integration by performing reconstruction and dimensional reduction of input
data. We applied a VAE model to the four PTSD omics datasets as an 82
sample x 970 feature matrix, and we used the 28 sample x 970 matrix from the
validation cohort for model evaluation. We tuned a series of hyperparameters to
optimize the VAE model for our data set. We then applied K-means clustering
to the reduced-dimensional hidden variables of the VAE to discover subgroups.
Similarly as with SNF, we tested for significant associations of recall status with
candidate subgroups. We used four criteria to choose the optimal number of
clusters: 1) model convergence with a low validation loss, 2) >0.1 Silhouette
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Fig. 3.2: SNF and VAE Subgroup Identification, A) Eigen gaps in SNF and
spectral clustering, B) Patient-patient similarity matrix with subgroup blocks,
C) SNF-derived subgroup visualization in training PTSD+ samples, D) VAE
training process in 500 epochs, E) K-means clustering in VAE hidden variables,
F) VAE-derived subgroup visualization in training PTSD+ samples.

score from K-means clusters, 3) fewer than 5 subgroups, 4) an association test
between candidate subgroups and recall PTSD status. We then visualized the
subgroups as before using t-SNE. We again identified an optimal 2 subgroups,
consisting of 50 and 32 samples, respectively, with a Silhouette score of 0.12 and
recall status p-value of 0.0213. Figure 3.2 D-F) show the numbers of subgroups
versus their Silhouette scores and recall status p-values, the training and
validation losses as training progresses, and the t-SNE subgroup visualization.
We also evaluated PCA as a simpler data integration method for
comparison with SNF and VAE. We selected all 82 principal components for
data integration, which represent 100% of the variance in the input data. Similar
to the VAE approach above, we applied K-means clustering on the
reduced-dimensional set of principal components and selected optimal clusters
based on Silhouette score. We identified an optimal 2 subgroups, consisting of 38
and 44 samples, respectively, with a Silhouette score of 0.142 and recall status
p-value of 0.142. Unlike with the SNF and VAE subgroups, the PCA subgroups
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did not demonstrate a significant association with recall status, so we did not
perform downstream analyses of these groups. Table 3.2 summarizes results of
the three approaches used for subgroup identification.
Table 3.2: Subgroup Identification and Fisher’s Exact Test on Recall Status
Methods

Subgroups

Separation

SNF
PCA
VAE

48 – 34
38 – 44
50 – 32

0.166
0.142
0.12

Batch
Effect Recall Status Test
Test p value
p value
0.2456
0.0213
0.8157
0.1423
0.8119
0.0213

Given the SNF and VAE subgroups, we next compared group
membership between the two methods to detect subgroup overlap. A majority of
the 82 samples were placed in the same subgroups by the two methods, with the
exception of 14 samples that had switched membership (Table 3.3). When
considering only the subset of recalled samples, we found that all 29 samples
were placed in the same subgroups by both methods. Furthermore, recalled
samples in subgroup 2 have lower CAPS scores upon recall than those in
subgroup 1(t-test p-value 0.02). Figure 3.3-A indicates the change in CAPS for
the recalled samples between Training and Recall cohorts, and Figure 3.3-B
summarizes the difference in recall CAPS scores for the two subgroups. We used
t test and found p value 0.028 for the CAPS score difference between the two
subgroups in the Recall status.
Table 3.3: Overlap of Subgroups Identified Using SNF and VAE
SNF
1
1
2
2
3.4.2

VAE
1
2
1
2

Counts
42
6
8
26

Clinical Characterization Of Subgroups
To enable biological interpretation of the PTSD subgroups, we performed

association analysis of 602 clinical characteristics, among which 101 are binary,
427 are categorical and 74 are continuous. We applied Fisher’s Exact tests on
binary or categorical features and t-tests on continuous features. We then
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Fig. 3.3: Subgroup Recall Status Change, A) CAPS score change in SNF-derived
training PTSD+ subgroups, B) CAPS score change in Recall samples using
SNF-derived subgroups, C) Confusion matrix between SNF-derived subgroups
and Recall status changes.

performed multiple test adjustment of the original p-values using the
Benjamini-Hochberg (BH) method. We performed this analysis separately for
the subgroups identified by the SNF and VAE methods. For comparison, we also
tested for clinical associations with case and control status in the Training and
Validation cohorts. In the latter comparison, 332 clinical features were
significantly associated with case-control in both cohorts. Among those features,
62 were significantly associated with SNF-based subgroups while 60 were
significantly associated with VAE-based subgroups. Taken together, 59 clinical
features from six categories were significantly associated with subgroups detected
by both methods. These 59 clinical features were from 5 categories and the
members from the same category look quite similar. For the further analyses, we
chose one member from each category, but two from the ABM category in the
total of six clinical features. Figure 4 summarizes the values of six clinical
features–ABM10 (Body Mass Index), ABM2 (Pulse), FASA_C, insulin, psai1a,
SAS23–from five categories between the subgroups and control samples. Figure
3.4A displays values for SNF-based subgroups, while Figure 3.4B illustrates
VAE-based subgroups. We note that ABM10 and ABM2 show significantly
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Fig. 3.4: Clinical Association with Predicted PTSD Subgroups in Training Data
Set. A) six selected clinical features expression in PTSD- and SNF-based
identified PTSD subgroups, B) six selected clinical features expression in PTSDand VAE-based identified PTSD subgroups.

higher values in cases than controls, while FASA_C exhibits the opposite trend.
Table 3.4 lists a detailed result of the association analysis for the top 30 clinical
features. The full names for clinical categories are provided in the Appendix C.
The FDR indicates the False Discovery Rate on the original p values.
3.4.3

Differential Expression Between Subgroups
To better understand differences in molecular expression between

subgroups, we applied differential expression (DE) analysis. We used the R
package “Limma” to test for expression differences across the four omics data sets
between (1) case and control samples, (2) SNF-based subgroups, (3) VAE-based
subgroups, and (4,5) three-way comparisons for both SNF and VAE (control vs
subgroup 1 vs subgroup 2). We considered significantly differentially expressed
molecules as those with BH-adjusted p-values ≤0.05. We detected the largest
numbers of DE molecules in the miRNA-Deplete and miRNA-Exosome data sets
from the SNF and VAE subgroup comparisons. In the miRNA-Plasma data set,
the highest overall number (247) of DE molecules were detected between cases
and controls, although DE molecules from the subgroup comparisons (206 from
SNF and 211 from VAE) were a close second. Figure 3.5A and Figure 3.5C
illustrate these findings. Figure 3.5B and Figure 3.5D summarize the
expression of the top five most significantly DE molecules (all miRNAs) from the
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Table 3.4: Clinical Association Test With the Identified PTSD Subgroups
Features

Categories

SNFSubgroups
FDR

ABM9-Syst
NYU-ABM 8.25E-83
ABM9-Dias
NYU-ABM 4.22E-76
WVisWorkMemConf2 NYU-WAIS- 8.39E-69
WMS
ABM10
NYU-ABM 1.65E-67
WVisWorkMemConf1 NYU-WAIS- 5.30E-64
WMS
WVisWorkIndex
NYU-WAIS- 1.13E-63
WMS
ABM2
NYU-ABM 2.20E-61
WMemLetterRS
NYU-WAIS- 2.60E-59
WMS
ABM1
NYU-ABM 6.92E-59
ABM6
NYU-ABM 1.28E-57
WMemDigRS
NYU-WAIS- 2.59E-57
WMS
WLongestForwRS
NYU-WAIS- 3.23E-54
WMS
WLongDSSRS
NYU-WAIS- 3.48E-54
WMS
ABM4
NYU-ABM 2.21E-53
WDigSpanForwardRS NYU-WAIS- 5.21E-51
WMS
DemoAge
NYU9.60E-50
Background
WProcSpeedCodRS NYU-WAIS- 2.80E-48
WMS
WMemLetterAgeSS NYU-WAIS- 3.75E-46
WMS
WVisWorkMemSum NYU-WAIS- 1.75E-44
WMS
WVocRS
NYU-WAIS- 9.39E-44
WMS
WDigSpanBackRS
NYU-WAIS- 2.77E-42
WMS
WMemDigAgeSS
NYU-WAIS- 5.08E-42
WMS
WSymbolSpan-RS
NYU-WAIS- 3.82E-38
WMS
FASF-C
NYU-FAS 1.64E-37
WProcSpeedCodAgeSSNYU-WAIS- 2.89E-37
WMS
WSymbolSpan-SS
NYU-WAIS- 3.44E-37
WMS
FASS-C
NYU-FAS 4.62E-36
WSpatialAdd-SS
NYU-WAIS- 5.13E-36
WMS
WLongestBackRS
NYU-WAIS- 1.17E-35
WMS
WSpatialAdd-RS
NYU-WAIS- 2.01E-35
WMS
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VAESubgroups
FDR
8.20E-83
4.17E-76
8.28E-69

Train Case- Validation
Control FDR CaseControl
FDR
1.96E-169
2.28E-50
8.63E-154
2.78E-47
8.83E-144
6.56E-45

1.62E-67
5.22E-64

9.90E-127
4.48E-134

2.30E-41
1.32E-41

1.11E-63

8.12E-134

9.46E-42

2.12E-61
2.49E-59

4.01E-126
8.30E-123

3.94E-32
3.48E-43

6.86E-59
1.24E-57
2.49E-57

3.19E-119
1.41E-124
6.10E-115

9.36E-36
8.85E-47
8.66E-32

2.55E-54

1.77E-128

7.88E-34

2.34E-54

3.67E-112

9.01E-34

2.12E-53
4.60E-51

6.79E-116
8.88E-109

6.46E-40
3.82E-29

9.13E-50

1.42E-101

2.15E-36

2.72E-48

1.07E-104

8.49E-35

3.17E-46

9.74E-56

2.58E-30

1.60E-44

2.22E-98

2.70E-30

8.94E-44

3.31E-96

4.96E-43

2.22E-42

1.50E-94

7.20E-25

4.22E-42

3.11E-90

1.24E-25

3.54E-38

4.36E-90

1.45E-26

1.42E-37
2.33E-37

9.56E-85
4.18E-88

7.67E-24
1.31E-28

2.82E-37

1.62E-91

3.47E-28

4.08E-36
4.21E-36

1.67E-85
1.07E-84

3.09E-23
1.07E-27

6.93E-36

1.05E-92

1.89E-25

1.76E-35

5.87E-81

1.30E-26
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Fig. 3.5: Molecular Differential Expression With Identified Subgroups, A)
Barplot of differentially expressed molecule numbers in SNF-based subgroups, B)
Top DE molecules in SNF-based subgroups, C) Barplot of differentially
expressed molecule numbers in VAE-based subgroups, D) Top DE molecules in
VAE-based subgroups.

three-way comparison for SNF and VAE subgroups, respectively. More detailed
lists of DE molecules show in Table 3.5 of SNF and Table 3.6 of VAE.
3.4.4

Supervised Classification Using Subgroup Labels
In order to detect whether knowledge of the discovered subgroups was

relevant to PTSD diagnosis, we next constructed a supervised classification
model to discriminate between case and control samples within each PTSD omic
data set. Our working hypothesis is that a subgroup-aware classifier can glean
additional information from data that will be useful for diagnosis. We trained an
SVM classifier to distinguish between three classes (control, subgroup 1 and
subgroup 2) in the Training cohort, and we evaluated classification performance
using prediction accuracy in the Validation cohort. Given that subgroups were
not yet defined in the latter cohort, we considered predictions for subgroups 1 or
2 equivalent to PTSD positive predictions when calculating Validation accuracy.
For comparison, we also trained a baseline two-class classifier (case versus
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Table 3.5: Top DE Molecules Between SNF-based Subgroups
Molecules

DataSets

hsa.miR.1260b.5p miRNA-Plasma
hsa.miR.27b.3p.2
miRNA-Plasma
hsa.miR.27a.3p.2
miRNA-Plasma
hsa.miR.99b.5p.2
miRNA-Plasma
hsa.miR.126.5p.2
miRNA-Plasma
hsa.miR.126.3p.2
miRNA-Plasma
hsa.miR.125a.5p.2 miRNA-Plasma
hsa.miR.223.3p.2
miRNA-Plasma
hsa.miR.335.5p.2
miRNA-Plasma
hsa.miR.223.3p.1
miRNA-Exosome
hsa.miR.199a.1.3p.2 miRNA-Plasma
hsa.miR.199a.2.3p miRNA-Plasma
hsa.miR.199b.3p
miRNA-Plasma
hsa.miR.146b.5p.2 miRNA-Plasma
hsa.miR.494.3p.2
miRNA-Plasma
hsa.miR.361.5p.2
miRNA-Plasma
hsa.miR.376c.3p.2 miRNA-Plasma
hsa.let.7d.3p.2
miRNA-Plasma
hsa.miR.24.1.3p.2 miRNA-Plasma
hsa.miR.24.2.3p
miRNA-Plasma
hsa.miR.425.3p
miRNA-Plasma
hsa.miR.10a.5p.2
miRNA-Plasma
hsa.miR.199a.1.3p.1 miRNA-Exosome
hsa.miR.376a.1.3p.2 miRNA-Plasma
hsa.miR.376a.2.3p miRNA-Plasma
hsa.miR.340.5p.2
miRNA-Plasma
hsa.miR.130a.3p.2 miRNA-Plasma
hsa.miR.744.5p.2
miRNA-Plasma
hsa.miR.628.3p.2
miRNA-Plasma
hsa.miR.146a.5p.2 miRNA-Plasma
hsa.miR.382.5p.2
miRNA-Plasma
hsa.miR.409.3p.2
miRNA-Plasma
hsa.miR.23a.3p.2
miRNA-Plasma
hsa.miR.23b.3p.2
miRNA-Plasma
hsa.miR.433.3p.2
miRNA-Plasma
hsa.miR.130b.5p.2 miRNA-Plasma
hsa.miR.197.3p.2
miRNA-Plasma
hsa.miR.326.3p
miRNA-Plasma
hsa.miR.28.3p.2
miRNA-Plasma
hsa.miR.584.5p.2
miRNA-Plasma
hsa.miR.151a.3p.2 miRNA-Plasma

Train FDR
0.00023
0.002
0.003
1.83E-05
0.0003
4.36E-06
1.82E-05
2.75E-05
0.00048
0.0026
1.15E-05
1.15E-05
1.15E-05
1.43E-05
1.07E-05
0.00039
2.30E-05
0.0016
1.39E-05
1.39E-05
6.02E-05
0.059
0.007
4.07E-05
4.07E-05
0.00021
0.000299
3.52E-06
7.92E-05
1.39E-05
4.86E-05
9.28E-06
2.65E-05
2.77E-05
0.00048
0.0005
3.17E-05
7.20E-05
7.97E-06
0.00078
1.15E-05
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Subgroup
FDR
2.81E-09
2.81E-09
2.81E-09
4.09E-09
4.09E-09
7.46E-09
7.46E-09
7.46E-09
8.13E-09
1.10E-08
1.10E-08
1.10E-08
1.10E-08
1.10E-08
1.65E-08
1.65E-08
1.68E-08
1.82E-08
1.96E-08
1.96E-08
2.34E-08
2.34E-08
2.37E-08
3.18E-08
3.18E-08
3.18E-08
3.18E-08
3.32E-08
3.51E-08
3.56E-08
3.65E-08
4.41E-08
4.41E-08
4.41E-08
4.41E-08
4.41E-08
4.79E-08
4.79E-08
5.76E-08
5.76E-08
6.54E-08

Three FDR
8.19E -14
1.58E -12
2.69E -12
2.44E -13
1.25E -12
6.14E -15
8.87E -13
1.64E -13
4.45E -12
9.01E -13
2.55E -14
2.54E -14
2.55E -14
3.65E -13
6.69E -14
2.87E -11
5.92E -14
3.42E -10
4.61E -13
4.61E -13
6.86E -12
2.28E-08
2.43E -11
1.41E -12
1.41E -12
5.27E -12
2.96E -11
1.01E -13
6.36E -12
1.93E -12
8.15E -12
1.09E -12
3.29E -12
4.21E -12
1.63E -10
2.29E -11
1.30E -11
5.15E -12
1.15E -12
6.31E -11
9.58E -13

Table 3.6: Top DE Molecules Between VAE-based Subgroups
Molecules

DataSets

hsa.miR.326.3p
miRNA-Plasma
hsa.miR.146a.5p.2 miRNA-Plasma
hsa.miR.126.3p.2
miRNA-Plasma
hsa.miR.199a.1.5p.2 miRNA-Plasma
hsa.miR.199a.2.5p miRNA-Plasma
hsa.miR.23a.3p.2
miRNA-Plasma
hsa.miR.23b.3p.2
miRNA-Plasma
hsa.miR.1260b.5p miRNA-Plasma
hsa.miR.27a.3p.2
miRNA-Plasma
hsa.miR.330.3p.2
miRNA-Plasma
hsa.miR.423.3p.2
miRNA-Plasma
hsa.miR.28.3p.2
miRNA-Plasma
hsa.miR.221.3p.2
miRNA-Plasma
hsa.miR.130b.3p.2 miRNA-Plasma
hsa.miR.27b.3p.2
miRNA-Plasma
hsa.miR.584.5p.2
miRNA-Plasma
hsa.miR.128.2.3p
miRNA-Plasma
hsa.miR.128.1.3p.2 miRNA-Plasma
hsa.miR.181d.5p.1 miRNA-Plasma
hsa.miR.151a.3p.2 miRNA-Plasma
hsa.miR.99b.5p.2
miRNA-Plasma
hsa.miR.425.3p
miRNA-Plasma
hsa.miR.197.3p.2
miRNA-Plasma
hsa.miR.339.5p.2
miRNA-Plasma
hsa.miR.21.3p.2
miRNA-Plasma
hsa.miR.181b.2.5p miRNA-Plasma
hsa.miR.130a.3p.2 miRNA-Plasma
hsa.miR.361.5p.2
miRNA-Plasma
hsa.miR.151a.5p.2 miRNA-Plasma
hsa.miR.125a.5p.2 miRNA-Plasma
hsa.miR.181b.1.5p.2 miRNA-Plasma
hsa.miR.1307.5p.2 miRNA-Plasma
hsa.miR.652.3p.2
miRNA-Plasma
hsa.miR.4286.5p.2 miRNA-Plasma
hsa.miR.130b.5p.2 miRNA-Plasma
hsa.miR.191.5p.2
miRNA-Plasma
hsa.miR.22.5p.2
miRNA-Plasma
hsa.miR.1307.3p.2 miRNA-Plasma
hsa.miR.331.3p.1
miRNA-Plasma
hsa.miR.142.3p.2
miRNA-Plasma

Train FDR
7.20E-05
1.39E-05
4.36E-06
4.36E-06
4.36E-06
2.65E-05
2.77E-05
0.0002
0.003
3.28E-06
4.36E-06
7.97E-06
2.99E-05
4.07E-05
0.002
0.00078
9.46E-05
7.00E-05
1.39E-05
1.15E-05
1.83E-05
6.02E-05
3.17E-05
7.25E-05
9.28E-06
1.39E-05
0.0003
0.00039
1.33E-05
1.82E-05
1.59E-05
2.65E-05
1.68E-05
0.0004
0.0005
5.47E-07
0.00017
2.22E-06
2.22E-06
1.07E-05
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Subgroup
FDR
3.08E-09
3.45E-09
3.70E-09
3.70E-09
3.70E-09
3.70E-09
3.70E-09
3.70E-09
3.70E-09
3.76E-09
3.76E-09
3.76E-09
3.76E-09
3.76E-09
3.80E-09
4.04E-09
4.77E-09
4.80E-09
5.40E-09
5.69E-09
5.69E-09
5.69E-09
5.77E-09
5.77E-09
6.69E-09
6.69E-09
7.58E-09
8.15E-09
8.45E-09
8.45E-09
8.54E-09
9.52E-09
1.06E-08
1.13E-08
1.33E-08
1.39E-08
1.45E-08
1.95E-08
1.95E-08
1.95E-08

Three FDR
1.27E-13
1.61E-13
7.77E-15
2.55E-14
2.55E-14
2.61E-13
3.47E-13
7.87E-13
1.85E-11
5.10E-15
3.39E-13
9.21E-14
9.72E-13
3.00E-12
1.27E-11
4.09E-12
4.90E-12
3.55E-12
1.78E-12
9.45E-14
1.25E-12
3.02E-12
2.38E-12
2.60E-12
6.42E-14
4.69E-12
1.32E-11
3.52E-11
4.74E-13
3.24E-12
8.02E-12
1.26E-12
8.77E-12
3.54E-11
9.84E-12
3.37E-14
3.04E-12
8.74E-13
7.51E-14
4.76E-13

control) using the Training cohort and evaluated using the Validation cohort.
We built and evaluated classifiers using SNF-based and VAE-based subgroups
separately. In the evaluation, we mainly compared the prediction accuracy in the
validation data after the model finished training. To note, the training accuracy
refers to accuracy in three groups in three-class models but it refers to accuracy
in two groups in two-class models.
Our results showed that classification using the miRNA-Plasma and
metabolomics data sets was improved by SNF-based subgroup-aware classifiers,
with Validation accuracies increasing over baseline from 0.567 to 0.582 and 0.552
to 0.582, respectively (Table 3.7). For the VAE-based subgroups, all four omics
data sets showed Validation accuracy improvement with subgroup aware
classifiers (Table 3.8). The classifier for the miRNA-Deplete data set showed the
best diagnostic performance overall, with Validation accuracy of 0.612 compared
to a 0.582 baseline. The improvements observed as a result of subgroup-aware
classification suggest the value of including multi-omic subgroup identification in
a diagnostic for PTSD.
Table 3.7: Supervised Classification Performance Using SNF-based Subgroups
Data

Two Class Model
Three Class Model
Discovery ACC Validation ACC Discovery ACC Validation ACC
miRNA-Plasma 0.594 ± 0.113 0.567
0.573 ± 0.112 0.582
miRNA-Exosome 0.547 ± 0.103 0.552
0.5 ± 0.092
0.448
miRNA-Deplete 0.623 ± 0.07 0.582
0.5 ± 0.019
0.582
Metabolomics
0.629 ± 0.108 0.552
0.531 ± 0.046 0.582

Table 3.8: Supervised Classification Performance Using VAE-based Subgroups
Data

Two Class Model
Three Class Model
Discovery ACC Validation ACC Discovery ACC Validation ACC
miRNA-Plasma 0.594 ± 0.113 0.567
0.545 ± 0.087 0.582
miRNA-Exosome 0.547 ± 0.103 0.552
0.5 ± 0.034
0.582
miRNA-Deplete 0.623 ± 0.07 0.582
0.554 ± 0.08 0.612
Metabolomics
0.629 ± 0.108 0.552
0.507 ± 0.084 0.582

3.4.5

PTSD Subgroup Prediction
Stratification of PTSD samples is an important first step in the practice

of precision medicine for PTSD. To facilitate this step, we also constructed a
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PTSD subgroup binary classifier. Given the two subgroups identified in the 82
PTSD positive Training samples, we trained a multi-omic binary SVM classifier
using all four data sets. Since subgroup assignments do not exist a priori in the
Validation cohort, we used 10-fold cross validation to tune the SVM
hyperparameter C based on AUC, as described in the Materials and Methods
section. We trained a classifier using the optimal hyperparameter, determined by
the largest mean AUC, on Training cohort data, followed by application of this
classifier to predict subgroups in PTSD cases from the Validation cohort. In
cases where all Validation predictions were for a single subgroup, we instead
selected the second-best performing hyperparameter for model training and
validation. Figure 3.6A and Figure 3.6C show Receiver Operating
Characteristic (ROC) curves for SNF and VAE subgroup classifiers, respectively.
The training AUC for SNF-based subgroups was 0.93, while the AUC for
VAE-based subgroups reached higher to 0.98. Validation predictions based on
the two subgroup definitions were similar, with the difference being that five
additional samples were predicted to be from subgroup 2 using the SNF-based
classifier. Figures 6B and 6D show t-SNE visualizations of the predicted
Validation subgroups derived from SNF- and VAE-based classifiers, respectively.
In addition, we performed clinical feature association analysis given our
predicted subgroups for the Validation cohort. We used t-tests for continuous
features and Fisher’s Exact Tests for binary or categorical features. As before, we
adjusted raw p-values for multiple testing using the BH method. We found that
the same six clinical features that were significantly DE between subgroups from
the Training cohort were also significantly DE in the Validation cohort. Figure
3.7A and Figure 3.7B summarize the values of these features between the SNFand VAE-based Validation subgroups, respectively. The consistency observed in
the clinical characterization of Training and Validation subgroups supports the
biological plausibility and robustness of the identified PTSD subgroups.
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Fig. 3.6: PTSD Subgroup Classification AUC Plot and Subgroup Visualization,
A) SNF identified subgroups AUC plot using all omic data sets, B) Visualization
of SNF-based subgroups in validation data set, C) VAE identified subgroups
AUC plot using all omic data sets, D) Visualization of VAE-based subgroups in
validation data set.
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Fig. 3.7: Clinical Association with Predicted PTSD Subgroups in Validation
Data Set. A) six selected clinical features expression in PTSD- and SNF-based
predicted PTSD subgroups, B) six selected clinical features expression in PTSDand VAE-based predicted PTSD subgroups.
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3.5

Discussion
In this study, we applied three methods–SNF, VAE and PCA–to integrate

and discover subgroups from four PTSD omics datasets. The subgroups
identified by SNF and VAE show good separation and significant association
with recall sample PTSD status. Moreover, the SNF and VAE subgroups largely
overlapped, and the subgroup assignment of the recalled sample subset is the
same between the two methods. These subgroups also exhibited considerable
numbers of DE molecules in each omic dataset. To clinically characterize the
subgroups, we identified 59 significantly associated clinical features associated
with the subgroups identified by both methods as well as with case-control
status. In a diagnostic model, knowledge of these subgroups improved the
performance of classifying PTSD positive and negative samples. We also
observed excellent classification performance for subgroup prediction models
constructed based on SNF and VAE subgroups.
The complexity and heterogeneity of biological systems have made data
integration crucial in the advancement of understanding in support of precision
medicine [89]. SNF and VAE have been applied to subgroup discovery in cancers
[78] [79] [80]; however, our work represents the first time these two approaches
have been applied to PTSD. VAEs have been successfully applied in image
generation [90]. In our study, VAEs learn the distribution of latent variables and
reconstruct input data that are likely to be generative models for PTSD
subgroup/biomarker analysis.
PTSD symptoms often exhibit the characteristics of hyperarousal and
exaggerated startle responses. It was previously reported that PTSD patients
have a high risk of developing cardiovascular issues, such as increased heart
rate/pulse rate and blood pressure [65] and increased BMI and weight [66] as a
result of traumas. PTSD re-experiencing symptoms were inversely associated
with high-frequency pulse rate variability [91]. It was reported that the cortisol
and Glucocorticoid Receptor (GR) alterations in the dysregulation of the

65

hypothalamic-pituitary-adrenal axis (HPA) -axis are associated with insulin
resistance [92] [93]. A recent study discovered both heart rate and insulin levels
as potential biomarkers for PTSD [68]. MicroRNAs (miRNAs) are involved in
critical aspects of PTSD pathophysiology and are also potential biomarkers [94].
The expression changes of miRNAs could decrease vulnerability to stress or
promote resilience, as evidenced by a decreased expression of miR-99b-5p and
miR-27a-3p in rats leading to an increased vulnerability to stress [95]. The
miRNAs miR-199b and miR-24 were also reported to be correlatively implicated
in fear- and trauma-related disorders [96]. MicroRNAs miR-99b-5p and
miR-27a-3p were two of the most significant molecules we found to be
differentially expressed between subgroups.
Several limitations exist in the current study. First, the subjects analyzed
in our study were restricted to a pool of men deployed to Iraq and/or
Afghanistan with moderate to severe cases of combat-related PTSD compared to
a pool of similarly combat-exposed asymptomatic controls. Moreover, the
subjects were diagnosed using DSM-IV, which is an older version of the now
current DSM-5. This may complicate efforts to reconcile findings from our study
with newer datasets collected using DSM-5. Second, the relatively small sample
sizes of our study cohorts pose challenges to the application of machine learning
approaches, especially deep learning methods such as VAE. We used 82 PTSD
positive samples measured for 971 features from the Training cohort for data
integration and subgroup discovery, while we validated the discovered subgroups
using 28 samples from the Validation cohort. Although our training of the VAE
model showed converged minimum losses for both cohorts, this small sample size
may cause model overfitting and decreased generalization. Moreover, the
assumption of a Gaussian distribution in VAE formulation may exhibit a
potential limitation for our study. Finally, there are no other independent
datasets that can be used to validate our results. Future work will involve using
datasets with larger sample sizes and including additional test datasets to

66

further improve our understanding of PTSD stratification the unique signatures
underlying PTSD subgroups.
3.6

Conclusions
We integrated four omics datasets and discovered two clinically-plausible

PTSD subgroups. These subgroups showed significant association with clinical
characterization and molecular differential expression. Supervised classification
with a subgroup-aware classifier showed improved accuracy for PTSD diagnosis.
Future work will involve leveraging knowledge of these subgroups to enable
precision medicine for PTSD.
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Chapter 4
Conclusions
The objective for this research was to apply machine learning approaches
for disease subgroup discovery and classification, applied in particular to PTSD
and, secondarily, cancer. Overall, we completed two applications on PTSD and
two supplementary applications on various forms of cancer.
In chapter 2, we presented the project “Clinical Subgroup-Specific PTSD
Classification and Biomarker Discovery.” Using a cohort of 234 samples with 166
for training and 68 for validation, we applied machine learning approaches to
classify PTSD patients based on three molecular datasets (miRNA-Exosome:
miRNAs enriched in exosomes, miRNA-Deplete: miRNAs in plasma depleted for
exosomes, and Metabolomics). We first divided patients into multiple sets of two
subgroups based on values of 112 clinical and endocrine measurements. We then
performed supervised classification across all samples and within each subgroup
using two feature selection strategies (Recursive Feature Elimination [RFE] and
ANOVA), four classifiers (logistic regression [LR], support vector machine
[SVM], random forest, and extra trees), and 10-fold nested cross validation. We
evaluated each subgroup for significantly improved classification performance by
statistical tests based on accuracy and AUC values. Finally, we combined those
significant clinical features with molecular measurements and constructed an
overall PTSD classifier. We fit all data using the best classification model from
training and selected features as biomarkers. In total, 85 clinical subgroups from
72 clinical and endocrine features led to improved classification performance
compared to the baseline, among which 38 yielded improved performance using
more than one method. Tree-based models yielded the greatest number of
improved subgroups in the Metabolomics and miRNA-Exosome datasets, while
Logistic Regression showed the greatest improvement in the miRNA-Deplete
dataset. Using an overall PTSD classifier including both molecular and clinical
features, we observed that the majority of classification models show improved

68

accuracy in both training and testing. Applied to Metabolomics data, the overall
classifier achieved the best AUC = 0.79 ± 0.13 and accuracy (ACC) = 0.722 ±
0.078 using ANOVA-SVM, which was a significantly better ACC than the
baseline models composed of only molecular or clinical features. Using
miRNA-Exosome data, the ANOVA-LR classifier reached the best AUC = 0.758
± 0.097 and ACC = 0.701 ± 0.116, with a significantly higher ACC than the
baseline model with clinical features. In the miRNA-Deplete data set, the
RFE-SVM classifier reached the best AUC = 0.677 ± 0.134 and ACC = 0.605 ±
0.128. These best-performing models showed fair performance in the validation
samples as well. Finally, we selected the resulting molecular and clinical features
from these models and listed them as potential biomarkers for PTSD.
In chapter 3, we described the project “Multi-Omic PTSD Subgroup
Identification and Clinical Characterization.” Given 284 total samples (124
PTSD positives) from four omics data sets (miRNA-Exosome: miRNAs enriched
in exosomes, miRNA-Deplete: miRNAs in plasma depleted for exosomes,
miRNA-Plasma: total miRNAs in plasma, and Metabolomics) in cohorts of
Training, Validation and Recall, we applied two methods–Similarity Network
Fusion (SNF) and Variational Autoencoder (VAE)–to integrate the data sets.
SNF performs integration by efficiently fusing sample similarities matrices from
each data set into one network representing the full spectrum of underlying data.
Next, spectral clustering is used to identify subgroups from this network. The
VAE method uses a symmetric deep neural network to reconstruct multiple
omics input data sets by estimating data distributions and identifying
representative hidden variables. K-means clustering is then used to identify
subgroups from the lower-dimensional hidden variables. In order to interpret the
subgroups, we tested the associations between identified subgroups and clinical
characteristics. We also calculated differentially expressed molecules between
subgroups in each omics dataset. We then built supervised classification models
for PTSD diagnosis with/without subgroups and compared the accuracy of
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predicting PTSD status in the context of subgroups to the accuracy of predicting
PTSD status without any knowledge of subgroups. Finally, we built a
classification model to predict subgroups in PTSD positive samples. Our results
suggest the presence of 2 PTSD subgroups in 82 training PTSD positive samples,
using both SNF- and VAE-based methods. These subgroups show a significant
association with recalled sample PTSD status change (p-value 0.0213). We also
found that a majority of samples associated with the same subgroups when
comparing results from the two methods. Upon statistical testing for association
of the subgroups with over 600 clinical features, we found a significant
association with features including heart rate and insulin. The two identified
subgroups also exhibit a number of differentially expressed molecules from each
omics data set. For diagnostic classification, we observed improved performance
for subgroup-aware PTSD status prediction in miRNA-Plasma and
Metabolomics data sets using SNF-based subgroups and in all four omics data
sets using VAE-based subgroups. Finally, using our classification model for
subgroup prediction, we found that identified subgroups in the validation cohort
were significantly associated with many of the same clinical features associated
with subgroups from the training cohort.
In two supplementary chapters, we discussed the projects “GEOlimma:
Differential Expression Analysis and Feature Selection Using Pre-Existing
Microarray Data” and “Prognostic Analysis of Histopathological Images Using
Pre-Trained Convolutional Neural Networks: Application to Hepatocellular
Carcinoma (HCC)”. In the former, we first quantified differential gene expression
across 2481 pairwise comparisons from 602 curated Gene Expression Omnibus
(GEO) Datasets, and we converted differential expression frequencies to DE
prior probabilities. Genes with high DE prior probabilities show enrichment in
cell growth and death, signal transduction, and cancer-related biological
pathways, while genes with low prior probabilities were enriched in sensory
system pathways. We then applied GEOlimma to four differential expression
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comparisons within two human disease datasets and performed differential
expression, feature selection, and supervised classification analyses. Our results
suggest that use of GEOlimma provides greater experimental power to detect
DE genes compared to the popular Limma technique, due to its increased
effective sample size. Furthermore, in a supervised classification analysis using
GEOlimma as a feature selection method, we observed similar or better
classification performance than Limma given small, noisy subsets of an asthma
dataset. Due to its focus on gene-level differential expression, GEOlimma also
has the potential to be applied to other high-throughput biological datasets.
In the latter supplementary project, we applied three pre-trained CNN
models–VGG 16, Inception V3, and ResNet 50–to extract features from HCC
histopathological images. Sample visualization and classification analyses based
on these features showed a very clear separation between cancer and normal
samples. In a univariate Cox regression analysis, 21.4% and 16% of image
features on average were significantly associated with overall survival and
disease-free survival, respectively. We also observed significant correlations
between these features and integrated biological pathways derived from gene
expression and copy number variation. Using an elastic net regularized CoxPH
model of overall survival constructed from Inception image features, we obtained
a concordance index (C-index) of 0.789 and a significant log-rank test (p =
7.6E18). We also performed unsupervised classification to identify HCC
subgroups from image features. The optimal two subgroups discovered using
Inception model image features showed significant differences in both overall
(C-index = 0.628 and p = 7.39E-07) and disease-free survival (C-index = 0.558
and p = 0.012). Our work demonstrates the utility of extracting image features
using pre-trained models by using them to build accurate prognostic models of
HCC as well as highlight significant correlations between these features, clinical
survival, and relevant biological pathways. Image features extracted from HCC
histopathological images using the pre-trained CNN models VGG 16, Inception
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V3 and ResNet 50 can accurately distinguish normal and cancer samples.
Furthermore, these image features are significantly correlated with survival and
relevant biological pathways.
Despite the progress we have made applying machine learning to disease
subgroup discovery and classification, we note several potential limitations in our
studies. First, we note that the initial study cohorts for PTSD were restricted to
a pool of men deployed to Iraq and/or Afghanistan with moderate to severe
cases of combat-related PTSD compared to a pool of similarly combat-exposed
asymptomatic controls. During data collection, PTSD diagnosis was formalized
using DSM-IV criteria for consistency across all cohorts. However, the more
recently released DSM-5 details three additional categories of symptoms, which
complicates efforts to reconcile newer datasets with those collected using
DSM-IV. As a result, our discoveries of biomarkers and subgroups may require
further validation in samples using updated collection criteria. Second, the
sample sizes of our PTSD cohorts are relatively small for machine learning given
the high dimensionality of the data. Taking all study cohorts together, there are
a total of 234 samples. To protect against overfitting, we have applied
cross-validation to train classification models, which enables internal evaluation
of these models before validating in a test data set. However, a more robust
strategy will involve validating and expanding our proposed biomarkers using
additional independently collected data sets. Along these lines, the PTSD
Systems Biology Consortium has recently collected a new cohort of nearly 1,800
active duty soldiers from Fort Campbell, KY assayed at some combination of
time points before and after deployment. As before, blood samples and clinical
measurements were collected from these individuals, and the same molecular
markers were isolated and extracted from the blood samples. These data offer
the potential to independently verify our previously discovered biomarkers as
well as improve the identification of both diagnostic and prognostic biomarkers.
Furthermore, such longitudinal data also allow the calculation of “delta
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measurements”–differences in clinical and molecular features pre- and
post-deployment, which enables assessment of effects from the combat events.
Delta measurements redefine features in terms of their differences between two
time points, allowing patient-specific, PTSD-nonspecific variability to be
subtracted away. The data from these “Fort Campbell cohort” samples thus
provide a unique opportunity to identify robust diagnostic and prognostic
biomarkers for PTSD. At last, we found limitations in visualizing features of
pre-trained CNNs for the HCC project.
In order to further improve understanding of our discoveries related to
PTSD, several future directions of research are needed. First, we plan to include
larger collections of PTSD data sets and better remove noise from input data.
Specifically, methods for missing value imputation and batch effect removal
could potentially improve downstream data analysis. In addition, public cancer
data bases and recent applications in cancer studies may provide opportunities
for transfer learning to PTSD. Second, we plan to develop and apply customized
machine learning methods for particular data sources. The success of deep
learning applications in computer vision and natural language processing may
suggest possible transferable applications to biomedical research. However, more
work is required to build customized approaches and benchmarks that are
particularly beneficial for biomedical applications such as precision medicine.
Furthermore, validation from additional clinical studies could help confirm the
biological relevance of our discovered biomarkers. At last, for the GEOlimma
project, future work will involve the application of GEOlimma to RNA-seq data
and develop disease such as asthma specialized GEOlimma approaches.
In conclusion, my dissertation research has involved working
collaboratively to improve our knowledge and understanding of PTSD
biomarkers and subgroups. We have also explored a range of applications of
machine learning to cancer research using public data sets. Future work will
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continue leveraging knowledge of machine learning and deep learning to
ultimately enable precision medicine for human diseases.
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Appendix A
GEOlimma: Differential Expression Analysis and Feature Selection
Using Pre-Existing Microarray Data
A.1

Abstract
Differential expression and feature selection analyses are essential steps

for the development of accurate diagnostic/prognostic classifiers of complicated
human diseases using transcriptomics data. These steps are particularly
challenging due to the curse of dimensionality and the presence of technical and
biological noise. A promising strategy for overcoming these challenges is the
incorporation of pre-existing transcriptomics data in the identification of
differentially expressed (DE) genes. This approach has the potential to improve
the quality of selected genes, increase classification performance, and enhance
biological interpretability. While a number of methods have been developed that
use pre-existing data for differential expression analysis, existing methods do not
leverage the identities of experimental conditions to create a robust metric for
identifying DE genes.
In this study, we propose a novel differential expression and feature
selection method—GEOlimma—which combines pre-existing microarray data
from the Gene Expression Omnibus (GEO) with the widely-applied Limma
method for differential expression analysis. We first quantify differential gene
expression across 2481 pairwise comparisons from 602 curated GEO Datasets,
and we convert differential expression frequencies to DE prior probabilities.
Genes with high DE prior probabilities show enrichment in cell growth and
death, signal transduction, and cancer-related biological pathways, while genes
with low prior probabilities were enriched in sensory system pathways. We then
applied GEOlimma to four differential expression comparisons within two human
disease datasets and performed differential expression, feature selection, and
supervised classification analyses. Our results suggest that use of GEOlimma
provides greater experimental power to detect DE genes compared to Limma,
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due to its increased effective sample size. Furthermore, in a supervised
classification analysis using GEOlimma as a feature selection method, we
observed similar or better classification performance than Limma given small,
noisy subsets of an asthma dataset.
Our results demonstrate that GEOlimma is a more effective method for
differential gene expression and feature selection analyses compared to the
standard Limma method. Due to its focus on gene-level differential expression,
GEOlimma also has the potential to be applied to other high-throughput
biological datasets.
A.2

Introduction
DNA microarrays and RNA sequencing (RNA-Seq) have become

indispensable experimental tools for characterizing the effects of biological
interventions on genome-wide gene expression (“transcriptomics”) [97] [98].
Applications of these tools have been transformative in many areas of biological
research, including cancer biology, biomarker discovery, and drug target
identification [99] [100] [101]. These applications often involve differential
expression analysis: the isolation of differentially expressed (DE) genes between
healthy and disease conditions. Knowledge of DE genes facilitates the discovery
of causative genes and gene pathways for a disease of interest. For example,
many studies of carcinogenesis focus on identifying the genes directly responsible
for promoting cancer occurrence (“driver genes”) out of all DE genes [102] .
Furthermore, DE gene identification is an important first step for disease
biomarker discovery. The discovery of biomarkers from transcriptomics data
typically involves selecting the most discriminative genes between a healthy and
diseased state or between different disease states [103] . A comprehensive list of
DE genes provides a biologically plausible set of candidates for these
discriminative genes and can greatly streamline the search [104]. Common
applications of transcriptomics-derived biomarkers include predicting diagnosis,
prognosis, and therapeutic response for a disease of interest through a process
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known as supervised classification [105]. In this context, DE gene identification
can be viewed as a means of performing feature selection for classification. In
general, feature selection is a process for dimensionality reduction that removes
redundant or irrelevant features (genes), reduces classification model complexity,
and improves classification performance [106].
Despite their widespread use for DE gene identification, transcriptomics
data are notorious for their inclusion of technical and biological noise [107]. This
noise complicates differential expression analysis by reducing the accuracy of DE
gene identification relative to other assays (e.g., real-time or quantitative PCR
[108] ), lowering the reproducibility of experiments conducted on different
platforms [109], and reducing the statistical power associated with the detection
of DE genes at a particular fold change [110]. A straightforward strategy for
mitigating the effects of noise is to increase the number of replicates assayed
(“sample size”) for each condition of interest. However, this practice can be cost
prohibitive or even impossible for conditions with limited sample availability.
Furthermore, even with larger sample sizes, transcriptomics data pose a
considerable challenge to feature selection methods due to the curse of
dimensionality. Specifically, it is well known that optimal fitting of classification
models (including the selection of features) breaks down when the feature
dimensionality is substantially larger than the sample size [43].
One promising solution for the above challenges is to incorporate prior
biological knowledge into differential expression and feature selection analyses
[111]. This Bayesian approach can mitigate problems associated with a small
sample size [112], while also improving biological interpretability of the resulting
DE genes/features [106]. Prior biological knowledge for transcriptomics data can
take several forms, including pre-existing transcriptomics data from other
studies, data from complementary high-throughput assays (e.g., chromatin
immunoprecipitation or protein-protein interactions), and gene functional
annotation (e.g., Gene Ontology [113] [114] or KEGG [115] [116] ). For the
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purposes of this study, we will focus on the first type of knowledge, although we
note that analytical methods are available to incorporate the other types as well
[117] [118]. Thanks to functional genomics repositories like the Gene Expression
Omnibus (GEO)[119] [120] and ArrayExpress [121], transcriptomics data from
over 2.5 million samples are publicly available. Furthermore, the size of this
resource is growing exponentially, with numbers of samples in GEO doubling
every 3-4 years.
Over the last 15 years, a number of methods have been developed that
use prior knowledge in the form of transcriptomics data to inform differential
expression analyses [122] [123] [124] [125] [126]. However, these methods
typically either ignore the identities of the many experimental conditions in the
pre-existing data, or they do not leverage these identities to create a rigorous
statistical metric for identifying DE genes. For example, the SVD Augmented
Gene expression Analysis Tool (SAGAT) uses singular value decomposition
(SVD) to extract transcriptional modules from pre-existing DNA microarray
data [122]. These modules, which contain no information regarding assayed
conditions, are then incorporated into a statistical analog of the two-sample
t-test to improve the accuracy of DE gene identification. In contrast, a very
recent study made direct use of the experimental conditions in pre-existing data
to characterize empirical prior probabilities of differential expression [126].
However, although these prior probabilities were predictive of differential
expression patterns, they were not explicitly utilized in a Bayesian statistical
framework for identifying DE genes. Relatedly, although there have been many
studies contributing novel or adapted feature selection methodologies for
classification of biomedical data [127] [128] [129] [61] [130], to our knowledge no
method combines an experimental condition-aware analysis of pre-existing data
with a statistically principled means of feature selection.
To address these shortcomings, we propose a novel differential expression
and feature selection approach—GEOlimma—that leverages pre-existing
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GEO-derived transcriptomics data. As described below, our proposed method
modifies the popular Linear Models for Microarray and RNA-Seq Data
(“Limma”) method [131][132] . Specifically, GEOlimma incorporates empirical
prior probabilities of differential expression (DE prior probabilities) in a
Bayesian statistical test for DE genes. We first describe the computation and
biological characterization of DE prior probabilities from a large collection of
pre-existing DNA microarray experiments from GEO. Next, we apply
GEOlimma and Limma to four benchmark differential expression comparisons
from two validation datasets. Our results demonstrate a substantial increase in
experimental power for identifying DE genes due to use of GEOlimma. Finally,
we explore GEOlimma’s ability to improve feature selection for classification
across the four benchmark comparisons.
A.3
A.3.1

Materials & Methods
GEOlimma Method Formulation
We developed the GEOlimma method by combining the widely-used

differential expression (DE) analysis method Limma, which is typically used to
analyze gene expression microarray and RNA-seq data and assess differential
expression between biological conditions. Limma uses empirical Bayesian
methods to provide stable DE predictions, which is particularly useful when the
number of sample replicates is small. However, one simplifying assumption made
by Limma is that the DE prior probabilities for each gene are identical (set 0.01
by default). GEOlimma combines the Bayesian nature of Limma with gene-level
DE prior probabilities calculated from large-scale microarray datasets to better
select genes that are biologically relevant to a comparison of interest.
The Gene Expression Omnibus (GEO) is a public data repository for
high-throughput gene expression data including microarray and RNA-seq data
[120]. GEO DataSets (GDS) are a subset of the repository that store curated
gene expression datasets, along with the original data (GEO Series) and
experimental platform information. GPL570, also known as the HG-U133_Plus_2
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Affymetrix Human Genome U133 Plus 2.0 Array, is one of the best-represented
human genome microarray platforms in GEO, with 149,049 samples available (as
of June 7, 2019). GPL570 measures over 47,000 human transcripts, which consist
of the Human Genome U133 Set plus 6,500 additional genes. In this study, we
downloaded all 602 GPL570 GEO DataSets (GDS) (current as of June 7, 2019).
Specifically, for each dataset we obtained normalized, log-transformed expression
values at the probeset level. We then mapped these probesets to the
non-redundant Entrez Gene IDs (provided by the Bioconductor R package
hgu133plus2.db) and obtained gene-level expression values by computing
medians across any probe sets mapping to the same gene. With the minimum
requirement of 5 samples in each group, we performed pairwise DE analysis
among the largest possible collection of non-overlapping sample groups from each
GDS experiment. Specifically, for each DE comparison, we applied the Limma
moderated t-test [133] (using the “lmFit” and “eBayes” functions) to calculate
differential expression p-values for each gene. Given a list of p-values for a
particular comparison, we adjusted for multiple hypothesis testing using the
Benjamini-Hochberg (BH) procedure [86]. Genes with adjusted p-values (false
discovery rates or FDRs) ≤0.05 for a given pairwise comparison were considered
DE for that comparison. We calculated the DE frequencies across all
comparisons for each gene and converted these frequencies to DE prior
probabilities (P(DE)) as follows:
P
P (DEi ) =

j

I(Adj.Pij ≤ 0.05)
M

(A.1)

where i ∈ {1, . . . , N } indexes each gene, j ∈ {1, . . . , M } indexes each
comparison, Adj.Pij represents the FDR for the i-th gene in the j-th comparison,
and I(·) is the indicator function.
We chose human asthma and cancer validation datasets present as GEO
Series (GSE) but not as GEO DataSets (GDS), in order to avoid double
counting data. The asthma dataset [134] consists of 404 total samples
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(transformed lymphoblastoid cell lines) taken from 268 children afflicted with
asthma and 136 healthy children. The cancer dataset [135] consists of 870 total
bone marrow samples, of which 202, 164, and 69 are from individuals with acute
myeloid leukemia (AML), myelodysplastic syndrome (MDS), and neither AML
nor MDS, respectively. We considered the three possible comparisons between
these three groups. In total, we evaluated four comparisons: Asthma vs
Non-asthma, Nonleukemia vs AML, Nonleukemia vs MDS, and AML vs MDS.
For a given comparison, we compute GEOlimma DE posterior
probabilities using Bayes’ theorem:

P (DEi | Data) =

P (Data | DEi ) P (DEi )
P (Data)

(A.2)

where Data represents the samples making up the given comparison,
P (Data | DEi ) denotes the likelihood of the Data, as calculated by limma [131],
P (DEi ) is the previously calculated DE prior probability, and P (Data) is a
normalization constant [131]. Given these posterior probabilities, we then
calculate B scores (log odds of DE) for each gene as follows:
h P (DE | Data) i
i
Bi = log
1 − P (DEi | Data)

(A.3)

We implemented GEOlimma as modified R functions based on code from
the Limma package.
A.3.2

Enrichment Analysis for Gene Sets
To explore the DE prior probabilities biologically, we conducted KEGG

Enrichment Analysis using the R package ClusterProfiler [136]. Specifically, we
identified enriched KEGG pathways using the hypergeometric test in both the
top and bottom 500 most/least frequently DE genes, separately. Pathways with
BH-adjusted p-values less than 0.05 were considered significantly enriched. We
used the Pathview R package [137] to visualize the location of DE genes in
particular KEGG pathways.
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A.3.3

Differential Expression Analysis
Evaluation datasets As described above, we downloaded the GSEs for

two evaluation datasets from GEO. As with the GDS data, we mapped
normalized, log-transformed expression values at the probeset level to
non-redundant Entrez Gene IDs and consolidated expression values by
computing medians across probe sets mapping to the same gene. We included all
genes with unique probe mappings (20283 total) for subsequent analyses. For
each of the four evaluation comparisons, we performed DE analysis on all
samples using both GEOlimma and Limma. Genes were considered DE if their
BH-adjusted p-value ≤0.05 (Limma) or their B score exceeded the smallest
Limma B score for genes with adjusted p-value ≤0.05 (GEOlimma).
Sample Visualization To visualize samples, we first used Principal
Component Analysis (PCA) to reduce the dimensionality of genes as features.
We visualized the first two components of PCA. We further applied the
t-Distributed Stochastic Neighbor Embedding (t-SNE) method to visualize the
first 10 PCA components in 2 dimensions. t-SNE can reduce the dimensionality
of data based on conditional probabilities that preserve local similarity. We used
a t-SNE implementation that makes Barnes-Hut approximations, allowing it to
be applied on large real-world datasets [138]. We set the perplexity to 15, and
sample points were colored using the group information.
Experimental power To quantify the performance improvement
achieved by GEOlimma vs Limma, we performed DE analysis on small sample
size subsets for each comparison. As detailed below, we started with the
minimum subset size at which the group proportions for a given comparison
could be maintained and generated all non-overlapping sample subsets of this
size. We then increased this subset size by the smallest possible sample increment
and repeated the generation of subsets. For each sample subset, we first applied
both GEOlimma and Limma and ranked genes by their corresponding B scores.
Next, using the Limma DE genes previously identified from all samples as the
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ground truth (see Results section for specific numbers), we applied the R
package ROCR [139] to calculate Area under the ROC curves (AUCs) for the B
score-ranked genes of each subset. We calculated the performance improvement
of GEOlimma over Limma for each subset as the difference in AUC between the
two methods. In addition, we converted these AUC improvements into gains in
effective sample size by constructing and interpolating from a “standard curve” of
mean Limma AUC values calculated across the full range of possible sample
sizes. As an example, if GEOlimma delivered an AUC improvement of 0.1 over
Limma for a subset of size 10, the GEOlimma effective sample size is simply the
sample size of the standard curve corresponding to an AUC value 0.1 higher
than the mean Limma AUC value for 10-sample subsets.
A.3.4

Supervised Classification
We performed supervised classification for each comparison in the

evaluation datasets using both GEOlimma and Limma as feature selection
methods. Scikit-learn (sklearn) [140] is a Python module implementing machine
learning algorithms. It enables various tasks such as dimensionality reduction,
classification, regression and model selection. The sklearn classification pipeline
involves sequentially applying feature selection, classification, parameter
optimization and model selection to yield final classification results. We first
used the Python rpy2 module to build a connection between sklearn and the R
language, followed by creating customized feature selection methods for Limma
and GEOlimma which we compiled into the sklearn pipeline function. For
classification training, we first sampled 10 subsets of 40 samples (20 from each of
the two groups) at random and selected the 1000 genes with largest variance
across these samples. Next, we fed data from each subset to the sklearn pipeline
function and performed either Limma or GEOlimma-based feature selection by
selecting subsets of 100-1000 genes (in increments of 100) with the highest B
scores. We selected the Logistic Regression [141] classifier for classification. We
also included L1 and L2 penalties as hyperparameters and applied 10-fold cross
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validation to train the model and optimize the hyperparameters. We used
classification AUC as the criterion to evaluate classification performance. A high
AUC represents both high recall and high precision, which translate to low false
positive and false negative rates. For classification testing, we sampled an
additional 40 samples to evaluate the training models. We used a Wilcoxon
signed-rank test to identify significant AUC differences between performing
feature selection using Limma or GEOlimma.
A.4

Results
In this study, we developed a gene expression feature selection method,

GEOlimma, in which gene-level differential expression (DE) prior probabilities
were derived from large-scale microarray data freely available from the Gene
Expression Omnibus (GEO). We first explored enriched biological pathways in
genes with either high or low DE prior probabilities. We then applied
GEOlimma to DE analysis and supervised classification tasks on a collection of
four validation datasets.
A.4.1

Biological Analysis of DE Prior Probabilities
The goal of differential expression analysis is to identify differences in

gene expression across biological conditions in order to discover functional genes
and pathways involved in a biological process of interest. The Limma method
[133] is an empirical Bayesian approach for identifying DE genes that has been
widely applied. However, an important limitation of this method is that the
prior probabilities for differential expression are set to be constant for all genes.
This implies that all genes have the same chance of being expressed differently,
which is not biologically realistic [126]. Therefore, we developed and applied
GEOlimma, which uses a large collection of GEO datasets to compute gene level
DE prior probabilities (see Methods section). We first downloaded the 602 GEO
DataSets (GDS) currently available from the GPL570 platform (Affymetrix
Human Genome U133 Plus 2.0 Array), followed by performing pairwise DE
analysis among the largest possible collection of non-overlapping sample groups
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(number of samples 5) from each GDS experiment. We identified DE genes
using a Benjamini-Hochberg false discovery rate (FDR) threshold of 0.05. By
repeating this procedure for every GDS, we calculated DE frequencies for 21025
distinct Entrez genes (20283 genes with unique gene mappings) across all
experiments (2481 pairwise comparisons total) and converted these to prior
probabilities of DE. Given gene-level DE prior probabilities, we can then
compute posterior probabilities of DE for a given biological experiment using
Bayes’ theorem. Figure B.1 shows the distribution of DE prior probabilities,
which ranged between 0.0048 and 0.1769 and appeared to have two modes. The
median probability is 0.069, which we note is roughly seven times higher than
the default constant prior probability used by Limma (0.01). Figure SFigure1
lists the top most frequently DE genes, including TUBA1A (tubulin alpha 1a),
CD24, and SERPINB1 (serpin family B member 1), with DE prior probabilities
of 0.1769, 0.1761, and 0.1693, respectively. The three least frequently DE genes
were LOC102725116, TMCO5A (transmembrane and coiled-coil domains 5A),
and LINC01492 (long intergenic non-protein coding RNA 1492), with DE prior
probabilities of 0.0048, 0.0056, and 0.0060, respectively. Generally speaking, we
hypothesize that genes with high prior probabilities of DE are more likely to be
implicated in human disease and thus could function as biomarkers, while those
with low DE prior probabilities represent constitutively expressed genes that are
required for the maintenance of basic cellular functions (i.e., housekeeping genes).
In order to improve our biological understanding of the calculated DE
prior probabilities, we performed gene set enrichment analysis (GSEA) based on
KEGG pathways with the top 500 most and least frequently DE genes,
respectively. Table B.1 lists significantly enriched pathways (BH-adjusted
p-value ≤0.05), which include 19 pathways from the most frequently DE genes
and 4 from the least frequently DE genes. The most significant pathway in the
former category is hsa04110: Cell cycle (adjusted p = 7.83E-08); Figure B.2
illustrates the frequently DE genes mapped in this pathway. Two additional
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Fig. A.1: Distribution of DE prior probabilities for 20283 genes, calculated from
2481 pairwise comparisons made within 602 curated GEO Datasets.
pathways in this category directly related to cell growth and death include
hsa04115: p53 signaling pathway and hsa04210: Apoptosis. We also identified
six cancer-specific frequently DE pathways: hsa05222: Small cell lung cancer,
hsa05206: MicroRNAs in cancer, hsa05218: Melanoma, hsa05202:
Transcriptional misregulation in cancer, hsa05205: Proteoglycans in cancer, and
hsa05220: Chronic myeloid leukemia. Finally, the two frequently DE pathways
hsa04068: FoxO signaling pathway and hsa04668: TNF signaling pathway
function in Signal transduction. We note that signal transduction pathways are
involved in cell death mechanisms that function in colorectal carcinogenesis
progression [142].
The 4 least frequently DE pathways include two sensory system pathways:
hsa04740: Olfactory transduction and hsa04742: Taste transduction, Signaling
molecules and interaction pathway. The other two significant pathways in this
category were hsa04080: Neuroactive ligand-receptor interaction and hsa05320:
Autoimmune thyroid disease. Our results suggest that genes belonging to these
pathways show relatively stable expression across different biological conditions.
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Table A.1: KEGG Enrichment Analysis of top 500 genes with high and low DE
prior probabilities.
Pathway Description
GeneRatio
IDs
hsa04110 Cell cycle
21/242
hsa05222 Small cell lung can- 13/242
cer
hsa04115 p53 signaling path- 11/242
way
hsa05169 Epstein-Barr virus 18/242
infection
hsa05206 MicroRNAs in can- 23/242
cer
hsa05218 Melanoma
10/242
HighPrior
hsa05202 Transcriptional
17/242
misregulation
in
cancer
hsa04210 Apoptosis
14/242
hsa05205 Proteoglycans
in 17/242
cancer
hsa04068 FoxO
signaling 13/242
pathway
hsa05418 Fluid shear stress 13/242
and atherosclerosis
hsa05220 Chronic
myeloid 9/242
leukemia
hsa03030 DNA replication
6/242
hsa05130 Pathogenic
Es- 7/242
cherichia
coli
infection
hsa04540 Gap junction
9/242
hsa01524 Platinum drug re- 8/242
sistance
hsa05167 Kaposi
sarcoma- 14/242
associated
herpesvirus infection
hsa04380 Osteoclast differen- 11/242
tiation
hsa04668 TNF
signaling 10/242
pathway
hsa04740 Olfactory transduc- 17/68
tion
hsa04742 Taste transduction 8/68
hsa04080 Neuroactive ligand- 14/68
receptor interaction
hsa05320 Autoimmune thy- 4/68
roid disease

BgRatio Pvalue
124/7528 2.94E-10
93/7528 7.47E-06

P value Ad- Source
justment
7.83E-08
HighPrior
9.94E-04
HighPrior

72/7528 1.61E-05

1.43E-03

HighPrior

201/7528 7.63E-05

3.57E-03

HighPrior

299/7528 8.53E-05

3.57E-03

HighPrior

72/7528 9.09E-05

3.57E-03
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186/7528 9.40E-05

3.57E-03

HighPrior

136/7528 1.12E-04
201/7528 2.42E-04

3.71E-03
7.15E-03

HighPrior
HighPrior

132/7528 3.05E-04

8.11E-03

HighPrior

139/7528 5.05E-04

1.22E-02

HighPrior

76/7528 6.87E-04

1.52E-02

HighPrior

36/7528 8.98E-04
55/7528 1.77E-03

1.84E-02
3.36E-02

HighPrior
HighPrior

88/7528 1.97E-03
73/7528 2.25E-03

3.50E-02
3.74E-02

HighPrior
HighPrior

186/7528 2.60E-03

3.83E-02

HighPrior

128/7528 2.67E-03

3.83E-02

HighPrior

110/7528 2.74E-03

3.83E-02

HighPrior

448/7528 2.91E-07

3.08E-05

LowPrior

83/7528 6.70E-07
338/7528 1.40E-06

3.55E-05
4.96E-05

LowPrior
LowPrior

53/7528 1.28E-03

3.39E-02

LowPrior
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Fig. A.2: Significantly enriched Cell Cycle pathway from genes with high DE
prior probabilities. The red shaded blocks indicate genes with high prior
probabilities.
A.4.2

GEOLimma method application on four validation datasets
We investigated the utility of gene-specific DE prior probabilities by

performing DE analysis with GEOlimma in four evaluation datasets.
Specifically, we selected two GEO series—GSE8052 and GSE15061— from
platform GPL570 that enabled four DE comparisons to be made. Importantly,
neither of these datasets was represented by a GEO GDS, meaning that none of
the resulting comparisons were involved in DE prior probability computation.
The four comparisons include Asthma vs Non-asthma (GSE8052) and three
comparisons from GSE15061: Nonleukemia (Nonleuk) vs Myelodysplastic
syndrome (MDS), Nonleuk vs acute myeloid leukemia (AML), and AML vs
MDS. The probes for each of the datasets are represented by 20283 genes with
unique mappings. Any genes without available DE prior probabilities were
assigned the median value of all prior probabilities. We first identified DE genes
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using GEOlimma as well as the standard Limma method. This allowed us to
compare the two methods, as well as characterize the extent of differential
expression present in each comparison. For Limma, we considered genes to be
DE if their BH-adjusted p-value ≤ 0.05. In contrast, as GEOlimma enables the
calculation of a modified B score only (see Methods), we selected a B score
threshold for GEOlimma significance based on the smallest Limma B score for
which the Limma adjusted p-value ≤ 0.05. Using these criteria, we identified DE
genes based on all relevant samples for each of the four comparisons described
above. To assess the effect of small sample sizes on GEOlimma/Limma
performance, we also randomly sampled 10 subsets of 40 samples (20 in each
class) for each comparison and calculated the mean and standard deviation of
the number of DE genes across these subsets using both methods. Table B.2 lists
details of each DE comparison along with summaries of our analysis results using
both Limma and GEOlimma. We note that for the Asthma comparison, there
are no significant DE genes based on all samples (as well as in subsets) using the
Limma method. Therefore, we were not able to quantify the number of DE genes
for this comparison using GEOlimma. In the remaining three comparisons, our
results demonstrate that GEOlimma identifies more DE genes than Limma when
applied to either all samples or 40-sample subsets. Figure B.3 A helps illustrate
why this is, by examining the distributions of Limma and GEOlimma B scores
for the Asthma comparison. Despite the lack of significant DE genes in this
comparison, use of GEOlimma results in a wider B score distribution with a
marked shift to higher values compared to Limma. This difference is due to the
diverse set of gene-specific DE prior probabilities used by GEOlimma, the
median value of which is substantially higher than the constant value used by
Limma. The potential increase in numbers of DE genes identified by GEOlimma
also suggests that use of a small constant DE prior probability may result in
overly conservative DE gene identification. In our PCA and t-SNE visualizations
of all samples (Figures B.3 B and C), we note the lack of clear separation
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Fig. A.3: B score change and sample visualizations of asthma dataset. The top
figures are generated from all samples; the bottom figures are drawn using a
random subset with 40 samples. (A) and (D) depict Limma and GEOlimma B
score distributions of all genes, (B) and (E) show PCA visualizations of samples,
and (C) and (F) show t-SNE sample visualizations.
between the Asthma and Non-asthma groups, which helps explain why no
significant DE genes were detected. Figures B.3 D, E, and F show the same
information for a randomly selected subset of 40 samples. We note that the B
scores have a similar distribution as that of all samples.
Table A.2: Differential expression comparison details Limma and GEOlimma DE
gene counts for all samples and 10 subsets of 40 samples of each comparison.
Datasets

Samples Limma GEOlimma Limma DEGs* GEOlimma
DEGs DEGs
DEGs*
non- 268:136 0
–
0
–

Asthma vs
asthma [134]
Nonleuk vs MDS 164:69 2619
5823
98.5±161.4
404.3±600.9
[135]
Nonleuk vs AML 202:69 8610
13379
2788.9±901.5 5879.3±1415.2
[135]
AML vs MDS [135] 164:202 10975 15337
2881.5±1068.7 6017±1666.7
* indicates DE tests of subset samples
When looking at the top 20 most significantly DE genes for each
comparison, we noted that use of GEOlimma changes the order of these genes
compared to Limma, with an overall higher average B score (Figures SFigure2 ).
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To further explore this phenomenon, we counted the genes in common for the
top 100 to 1000 most significantly DE genes between GEOlimma and Limma
across 10 randomly selected 40-sample subsets for each comparison. The average
overlap percentages were 67.3% for the Asthma comparison, 87% for Nonleuk vs
MDS, while over 95% for both AML vs MDS (95.2%) and Nonleuk vs AML
(95.5%)(Figure SFigure3). These results suggest that GEOlimma DE prior
probabilities have a larger effect on the resulting DE gene list for datasets
showing a more modest overall degree of differential expression (e.g., Asthma
and Nonleuk vs MDS comparisons).
In order to explore the practical benefits of using GEOlimma, we
compared the accuracy of DE gene identification between GEOlimma and
Limma for each of the four DE comparisons. For each comparison, we first
performed DE analysis on all samples using Limma, with the resulting significant
DE genes (n = 1241 [FDR ≤ 0.4], 2619 [FDR ≤ 0.05], 8610 [FDR ≤ 0.05], and
10975 [FDR ≤ 0.05] for the Asthma, Nonleuk vs MDS, Nonleuk vs AML, and
AML vs MDS comparisons) being treated as the ground truth. We note that we
relaxed the significance thresholds for the Asthma comparison in order to include
a sufficient number of DE genes for subsequent evaluation. Next, we randomly
generated non-overlapping sample subsets for each comparison based on the
minimum sample size at which the group proportions of the dataset could be
maintained. For example, as GSE8052 contains 66% Asthma and 34%
Non-asthma samples, the smallest sample size considered was 6 (4 Asthma, 2
Non-asthma) in order to ensure 2 samples per group. We then increased this
sample size in increments of 3 to also consider subsets of 9, 12, and 15 samples.
We then applied both GEOlimma and Limma on each of the sample subsets to
determine which method best recovered the ground truth. Specifically, we used
the R package ROCR [139] to compute areas under the receiver operating
characteristic curve (AUCs) given the GEOlimma/Limma B scores and the
ground truth. Figure B.4 depicts the AUC improvement of GEOlimma over

108

Limma for all four comparisons. Notably, GEOlimma consistently increases the
average AUC for each of the subset sizes, with an overall average AUC
improvement of 0.04. Furthermore, in the three comparisons made within
GSE15061, GEOlimma increases AUC for every subset tested. Interestingly, the
AUC improvement is largest for the smallest sample sizes evaluated and
decreases slightly as sample size increases. This further supports the assertion
that GEOlimma has a bigger impact on datasets with more modest expression
differences (as would result from a small sample size). To confirm that these
improvements result specifically from the DE prior probabilities learned using
publicly available GPL570 data, we randomly shuffled the prior probabilities and
repeated the above analysis. As seen in Figure SFfigure4, GEOlimma using
randomized prior probabilities consistently decreases AUC compared to Limma.
To quantify the experimental power gained by using GEOlimma, we
converted AUC values into effective sample size. Specifically, for each of the
evaluation datasets, we first calculated AUCs resulting from applying Limma to
all non-overlapping sample subsets ranging in size from the minimum number
needed to maintain group proportions (described above) to the total number of
replicates. For example, in the Asthma comparison we considered all subsets of
size 6 to 402 in increments of 3. These AUCs enabled us to fit a “standard curve”
for each comparison, from which we could interpolate the mean number of
samples gained by using GEOlimma given initial numbers of 6, 9, 12, and 15
(Asthma) samples. Figure SFigure5 presents the AUC standard curves and
Table B.3 summarizes the distribution of GEOlimma effective sample sizes for
each comparison. Overall, GEOlimma leads to a substantial increase in mean
effective sample sizes, particularly when applied to smaller subsets, where we
observed gains of 157-288% for the smallest sample sizes evaluated for each
comparison. The Asthma comparison shows the largest relative increases across
all subsets, with the mean GEOlimma effective sample size more than doubling
that of Limma even for the largest subset tested (m = 15). These results

109

A

●

AUC improvement

●

0.10
0.05
0.00

−0.05

AUC improvement

C

●

● ●
●
●●●
●● ●
●
● ●
●
●
●●
●
●
●●
● ●●●● ●● ● ●● ● ●● ●
● ●●●
● ●●
●● ● ●● ● ●
●
●●
●
●
●
●
●
●
●● ●● ●● ● ●● ●
● ●● ● ●● ●● ●● ● ●●●
●
●
● ●●
● ● ● ●●● ● ●● ●
●
● ●●
●●
●
● ● ●●
●
●●● ●● ●● ● ●● ●●● ●
●●
●
●
●●
●●
●
●● ●
● ●
●
●
● ●
●
●
●●
●
●
●
●●
●● ● ●●
●
●
●
●
●●
●
●
●
● GEOlimma n=6
●
● GEOlimma n=9
● GEOlimma n=12
●
● GEOlimma n=15

0

50

0.15

●
● ●

●
●

0.10

●
●

0.05

●

●

●

● ●

100

●
●

●

●

●

●

●●

●
●
●
●

0

0.02
0.00
−0.02

D

0.10
0.08

●

●

0.06

●
● ●

●●

●
●●

0.00

0.04

●

●●

● ●

●

0.06

●

●

●

0.04

●●
● ●

0.02
0.00

GEOlimma n=8
GEOlimma n=12
GEOlimma n=16
GEOlimma n=20

10

0.10
0.08

150

trial

●
● ●

B

−0.02

20

trial

30

40

●

●

● ●
●
●
●
● ● ● ●● ● ● ●
●●
●● ●
● ● ● ●●● ●●
●
● ● ●
●●
●
●
●
●
● ●
●
●●
● ●●● ● ● ●●● ● ● ● ●
●
●
●
●
●
●
●
●
●
● ● ● ● ● ●
●
●● ● ● ● ●●
●
● ●
●
●

●
●
●
●

GEOlimma n=8
GEOlimma n=12
GEOlimma n=16
GEOlimma n=20

0

20

40

trial

60

80

●
● ●●
●
● ● ● ●●●●
●●
●
● ● ●● ● ● ●
●
●● ●
●●● ● ●
●
●
● ●
●
●
●
●
●
●
●
● ● ●
●
●
●
● ● ● ●
●
●●
● ●●
●
●
●●
● ●
●●● ●●
●
●●● ● ●
●●●●●
●
●
●
●
●
●
●

GEOlimma n=9
GEOlimma n=18
GEOlimma n=27
GEOlimma n=36

0

20

40

trial

60

80

Fig. A.4: Area under the ROC curve (AUC) improvement of GEOlimma over
Limma for identifying DE genes from a range of data subset sizes: A) Asthma vs
Non-asthma comparison, B) Nonleukemia vs AML comparison, C) Nonleukemia
vs MDS comparison, D) AML vs MDS comparison.
demonstrate the gains in experimental power for DE gene discovery that are
possible with the use of GEOlimma.
A.4.3

Classification performance using GEOLimma feature selection
method
Feature selection is a critical step in supervised classification for

diagnosis, prognosis and treatment. Here we compare the abilities of GEOlimma
and Limma as feature selection methods to perform accurate classification on the
four evaluation datasets. To focus on the most challenging classification tasks for
each comparison, we randomly sampled subsets of size 20 from each of the two
groups. Specifically, we generated 10 pairs of subsets for training, with each pair
containing 40 total samples (20 per group). In the same manner, we also
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generated an additional 10 pairs of samples for testing. During training, we
performed 10-fold cross-validation to estimate model performance. Given the
large numbers of genes present in these datasets, we focused on the 1000 genes
with the highest variance across all samples within each comparison. Within
these 1000 genes, we selected the top 100-1000, in increments of 100, using either
Limma or GEOlimma and performed classification using a logistic regression
(LR) classifier. For each sampled subset, we applied a one-sided (hypothesis:
GEOlimma AUC > Limma AUC) paired Wilcoxon test to compare the AUC
differences between GEOlimma and Limma at each feature size (10 total).
Because of the near perfect AUC observed for subsets of the AML vs MDS and
Nonleuk vs AML comparisons, we only evaluated AUC differences for the
Asthma and Nonleuk vs MDS comparisons using the Wilcoxon test. Table A.3
shows the mean AUC differences of Asthma for each of the 10 pairs of
subsets.Although many of the subsets do not show a significantly higher
GEOlimma AUC, we note that the average GEOlimma - Limma AUC difference
for both training and testing subsets is positive. Furthermore, subset pairs 7 and
9 show a significant GEOlimma AUC improvement in both training and testing
subsets, while none of the negative AUC differences observed were significantly
less than 0 (hypothesis: Limma AUC > GEOlimma AUC) in training sets.
Figure B.5 shows the GEOlimma and Limma AUC values at each number of
features for subset pairs 7 (A) and 9 (B). For the Nonleuk vs MDS comparison,
we find no significant differences between GEOlimma and Limma AUCs in
training or testing subset pairs. Figure B.5(C) shows one example of a training
pair for this comparison. Overall, our results suggest that use of GEOlimma for
feature selection can provide moderate improvements in classification
performance for datasets with a modest overall degree of differential expression
(e.g., Asthma comparison). For datasets with more pronounced degrees of
differential expression, use of GEOlimma resulted in very similar classification
performance compared to Limma.
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Fig. A.5: Classification performance of data subsets using a logistic regression
classifier with GEOlimma and Limma feature selection methods. The x-axis
indicates the number of selected features; y-axis indicates classification AUC.
The top three plots display training AUC values; the bottom three plots depict
validation AUCs. A) Asthma vs Non-asthma subset 7 AUCs, B) Asthma vs
Non-asthma subset 9 AUCs, C) Nonleukemia vs MDS subset 9 AUCs.
Table A.3: Differences in classification performance (GEOlimma AUC - Limma
AUC) for 10 data subsets of the Asthma comparison. Bold p-values (Wilcoxon
signed-rank test) denote statistically significant AUC improvements of
GEOlimma over Limma.
Sample Order
1
2
3
4
5
6
7
8
9
10
*asthma dataset on LR classification

A.5

AUCdiff
0.0075
-0.0275
-0.0075
-0.0075
-0.0175
-0.03
0.0675
0.025
0.0525
-0.0075

Wilcox p Value
2.36E-01
8.53E-01
6.07E-01
7.79E-01
9.31E-01
8.97E-01
3.98E-02
1.04E-01
1.23E-02
7.36E-01

VadAUCdiff
-0.01425
0.01375
-0.025
0.00525
0.0105
-0.0085
0.06025
-0.007
0.0385
-0.001

Wilcox p Value
9.78E-01
1.43E-01
9.97E-01
2.39E-01
3.12E-01
7.23E-01
9.77E-04
7.54E-01
1.95E-03
7.93E-01

Discussion
In this study, we developed a differential expression feature selection

method, GEOlimma, in which we calculated gene-level differential expression
(DE) prior probabilities from large-scale GEO transcriptomics data and
incorporated them into a Bayesian framework. In a DE analysis, GEOlimma
detected a larger number of DE genes in four comparisons within two evaluation
datasets, compared to Limma. By analyzing small sample subsets of each
dataset, we showed that knowledge-driven GEOlimma substantially improved
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experimental power in terms of effective sample size. Furthermore, in a
supervised classification analysis, GEOlimma used as a feature selection
technique led to similar or better classification performance than standard
Limma given noisy, small sample subsets from the Asthma comparison.
We also biologically characterized genes with especially high or low DE
prior probabilities using KEGG pathway enrichment analysis. The strongest
signal came from genes with high DE prior probabilities, where we detected
enrichment in cell growth and death, signal transduction and cancer-related
pathways. Cell growth and death are fundamental biological processes; however,
deregulation of these processes is often involved in carcinosis. Specifically,
resisting cell death and sustaining proliferative signaling were reported to be
hallmarks of cancer [143]. This prevalence of enriched cancer-specific pathways
may be indicative of an over-representation of cancer-related studies in data
repositories such as GEO, which has been previously reported [144] [123].
However, while we saw excellent improvements in experimental power in
differential expression analysis of three cancer-related comparisons, we note that
the largest relative increases in effective sample size were observed in the Asthma
comparison. This suggests that GEOlimma can also provide a substantial benefit
to datasets that are unrelated to cancer.
We closely modeled GEOlimma after the widely-used differential
expression analysis method Limma. Since its first publication nearly 15 years
ago, papers describing the Limma method [145] [133] [132] have been cited over
10,000 times for applications in differential expression analysis of DNA
microarray or RNA-Seq transcriptomics data. For the latter application, the
more recently-developed voom method [145] adapts the Limma empirical
Bayesian framework to read count data, which enables computation of posterior
DE probabilities for RNA-Seq experiments. Although we only applied
GEOlimma to DNA microarray data in this study, our approach is readily
transferable to RNA-Seq data through the use of the voom methodology.
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In this study, we made use of all available GPL570 GEO datasets (GDS),
which we acknowledge represent a relatively small subset of all available GPL570
data at GEO. We made this selection in large part due to the high-quality
curation of GDS datasets compared to the more abundant GSEs, which allowed
us to easily perform multiple differential expression comparisons within each
dataset. Given recent advances in natural language processing and the
extraction of experimental metadata (e.g., [146] ), an exciting future direction is
the automatic annotation and inclusion of the larger number of GSEs (5154 for
GPL570 as of June 2019) in the DE prior probability calculations. Such an
expansion of a pre-existing data collection would enable subdivision and
calculation of condition-specific DE prior probabilities (e.g., stem cell-related or
viral infection-related), which could further improve GEOlimma performance
when applied to the analysis of related datasets. One final future direction is the
generalization of GEOlimma DE prior probabilities from individual values to
probability distributions. In this case, DE hyperprior parameters could be
calculated from pre-existing data rather than explicit prior probabilities. This
modification would enable a more nuanced adjustment of DE posterior
probabilities by GEOlimma given the biological characteristics of the dataset of
interest.
A.6

Conclusions
Overall, our results demonstrate that GEOlimma effectively utilized

pre-existing transcriptomics data for improved differential expression and feature
selection analyses. Due to its focus on gene-level differential expression,
GEOlimma also has the potential to be applied to other high-throughput
biological datasets.
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Appendix B
Prognostic Analysis of Histopathological Images Using Pre-Trained
Convolutional Neural Networks: Application to Hepatocellular
Carcinoma
B.1

Abstract
Histopathological images contain rich phenotypic descriptions of the

molecular processes underlying disease progression. Convolutional neural
networks (CNNs), state-of-the-art image analysis techniques in computer vision,
automatically learn representative features from such images which can be useful
for disease diagnosis, prognosis, and subtyping. Hepatocellular carcinoma (HCC)
is the sixth most common type of primary liver malignancy. Despite the high
mortality rate of HCC, little previous work has made use of CNN models to
explore the use of histopathological images for prognosis and clinical survival
prediction of HCC.
We applied three pre-trained CNN models – VGG 16, Inception V3, and
ResNet 50 – to extract features from HCC histopathological images. Sample
visualization and classification analyses based on these features showed a very
clear separation between cancer and normal samples. In a univariate Cox
regression analysis, 21.4% and 16% of image features on average were
significantly associated with overall survival and disease-free survival,
respectively. We also observed significant correlations between these features and
integrated biological pathways derived from gene expression and copy number
variation. Using an elastic net regularized CoxPH model of overall survival
constructed from Inception image features, we obtained a concordance index
(C-index) of 0.789 and a significant log-rank test (p = 7.6E18). We also
performed unsupervised classification to identify HCC subgroups from image
features. The optimal two subgroups discovered using Inception model image
features showed significant differences in both overall (C-index = 0.628 and p =
7.39E-07) and disease-free survival (C-index = 0.558 and p = 0.012). Our work
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demonstrates the utility of extracting image features using pre-trained models by
using them to build accurate prognostic models of HCC as well as highlight
significant correlations between these features, clinical survival, and relevant
biological pathways.
Image features extracted from HCC histopathological images using the
pre-trained CNN models VGG 16, Inception V3 and ResNet 50 can accurately
distinguish normal and cancer samples. Furthermore, these image features are
significantly correlated with survival and relevant biological pathways.
B.2

Introduction
Histopathological images contain rich phenotypic descriptions of the

molecular processes underlying disease progression and have been used for
diagnosis, prognosis, and subtype discovery [147]. These images contain visual
features such as nuclear atypia, mitotic activity, cellular density, tissue
architecture and higher-order patterns, which are typically examined by
pathologists to diagnose and grade lesions. The recent accumulation of scanned
and digitized whole slide images (WSI) has enabled wide application of machine
learning algorithms to extract useful information and assist in lesion detection,
classification, segmentation, and image reconstruction [148].
Deep learning is a machine learning method based on deep neural
networks that has been widely applied in recent computer vision and natural
language processing tasks [149]. A convolutional neural network (CNN), a class
of deep learning architecture commonly used in computer vision, automatically
learns representative features from images. CNNs have been dominant since
their astonishing results at the ImageNet Large Scale Visual Recognition
Competition (ILSVRC) [150]. In various studies, CNNs have shown good
performance when applied to medical images, including those from radiology
[151] [152] [153]. Additional applications of CNNs in the areas of diabetic
retinopathy screening [154], skin lesion classification [155], age-related macular
degeneration diagnosis [156] and lymph node metastasis detection [157] have
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demonstrated expert-level performance in these tasks. In addition, a recent
study applied CNN models to develop a content-based histopathological image
retrieval tool for improving search efficiency of large histopathological image has
archived [158]. Compared with traditional machine learning techniques, CNNs
have achieved significantly improved performance in the areas of image
registration for localization, detection of anatomical and cellular structures,
tissue segmentation, and computer-aided disease prognosis and diagnosis [159].
One disadvantage of CNNs is their need for massive amounts of data,
which can be a challenge for biomedical image analysis studies. Furthermore,
deep feature learning depends on the size and degree of annotation of images,
which are often not standardized across different datasets. One possible solution
for analyzing image datasets with a small sample size is transfer learning, in
which pre-trained CNN models from large-scale natural image datasets are
applied to solve biomedical image tasks. In a previous study of CNN models
applied to both thoraco-abdominal lymph node detection and interstitial lung
disease classification, transfer-learning from large scale annotated image datasets
(ImageNet) was consistently beneficial in both tasks [160]. Furthermore, in a
breast cancer study [161], CNNs used for feature extraction followed by
supervised classification achieved 99.86% accuracy for the positive class.
The overarching goal of this work is to evaluate the potential of transfer
learning for histopathological image analysis of hepatocellular carcinoma (HCC).
Primary liver cancer is the sixth most common liver malignancy, with a high
mortality and morbidity rate. HCC is the representative type, resulting from the
malignant transformation of hepatocytes in a cirrhotic, non-fibrotic, or minimally
fibrotic liver [162]. With the development of high-throughput technologies, a
number of “omics” research studies have helped elucidate the mechanisms of
HCC molecular pathogenesis, which in turn have significantly contributed to our
understanding of cancer genomics, diagnostics, prognostics, and therapeutics
[163] [164] [165] [166]. In particular, the most frequent mutations and
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chromosome alterations leading to HCC were identified in the TERT promoter as
well as the CTNNB1, TP53, AXIN1, ARID1A, NFE2L2, ARID2 and RPS6KA3
genes [166]. The biological pathways Wnt/β-catenin signaling, oxidative stress
metabolism, and Ras/mitogen-activated protein kinase (MAPK) were reported
to be involved in liver carcinogenesis [163]. Frequent TP53-inactivating
mutations, higher expression of stemness markers (KRT19, EPCAM) and the
tumor marker BIRC5, and activated Wnt and Akt signaling pathways were also
reported to associate with stratification of HCC samples ([166]). The histological
subtypes of HCC have been shown relate to particular gene mutations and
molecular tumour classification [167]. Two recent studies have demonstrated
strong connections between molecular changes and disease phenotypes. In a
meta-analysis of 1494 HCC samples, consensus driver genes were identified that
showed strong impacts on cancer phenotypes [168]. In addition, a deep
learning-based multi-omics data integration study produced a model capable of
robust survival prediction [169]. These and other recent findings may help to
translate our knowledge of HCC biology into clinical practice [167].
At the pathological level, HCC exhibits as a morphologically
heterogeneous tumour. Although HCC neoplastic cells often grow in cords of
variable thickness lined by endothelial cells mimicking the trabeculae and
sinusoids of normal liver, other architectural patterns are frequently observed
and numerous cytological variants recognized. Though histopathologic criteria
for diagnosing classical, progressed HCC are well established and known, it is
challenging to detect increasingly small lesions in core needle biopsies during
routine screenings. Such lesions can be far more difficult to distinguish from one
another than progressed HCC, which is usually diagnosed in a straightforward
manner using hematoxylin and eosin staining [170] [171]. Although
prognostication increasingly relies on genomic biomarkers that measure genetic
alterations, gene expression changes, and epigenetic modifications, histology
remains an important tool in predicting the future course of a patient’s disease.
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Previous studies [172] [173] indicated the complementary nature of information
provided by histopathological and genomic data. Quantitative analysis of
histopathological images and their integration with genomics data require
innovations in integrative genomics and bioimage informatics.
In this study, we applied pre-trained CNN models on HCC
histopathological images to extract image features and characterize the
relationships between images, clinical survival and biological pathways. We first
downloaded Hematoxylin and Eosin (H&E) stained whole slide images from
HCC subjects (421 tumor samples and 105 normal tissue adjacent to tumor
samples) from the National Cancer Institute Genomic Data Commons Data
Portal. After image normalization, we then applied three pre-trained CNN
models–VGG 16, Inception V3, and ResNet 50–to extract representative image
features. Using these features, we (1) performed classification between cancer
and normal samples, (2) constructed models associating image features with
clinical survival, (3) discovered potential HCC subgroups and characterized
subgroup survival differences, and (4) calculated correlations between image
features and integrated biological pathways. To the best of our knowledge, this is
the first study to extract HCC image features using pre-trained CNN models and
assess correlations between image features and integrated pathways. Our results
indicate the feasibility of applying CNN models to histopathological images to
better understand disease diagnosis, prognosis, and pathophysiology.
B.3
B.3.1

Materials & Methods
HCC Datasets
We downloaded HCC histopathological images of diagnostic slides (access

by TCGA-LIHC Diagnostic Slide Images) from the National Cancer Institute
Genomic Data Commons Data Portal on January 23, 2019. In addition to
images, this Portal also provides multiple molecular datasets (e.g.,
Transcriptomics, DNA Methylation, Copy Number Variation) and clinical
information for the same cohort. In total, we obtained 966 H&E stained whole
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slide images from 421 scanned HCC subjects (421 tumor samples and 105
normal tissue samples adjacent to tumors). The images were digitized and stored
in .svs files, which contain pyramids of tiled images with differing levels of
magnification and resolution. We used the Python modules OpenSlide and
DeepZoomGenerator to read those image files. Most of the files contained three
or four levels of sizes and resolutions, with level 4 corresponding to the highest
resolution (median pixels: 89640 x 35870) and level 3 comprising 1/16th the size
of level 4 (median pixels: 5601 x 2249.5). To reduce memory usage and
processing time, we extracted either level 3 images or downsampled level 4
images (if available) by a factor of 16 to the level 3 equivalent. We removed two
files which were either corrupted or did not contain level 3 or 4 information. In
total, we used 964 files in our analysis.
We downloaded clinical files containing overall survival (OS) and disease
free survival (DFS) information on January 23, 2019 from the cBioPortal for
Cancer Genomics website (https://www.cbioportal.org/). The cBioPortal
provides visualization, analysis and downloading of large-scale cancer genomics
data sets. Importantly, cBioPortal includes data for the same patient cohort
from which the HCC images were taken. When performing OS analysis, the
event of interest is death (event = 1), while the censored event is being alive
(event = 0). Thus, the number of days for event 1 and event 0 are the number of
days until death and number of days until last contact, respectively. In DFS
analysis, the event of interest is new tumor occurrence (event = 1), while the
censored event is the lack of detection of a new tumor (event = 0). In this case,
the number of days for event 1 and event 0 are the number of days until
detection of a new tumor and number of days until last contact, respectively.
We downloaded molecular pathway information, including integrated gene
expression and copy number variation data, on January 28, 2019 from the Broad
GDAC Firehose (https://gdac.broadinstitute.org/). This resource provides an
open access web portal for exploring analysis-ready, standardized TCGA data
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including the cohort from which the TCGA-Liver Hepatocellular Carcinoma
image files were collected. Using this pathway information, we applied the
PAthway Representation and Analysis by Direct Inference on Graphical Models
(PARADIGM) algorithm [174] to infer Integrated Pathway Levels (IPLs).
Briefly, PARADIGM predicts the activities of molecular concepts including
genes, complexes, and processes and measures using a belief propagation
strategy within the pathway context. Given the copy numbers and gene
expression measurements of all genes, this belief propagation iteratively updates
hidden states reflecting the activities of all of the genes in a pathway so as to
maximize the likelihood of the observed data given the interactions within the
pathway. In the end, the IPLs reflect both the data observed for that pathway as
well as the neighborhood of activity surrounding the pathway. We used the
analysis-ready file of IPLs generated by PARADIGM for correlation analyses
between image features and biological pathways.
B.3.2

Image Pre-Processing and Feature Extraction
For each of the 964 image files from 421 tumor and 105 normal samples,

we performed stain-color normalization as described in previous image studies
[175] [176] [177]. After color normalization, we performed 50 random color
augmentations. We followed a previous study [178] and first deconvolved the
original RGB color into H&E color density space. We then estimated a specific
stain matrix for a given input image and multiplied the pixels with a random
value from the range [0.7, 1.3] to obtain the color augmented image. We
repeated the process to generate 50 augmentations. Next, we randomly selected
20 crops of size 256 x 256 and 512 x 512 pixels from each augmented image. We
separately input each crop to the three pre-trained CNN models (VGG 16,
Inception V3, and ResNet 50), each of which generated a total of 20 sets of
features. Within each model, we combined all sets of features associated with an
image into a single set by computing median values of features across all crops of
all augmented images.
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Deep CNN models such as VGG 16, Inception V3 and ResNet 50 contain
millions of parameters that require extensive training on large datasets. When
properly trained, these models have reached state-of-the-art performance in tasks
such as image recognition and classification. To avoid the challenges of training
an entire CNN from scratch, we used pre-trained versions of these models to
extract histopathological image features in an unsupervised manner. This
transfer learning approach was essential given the relatively small sample size of
the HCC cohort. For the Inception and ResNet models, we used nodes in the
second-to-last convolutional layer as image features. For the VGG model, we
concatenated nodes from the last 4 convolutional layers
(block2_conv2,block3_conv3, block4_conv3, block5_conv3) as image
features. In each case, the CNN network weights had been pre-trained using
ImageNet data [179]. We implemented the above steps using Keras, a popular
Python framework for deep learning.
B.3.3

Sample Visualization
To visualize samples, we first used Principal Component Analysis (PCA)

to reduce the dimensionality of image features. We then applied the
t-Distributed Stochastic Neighbor Embedding (t-SNE) method to visualize the
first 10 components in 2 dimensions. The t-SNE method reduces data
dimensionality based on conditional probabilities that preserve local similarity.
We applied a t-SNE implementation that uses Barnes-Hut approximations,
allowing it to be applied on large real-world datasets [138]. We set the perplexity
to 15, and colored the sample points using the group information.
B.3.4

Supervised Classification from Image Features
We applied a linear Support Vector Machine (SVM) classifier [180] to

discriminate between cancer and normal samples using the extracted image
features (derived as described above). We used stratified 6-fold cross validation
to train the model. To evaluate classifier performance, we visualized the Receiver
Operating Characteristic (ROC) curve generated using cross-validation, with
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false positive rate on the X axis and true positive rate on the Y axis. We
calculated the Area under the ROC curve (AUC) for each cross-validation fold,
as well as the overall mean value. We also plotted the 2-class precision-recall
curve to visualize the tradeoff between precision and recall for different
prediction thresholds. A high AUC represents both high recall and high
precision, which translates to low false positive and negative rates. Using average
precision (AP), we summarized the mean precision achieved at each prediction
threshold. We used the Python module Scikit-learn to perform classification
with a linear SVM, setting the parameter C to its default value of 1.0.
B.3.5

Survival Analysis
To perform univariate survival analysis for each image feature

individually, we applied Cox Proportional Hazards (CoxPH) regression models
using the R package ‘survival’ for both overall (OS) and disease-free survival
(DFS). We used a log-rank test to select significant image features with p-value
≤ 0.05.
For multivariate survival analysis, we used the R package ‘glmnet’ to
build separate CoxPH OS models based on image features from each of the three
pre-trained CNN models. We applied elastic net regularization with fixed alpha
= 0.5, which corresponds to equal parts lasso and ridge regularization. In order
to learn the optimal penalty coefficient lambda, we applied 10-fold cross
validation. We evaluated models with the Concordance index (C-index) and a
log-rank test. The C-index quantifies the quality of rankings and can be
interpreted as the fraction of all pairs of individuals whose predicted survival
times are correctly ordered [181] [182]. A C-index of 0.5 indicates that
predictions are no better than random.
B.3.6

Subgroup Discovery
Using the Scikit-learn Python module, we applied K-means clustering

across all cancer samples to discover HCC subgroups. Specifically, we clustered
all image features which were significantly associated with both overall and

123

disease-free survival. The K-means algorithm [183] clusters samples by
minimizing within-cluster sum-of-squares distances for a given number of groups
(K), which we varied between 2-12. To identify the optimal number of
subgroups, we applied two metrics: the mean Silhouette coefficient and the
Davies-Bouldin index. The Silhouette coefficient [184] takes values between -1
and 1, and it is calculated based on the mean intra-cluster distance and the
mean nearest-cluster distance for each sample. Higher positive Silhouette values
correspond to good cluster separation, values near 0 indicate overlapping
clusters, and negative values indicate assignment of samples to the wrong cluster.
The Davies-Bouldin index [185] is calculated based on the average similarity
between each cluster and its most similar one, where an index close to 0
indicates a good partition. Given the optimal number of subgroups, we
constructed CoxPH models to detect survival differences between the subgroups,
again using C-index and log-rank test for evaluation. We fit Kaplan–Meier
curves to visualize the survival probabilities for each subgroup.
B.3.7

Correlation Between Image Features and Pathways
We calculated the Pearson correlation between image features and

Integrated Pathway Levels (IPLs) using the scipy Python module. Pearson
correlation coefficients range between -1 and 1, with 0 implying no correlation.
Each correlation coefficient is accompanied by a p-value, which indicates the
significance of the coefficient in either the positive or negative direction. To
correct for multiple hypothesis testing, we adjusted p-values using the Benjamini
& Hochberg (BH) method [86]. We selected significant correlations between
image features and IPLs as those whose adjusted p-values were ≤ 0.05.
B.3.8

Differential Expression Analysis
To identify differentially expressed (DE) pathways between two HCC

subgroups, we applied the widely-used "Limma" R package [186]. We selected
significantly DE pathways as those whose Benjamini & Hochberg (BH)-adjusted
p-values were ≤ 0.1.
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B.4

Results
In this study, we made use of pre-trained CNN models VGG 16, Inception

V3 and ResNet 50 to extract features from HCC histopathological whole slide
images. We first downsampled the whole slide images, normalized the color, and
generated augmented images. We then aggregated the features extracted from
randomly selected crops using pre-trained CNN models. Using these image
features, we performed survival analysis and subgroup discovery. We also
performed correlation analysis between image features and integrated biological
pathways. The workflow of these analysis steps can be seen in Figure B.1.
B.4.1

Image Feature Extraction and Survival Analysis
Histopathology assessment is mandatory in HCC diagnosis [187], and the

characteristics such as tumor number, size, cell differentiation and grade, and
presence of satellite nodules were reported to be prognostic biomarkers [188].
Given a histopathological image, CNNs enable efficient feature extraction and
representation using convolutional, pooling, and fully connected network layers.
To examine image features relevant to HCC, we first downloaded HCC
histopathological images from the National Cancer Institute Genomic Data
Commons Data Portal. In addition to images, this Portal also provides multiple
molecular datasets and clinical information for the same cohort of samples. We
downloaded a total of 966 .svs image files from 421 cancer tissues and 105
tumor-adjacent normal tissues, of which 964 had sufficient information for the
following analysis. For all image files, we used the equivalent of level 3
magnification (median 5601 x 2249.5 pixels) as described in the Materials &
Methods section. We performed staining color normalization, followed by image
augmentation to improve sample variety. We randomly selected 20 crops of sizes
512 x 512 pixels or 256 x 256 pixels from each augmented image. The 20 512 x
512 crops represent 41.6% of the input image pixels on average, while the 20 256
x 256 crops represent 10.4% on average.
The deep CNN models VGG 16, Inception V3 and ResNet 50 contain
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Fig. B.1: HCC image analysis flow. A-1) For whole slide .svs files, downsampled
images were generated, B-2) color normalization was performed, C-3) 50
augmented images were made for each original image and 20 crops were selected
at random from each augmented image, D-4) three CNN models, VGG 16,
Inception 3 and ResNet 50 were applied to extract features from each crop, E-5)
features from all crops were aggregated and 50 sets of image features were
obtained from each CNN model, F-6) image features were used for classification,
G-7) image features were fit for survival analysis, H-8) image features were used
for subgroup discovery, I-9) correlation between image features and biological
pathways.
millions of parameters, and extensive training of these models has led to
state-of-the-art performance in image recognition and detection [189]. Given the
small sample size in our cohort, we extracted features from each image crop by
applying pre-trained versions of these models. This approach, which is a form of
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transfer learning, allows us to avoid the challenges of CNN model training from
scratch. For the Inception and ResNet models, we chose all nodes in the
second-to-last network layer as features after excluding the final fully-connected
layers. For the VGG model, we chose all nodes from the last four convolutional
layers as features. For each full image, we combined features from the 20 random
crops into a single set of features representing that image.
In total, we obtained 1408, 2408, and 2408 features for each image using
the VGG 16, Inception V3, and ResNet 50 models, respectively. To aggregate
these features across all augmented images, we computed median values for each
feature. We then visualized cancer and normal samples in the context of these
features by using PCA to reduce the feature dimensionality followed by applying
t-SNE to the first 10 principal components. We also performed supervised
classification of the samples using a linear Support Vector Machine applied to
each set of image features. Figure B.2 shows these results using features derived
from 256 x 256 crop sizes, with classification performance displayed as receiver
operating characteristic (ROC) and two-class precision-recall curves. The
average AUC achieved by all three models is between 0.99 and 1, illustrating the
clear separation achieved between tumor and normal samples using the extracted
image features. Similarly, the AUCs achieved for features derived from 512 x 512
crop sizes were very close to 1. To compare this performance with that of an
alternate method, we also applied PCA (randomized SVD) and SVD (full SVD)
on the downsampled images without augmentation. Specifically, we extracted
the first 100 principal components (PCA) or singular vectors (SVD) as features
and performed supervised classification. Figure S1 shows that performance using
PCA- and SVD-derived features is very poor. Finally, we performed classification
on features derived without using image augmentation. Here, performance is
only slightly worse, with AUCs ranging between 0.98 and 0.99 (Figure S2).
We next compared the performance of a simpler network to that of the
three CNNs evaluated in this study. Specifically, we applied a MobileNet v1
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Fig. B.2: Visualization of extracted image features and classification between
cancer and normal samples. A), D) and G) indicate t-SNE visualization, B), E)
and H) indicate ROC curves from linear SVM and C), F) and I) indicate Recall
and Precision curves measured using VGG image features, Inception features
and ResNet features, respectively.
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pre-trained network, which has many fewer tunable parameters (4.2x106 ) than
VGG 16 (1.4x108 ), Inception v3 (2.4x107 ), and ResNet 50 (2.3x107 ). As with the
other networks, we removed the final layer of MobileNet v1 and used the network
to extract features for each image. We aggregated these features as before,
followed by performing SVM classification. We found that the classification
performance using MobileNet v1 was indistinguishable from those achieved by
the larger networks. This result suggests that the pre-trained networks used in
our study contain many more tunable parameters than are strictly necessary to
yield very good classification performance.
We also explored reduction of model complexity by selecting smaller and
smaller subsets of pre-trained CNN image features for classification. Figure S3
displays performance using randomly-selected image feature subsets of size 10,
25, 50 and 100 in each of the three pre-trained CNNs using 256 x 256 pixel
crops. Our results show that when using smaller and smaller sets of features,
classification AUC reached as low as 0.84, which was substantially worse than
our original results. However, using random sets of 100 features led to
performance that was nearly as good as that achieved using all features. Overall,
our results show that use of CNN-derived image features is extremely effective
for distinguishing HCC tumor from normal samples, which suggests that
pre-trained CNN models capture the most relevant characteristics from HCC
histopathological images.
To aid in interpreting CNN-derived image features of HCC, we visualized
feature mappings of VGG model convolutional layer blocks when applied to 256
x 256 pixel crops of histopathological images (Figure B.3 and Figure S4). We
note that the first convolutional layers tend to resemble the original image, but
subsequent layers seem to intensify partial objects. In order to study whether
the CNN-derived image features are associated with clinical survival, we next
performed univariate CoxPH regression survival analysis on each feature. We
obtained clinical information for each sample from the cBioPortal for Cancer
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Fig. B.3: Example of feature mapping visualization in VGG 16 model in one
cancer sample. A) shows an image patch with 256 x 256 pixels. B-P) indicates
the corresponding feature mapping from convolutional block 1 (B-D) to
convolutional block 5 (N-P)

Genomics, as described in the Materials & Methods section. For the subjects
with multiple histopathological images, we computed median feature values
across the images for the following survival analysis. For each image feature, we
applied CoxPH regression models for both overall survival (OS) and disease-free
survival (DFS) and selected significantly associated features (p-value ≤ 0.05)
based on a Score (log-rank) test. We also validated the predictive ability of the
survival models using Concordance index (C-index). Table B.1 shows the
number of significant features for each model and survival type. 21.4% and 16%
of image features on average were significantly associated with OS and DFS,
respectively. Each model had a slightly different number of significant features,
with more features associated with OS than DFS.
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Table B.1: Significant Image Feature Number from Univariate CoxPH
Regression Models
Model

Feature Num- Crop Size
ber

VGG
Inception
ResNet
VGG
Inception
ResNet

1408
2048
2048
1408
2048
2048

256
256
256
512
512
512

Significant
Significant
Features
of Features
of
OS
DFS
272 (19.3%)
219 (15.6%)
574 (28.0%)
294 (14.4%)
522 (25.5%)
385 (18.8%)
300 (21.3%)
201 (14.3%)
356 (17.4%)
290 (14.2%)
347 (17.0%)
390 (19.0%)

Finally, we performed multivariate CoxPH regression analyses for each
survival type on all image features from each model. We employed elastic net
regularization using equally weighted lasso and ridge regularization during model
training. Optimal hyperparameters were selected using 10-fold cross-validation
and subsequently used for model prediction. Overall, we identified three
multivariate OS models with the following log-rank p-values and C-indices:
1.2E-23 and 0.788 (VGG), 7.6E-18 and 0.789 (Inception), and 1.2E-12 and 0.739
(ResNet) from the 256 x 256 crop sizes. Table B.2 displays the C-indices and
p-values achieved for each pre-trained network, image crop size and survival
type. The Inception-derived model achieved the highest indices of 0.789 at OS
and 0.744 at DFS. Overall, our results show that CNN-derived image features
are significantly associated with clinical survival and can be used to build
accurate survival models.
Table B.2: Multivariate CoxPH Regression Model in Three Models
Model
Crop
VGG
256
Inception 256
ResNet
256
VGG
256
Inception 256
ResNet
256

Survival
C-index
OS
0.788 ± 0.022
OS
0.789 ± 0.021
OS
0.739 ± 0.025
DFS
0.655 ± 0.019
DFS
0.744 ± 0.018
DFS
0.7 ± 0.019
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P value
1.2E-23
7.6E-18
1.2E-12
1.5E-08
3.2E-13
4.1E-11

B.4.2

Subgroup Discovery from Image Features
To investigate whether our CNN-derived image features relate to HCC

prognosis, we next used these features to discover subgroups within tumor
samples. We considered all image features which were significantly associated
with both OS and DFS. Using these features, we clustered the tumor samples
using K-means (K = 2-12) and used both Silhouette coefficients and
Davies-Bouldin values to choose the optimal number of subgroups. As shown in
Figure B.4, two subgroups were determined to be optimal for all three models.
We visualized these subgroups using t-SNE to reduce dimensionality.
We then examined survival differences between the subgroups. For each
model and survival type, we generated Kaplan-Meier survival curves stratified by
subgroup. Our results (Figure B.5) note that the subgroups discovered using the
Inception and ResNet models show a significant difference in both OS and DFS
using a log-rank test. The two subgroups from Inception have the most
significant OS difference, with p-value 7.39E-07 and C-index 0.628, followed by
the two subgroups from ResNet with p-value 0.001 and C-index 0.582. We also
observed significant differences in DFS between subgroups in both models, with
p-values and C-indices of 0.012 and 0.558 (Inception) and 0.014 and 0.56
(ResNet), respectively. For the VGG model, we only detected a significant
difference for DFS (p-value 0.007 and C-index 0.536). In all models, we note that
the second subgroup (“group 2”) has consistently better OS and DFS survival
than the first subgroup (“group 1”). Table B.3 shows the subgroup overlap
between the three models. Overall, 176 samples from the Inception group 1 were
also labeled group 1 in VGG and ResNet models. In contrast, 109 samples from
the Inception group 2 were identified as group 2 in ResNet but group 1 in VGG.
Taken together, the significant survival differences detected between sample
subgroups demonstrate the feasibility of discovering clinically-relevant HCC
subgroups using CNN-derived image features.
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Fig. B.4: Subgroup discovery from image features using 256 x 256 pixel crop size.
A), C) and E) display two different metrics for selecting the optimal number of
clusters, and B), D) and F) indicate the t-SNE visualization of best clusters
using VGG image features, Inception image features and ResNet image features,
respectively.

B.4.3

Correlation Between Image Features and Biological Pathways
Previous studies examined the molecular mechanisms underlying HCC

[163] [164] [165] [166]. To relate our CNN-derived image features to such
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Fig. B.5: Survival analysis from discovered subgroups. A), C) and E) correspond
to the CoxPH model applied to OS, B), D) and F) correspond to DFS. The two
groups are indicated in red and green, using VGG image features, Inception
image features and ResNet image features, respectively.

mechanisms, we identified correlations between features and a collection of
molecular pathways. Specifically, we first obtained integrated pathway levels
(IPLs) using the Firehose Genome Browser, which provides analysis-ready files
inferred from both gene expression and DNA copy number variation using the
PARADIGM algorithm [174]. IPLs indicate the predicted activities of biological
concepts using both copy number and gene expression data (described in
Materials & Methods). The IPL matrix contains a total of 7202 entities derived
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Table B.3: Overlaps of Subgroup (1/2) Frequency Counts Between Three
Pre-trained CNNs
Inception
1
1
1
1
2
2
2
2

VGG 16
1
1
2
2
1
1
2
2

ResNet
1
2
1
2
1
2
1
2

Sample Count
176
18
20
4
48
109
16
30

from 3656 concepts in 135 merged pathways. Each entity is annotated with the
concept (gene) and pathway index as shown by the example 19_EPHB3. Here, the
EPHB3 gene participates in EPHB forward signaling whose pathway index is 19.
We first computed Pearson correlation coefficients between these IPLs and each
feature significantly associated with both OS and DFS. We then selected
significantly correlated IPL-feature pairs based on Benjamini & Hochberg (BH)
[86] -adjusted p-values ≤ 0.05. With 256 x 256 crop sizes, 90 (out of 97), 199 (out
of 203) and 192 (out of 203) survival-associated image features from the VGG,
Inception and ResNet models, respectively, were significantly correlated with
IPLs. On average, 90.2% of the image features showed a significant correlation,
with Pearson correlation coefficients ranging between -0.536 and 0.385.
Finally, we performed differential expression analysis to identify IPL
differences between each pair of sample subgroups. For each model, we selected
pathways with BH-adjusted p-values 0.05. Surprisingly, we found no significant
pathways at this threshold for all three models and both crop sizes. After
relaxing the p-value threshold to 0.1, we detected five significant entities from
two pathways: 19: EPHB forward signaling (EPHB3, ROCK1, Ephrin
B1/EPHB3) and 66: Glucocorticoid receptor regulatory network (IL8, ICAM1).
The two entities at pathway 66 were calculated between two subgroups from
Inception model with 256 x 256 crops while the three entities at pathway 19 were
from VGG model with 512 x 512 crops. Figure B.6 shows a network
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visualization of these pathways with significantly-correlated image features. The
nodes represent image features and pathways, while the thickness of the edges
denote the observed Pearson correlation coefficients. The numbers on the image
feature nodes were assigned according to the order from the initial feature
extraction. We note that some image features showed correlation with more than
one entity from the same pathway, while others seemed to be related to only one
entity. Overall, 31 out of 49 image features with significant correlations were
found using the Inception model, of which three features (324, 1859, and 1292)
were correlated with pathway 19: EPHB forward signaling. The VGG model
identified a total of four significantly-associated features (two each of 870 and
871) from 256 x 256 and 512 x 512 crops. Feature 870 showed correlation with
only 19: EPHB forward signaling, while feature 871 was correlated with both 19:
EPHB forward signaling and 66: Glucocorticoid receptor regulatory network.
The observation that consecutive features from the VGG model were correlated
with similar pathways suggests that these features represent related attributes of
the original images. In addition, it is noteworthy that the model with the largest
proportion of significantly-associated features (Inception) also showed the most
significant survival analysis results.
B.5

Discussion
In this study, we applied the pre-trained CNN models VGG 16, Inception

V3, and ResNet 50 to extract features from HCC histopathological whole slide
images. Using these image features, we observed clear separation between cancer
and normal samples both visually (t-SNE) and through supervised classification.
By performing univariate CoxPH regression, we identified averages of 21.4% and
16.0% of image features significantly associated with overall (OS) and
disease-free survival (DFS), respectively. Many of these image features were also
significantly associated with OS in a multivariate CoxPH regression model. We
utilized the CNN-derived image features to discover HCC subgroups, with the
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Fig. B.6: Correlation network between image features and example pathways.
Colors of nodes indicate CNN models VGG, Inception and ResNet, as well as
pathways. The labeled names of image features consist of the model name, crop
size and feature order number. The thickness of each edge corresponds to the
magnitude of correlation coefficients ranging between -0.536 and 0.385 that were
statistically significant with the range.

optimal two subgroups showing a significant difference in both OS and DFS in
the Inception model.
Notably, we found that 90.2% of the image features significantly
associated with both OS and DFS were also significantly correlated with
measures of integrated pathway levels (IPLs). The five most significant IPL
entities were found in two pathways–EPHB forward signaling and Glucocorticoid
receptor (GR) regulatory network–implying a potential role for these pathways
in the prognosis of HCC. Previous studies of EPHB forward signaling have
shown that it induces cell repulsion and controls actin cell adhesion and
migration [190]. It has also been reported that EPHB receptors and ephrin
ligands are involved in carcinogenesis and cancer progression [191]. Finally, the
EPHB3 receptor also inhibits the Wnt signaling pathway [192], which was
reported to be useful for HCC stratification [166]. In addition, previous studies
have reported that the glucocorticoid receptor binds promoters, interacts with
other transcription factors [193], and causes hepatocellular carcinoma [194] in
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mice when receptor signaling is impaired. GR regulatory network member
Interleukin-8 (IL8), a proinflammatory CXC chemokine, was reported to promote
malignant cancer progression [195], while member Intercellular cell adhesion
molecule-1 (ICAM-1) has functions in immune and inflammatory responses and
was reported to play a role in liver metastasis [196]. We note that a previous
study performed integration of genomic data and cellular morphological features
of histopathological images for clear cell renal cell carcinoma, finding that an
integrated risk index from genomics and histopathological images correlated well
with survival [172]. In addition, a second study [173] developed a CNN model
using both histopathological and genomic data from brain tumors, which
surpassed the current state of the art in predicting overall survival.
Stratification of patients is an important step to better understand
disease mechanisms and ultimately enable personalized medicine. Previous
studies of HCC have suggested molecular-level subgroups [197] [198] [169]. In the
recent study, the authors applied deep learning to integrate three omic datasets
from 360 HCC patients (the same cohort used in our study), discovering two
subgroups with survival differences. In our work, we identified subgroups using
all three CNN models, with the subgroups from both Inception (C-index =
0.628; P value = 7.39E-07) and ResNet (C-index = 0.582; P value = 0.001)
models showing significant differences in OS. We note that this significance of
the Inception model is lower than that achieved using subgroups identified using
multiple omic data integration (C-index = 0.68 and P value = 7.13E-6) [169],
although the C-index is also slightly lower. We also detected significant survival
differences in DFS using all three models, which to our knowledge has not been
previously investigated. Interestingly, the subgroups from Inception model were
most significantly different in OS.
In the analysis of histopathological images, the large image size and
different levels of resolution from whole slide images (WSIs) pose challenges to
accurate and efficient feature selection [148]. To avoid information loss, WSIs are

138

often divided into small patches (e.g., 256 x 256 pixels) and each patch is
analyzed individually as a Region of interest (ROI). These ROIs are first labeled
using active learning [199] or by professionally trained pathologists [200].
Subsequently, averaged regions of patches representing WSIs are studied for
specific tasks [148]. In our work, we randomly selected 20 patches of 256 x 256
and 512 x 512 pixels from each WSI and extracted features from the last layers
of CNN models to represent each image for visualization and classification. To
robustly deal with color variation and image artifact issues, we conducted color
normalization and augmentation before applying CNN models. Color
normalization adjusts pixel-level image values [201], and color augmentation
generates more data by altering hue and contrast in the raw images [202]. We
achieved very good classification performance, with AUCs between 0.99 and 1 for
distinguishing between normal and tumor samples. To illustrate the power of a
transfer learning approach using pre-trained CNNs, we also applied a simple (not
pre-trained) CNN model (Figure S5) for classifying tumor and normal samples.
This approach achieved a best validation accuracy of 87.8% (Figure S6), which
was substantially worse than the transfer learning performance.
Comparing our performance to previous work, we note that in one study
of histopathological images [203], classification performance reached 81.14%
accuracy using the extracted features from a pre-trained VGG 19 (similar to
VGG 16) network. In a similar study of histopathological images of breast
cancer [204], classification performance on 400 H&E-stained images of 2048 1536
pixels each reached an AUC of 0.963 for distinguishing between non-carcinomas
vs carcinomas samples. We note that our study uses higher resolution
histopathological images (median 5601 x 2249.5 pixels), which may explain the
better performance.
Recent related work in histopathological image analysis include a
deep-learning-based reverse image search tool for images called SMILY (Similar
Medical Images Like Yours) [158]. By building an embedding database using a
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specialized CNN architecture called a deep ranking network, SMILY enables
search for similar histopathological images based on a query image. SMILY’s
deep ranking network utilizes an embedding-computing module that compresses
input image patches into a fixed-length vector. This module contains layers of
convolutional, pooling, and concatenation operations. SMILY retrieves image
search results with similar histological features, organ sites, and cancer grades,
based on both large-scale quantitative analysis of annotated tissue regions and
prospective studies with pathologists blinded to the source of the search results.
SMILY’s creators comprehensively assessed its ability to retrieve search results in
two ways: using pathologist-provided annotations, and via prospective studies
where pathologists evaluated the quality of SMILY search results.
Additional related work has made use of deep learning generative models
to help delineate fundamental characteristics of histopathological images.
Generative Adversarial Networks (GANs) have enjoyed wide success in image
generation. GANs involve training a generator to fool a discriminator, while a
discriminator is trained to distinguish the generated samples from real samples.
This approach eventually produces high-quality images [205]. The creators of
Pathology GAN recently demonstrated its abilities to create artificial histological
images and learn biological representations of cancer tissues [206]. A second type
of generative model known as a variational autoencoder (VAE) learns the
distribution of latent variables and reconstructs images. VAEs have been
successfully applied in image generation [90], and a specialized version known as
a conditional VAE can be suitable for pathology detection in medical images
[207].
We note that our study has several limitations, including limited
interpretability of the most discriminative HCC image features and a lack of
external validation datasets. We also did not address multiclass grading on the
HCC samples, instead focusing on a binary classification. Despite using
pre-trained CNN models for feature selection, our results may still be limited by
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the somewhat small and unbalanced sample sizes of our dataset. Additional
studies on other independent data sets should be evaluated to further explore the
correlation between deep learning-based extracted images, clinical survival and
biological pathways. Future work will involve experimenting with other CNN
models, as well as improving the biological interpretation of features from
pre-trained models.
B.6

Conclusions
The image features extracted from HCC histopathological images using

pre-trained CNN models VGG 16, Inception V3 and ResNet 50 can accurately
distinguish normal and cancer samples. Furthermore, these image features are
significantly correlated with clinical survival and biological pathways.
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Appendix C
Abbreviations of Clinical Features
ABM1: 1. Body Weight
ABM2: 2. BMI
ABM3A: 3. Standing Height
ABM3B: 3. Standing Height
ABM4: 4. Waist Circumference
ABM5: 5. Waist Circumference
ABM6: 6. Hip Circumference
ABM7: 7. Hip Circumference
ABM8: 8. Waist to Hip Ratio
ABM9-Syst: 9. Systolic Blood Pressure
ABM9-Dias: 9. Diastolic Blood Pressure
ABM10: 10. Pulse
DemoRel: Relationship Status
DemoRel-Married: Relationship Status
DemoRel-Living: Relationship Status
DemoRel-SteadyRel: Relationship Status
DemoRel-Divorced: Relationship Status
DemoRel-Widow: Relationship Status
DemoRel-Single: Relationship Status
DemoChi: Children Status
baso: Basophils
eosino: Eosinophils
hct: hematocrit
lymph: Lymphocytes
monos: Monocytes
neut: Neutrophils
rdw: Red cell distribution width
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utox: ny urine tox
mcv: mean corpuscular volume
mpv: Mean platelet volume
ALB: albumin
hgb: hemoglobin
mchc: mean corpuscular hemoglobin concentration
ProTot: total serum protein
baso .: Basophils .
eosino.: Eosinophils .
lymph.: Lymphocytes .
monos.: Monocytes .
Neut.: Neutrophils .
plt: Platelet count
wbc: white blood cells
efgraa: Estimated Glomerular Filtration Rate African American
efgrnaa: Estimated Glomerular Filtration Rate Non-African American
rbc: red blood cells
Cl: chloride
CO2: bicarbonate
K: potassium
Na: sodium
BILITOT: bilirubin
bun: blood urea nitrotgen
Ca: calcium
cholest: total cholesterol
creatinine: creatinine
glucose: fasting glucose
hbA1c: glycosylated hemoglobin
hdl: HDL cholesterol
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ldl: LDL cholesterol
triglyc: triglycerides
hscrp: C reactive protein
dotclinlabs: date of clinical labs
mch: mean corpuscular hemoglobin
alkphos: Alkaline phosphatase
alt: Alanine Aminotransferase
ast: Aspartate transaminase
ggt: Gamma-glutamyltransferase
bmkrid: subject ID
acth1: ACTH DST 1
acth2: ACTH DST 2
acthdif: acth1-acth2
acthsup: (acth1-acth2)/acth1
athf: 5a-tetrahydrocortisol
athftobthf: aTHF/bTHF
athftof: 5-reductase (aTHF/F)
bthf: 5b-tetrahydrocortisol
bthftof: 5-reductase (bTHF/F)
cor1: plasma cortisol DST 1
cor2: plasma cortisol DST 2
cordif: cor1-cor2
corsup: (cor1-cor2)/cor1
dex: Dexamethasone
dhea: DHEA
dheas: DHEA-S
dheatodheas: dhea/dheas
dotdsta: date of blood collection DST 1
dotdstb: Date of blood collection DST 2
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doturn: urine collection date
e: cortisone
estrogen: estrogen
f: free cortisol
ic50: Lysosyme IC50
npy: Neuropeptide Y
the: tetrahydrocortisone
thetoe: the/e
totgluc: f+e+athf+bthf+the
urncatot: ne,da,epi total
urncor: Urine Cortisol
urncr: Urine Creatinine
urnda: Urine Dopamine
urnepi: Urine Epinephrine
urnne: Urine Norepinephrine
urnnetocor: urnne/urncor
urnvol: urine volume
psqi1a: 1. During the past month,when have you usually gone to bed at
night?
psqi1b: 1. During the past month,when have you usually gone to bed at
night?
psqi1c: 1. During the past month,when have you usually gone to bed at
night?
psqi2: "2. During the past month, how long (in minutes) has it usually
taken you to fall asleep each night?
" psqi3a: 3. During the past month, when have you usually gotten up in
the morning?
psqi3b: 3. During the past month, when have you usually gotten up in
the morning?
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psqi3c: 3. During the past month, when have you usually gotten up in
the morning?
psqi4a: 4. During the past month, how many hours of actual sleep did
you get at night? (This may be different from the number of hours you spent in
bed.)
psqi4b: 4. During the past month, how many hours of actual sleep did
you get at night? (This may be different from the number of hours you spent in
bed.)
psqi5a: "5. During the past month, how often have you had trouble
sleeping because you . . .A. Cannot get to sleep within 30 minutes
" psqi5b: B. Wake up in the middle of the night or early morning
psqi5c: C. Have to get up to use the bathroom
psqi5d: D. Cannot breathe comfortably
psqi5e: E. Cough or snore loudly
psqi5f: F. Feel too cold
psqi5g: G. Feel too hot
psqi5h: H. Had bad dreams
psqi5i: I. Have pain
psqi5j: J. How often during the past month have you had trouble
sleeping because of one or more problems NOT listed above?
psqi6: 6. During the past month, how would you rate your sleep quality
overall?
psqi7: 7. During the past month, how often have you taken medicine
(prescribed or "over counter") to help you sleep?
psqi8: 8. During the past month, how often have you had trouble staying
awake while driving, eating meals, or engaging in social activities?
psqi9: 9. During the past week, how much of a problem has it been for
you to keep up enough enthusiasm to get things done?
psqi10: 10. Do you have a bed partner or roommate?
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:
WVocRS: Vocabulary:Raw score
WVocAS: Vocabulary:age scaked score
WVocPR: Vocabulary:percentile range
WEstimateIntelligence: Standard Score (Estimate of Intelligence)
WMemDigRS: Digit Span:Raw Score
WMemDigAgeSS: Digit Span:Age scaled score
WMemDigPR: Digit Span:Percentile Range
WMemLetterRS: Letter number:Raw Score
WMemLetterAgeSS: Letter number:Age Scaled Score
WMemLetterPR: Letter number:percentile Range
WProcSpeedCodRS: Coding:Raw Score
WProcSpeedCodAgeSS: Coding:Age Scaled Score
WProcSpeedCodPR: Coding: Percentile Range
WDigSpanForwardRS: Digit Span Forward: Raw Score
WDigSpanBackRS: Digit Span Backwards: Raw Score
WLongestForwRS: Longest Digit Span Forward: Raw Score
WLongestBackRS: Longest Digit Span Backwards:Raw Score
WForwardPercent: Longest Digit Span Forward:cumulative percentage
WBackPercent: Longest Digit Span Backwards:Cumulative percentage
WAuditMemSum: Auditory Memory Sum of Scaled Scores
WAuditMemIndex: Auditory Memory Index Score
WAuditMemPR: Auditory Memory PR
WAuditMemConf1: Auditory Memory Index 95% Confidence Interval
WAuditMemConf2: Auditory Memory Index 95% Confidence Interval
WAuditMemoryDesc: Auditory Memory Qualitative Description
WVisWorkMemSum: Visual Working Memory Sum of Scaled Scores
WVisWorkIndex: Visual Working Memory Index
WVisWorkMemPR: Visual Working Memory PR
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WVisWorkMemConf1: Visual Working Memory Index 95%
Confidence Interval
WVisWorkMemConf2: Visual Working Memory Index 95%
Confidence Interval
WVisWorkMemQual: "Visual Working Memory Qualitative
Description
" WVisReprod-1-RS: Visual Reproduction I:raw score
WVisReprod-1-SS: Visual Reproduction I:scaled score
WVisReprod-1-PR: Visual Reproduction I:percentile range
WVisReprod-2-RS: Visual Reproduction II: raw score
WVisReprod-2-SS: Visual Reproduction II:scaled score
WVisReprod-2-PR: Visual Reproduction II:percentile range
WLogicalMem-1-RS: Logical Memory I:Raw Score
WLogicalMem-1-SS: Logical Memory I:Scaled Score
WLogicalMem-1-PR: Logical Memory I:Percentile Range
WLogicalMem-2-RS: Logical Memory 2:Raw Score
WLogicalMem-2-SS: Logical Memory 2:Scaled Score
WLogicalMem-2-PR: Logical Memory 2:Percentile Range
WVerbalPairedAss-1-RS: Verbal Paired Associates I: Raw Score
WVerbalPairedAss-1-SS: Verbal Paired Associates I:scaled score
WVerbalPairedAss-1-PR: Verbal Paired Associates I:percentile range
WVerbalPairedAss-2-RS: Verbal Paired Associates 2: Raw Score
WVerbalPairedAss-2-SS: Verbal Paired Associates 2:scaled score
WVerbalPairedAss-2-PR: Verbal Paired Associates 2:percentile range
WSpatialAdd-RS: Spatial Addition:Raw Score
WSpatialAdd-SS: Spatial Addition:Scaled score
WSpatialAdd-PR: Spatial Addition:Perecntile Range
WSymbolSpan-RS: Symbol Span:Raw Score
WSymbolSpan-SS: Symbol Span:Scaled Score
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WSymbolSpan-PR: Symbol Span:Percentile Range
WLongDSSRS: Longest Digit Span Sequence:Raw Score
WLongDSSPercent: Longest Digit Span Sequence:percentile
Age-A: A. Did you ever suffer a serious personal injury or illness?
(occured once)
Age-B: B. Were you involved in a serious accident? (occured twice)
Age-C: C. Did your parents or primary caretaker have a problem with
alcohol? (ongoing)
Army: Military Service
Navy: Military Service
AirForce: Military Service
Marine: Military Service
NatGuard: Military Service
Reserve: Military Service
DemoMilServiceTours: Number of Military Tours
DemoMilService-Iraq: Military Service
DemoMilServiceIraqFrom-1: Military Service
DemoMilServiceIraqTo-1: Military Service
DemoMilServiceIraqMOS-1: Military Service
DemoMilServiceIraqFrom-2: Military Service
DemoMilServiceIraqTo-2: Military Service
DemoMilServiceIraqMOS-2: Military Service
DemoMilServiceIraqFrom-3: Military Service
DemoMilServiceIraqTo-3: Military Service
DemoMilServiceIraqMOS-3: Military Service
DemoMilService-Afgh: Military Service
DemoMilServiceAfghFrom-1: Military Service
DemoMilServiceAfghTo-1: Military Service
DemoMilServiceAfghMOS-1: Military Service
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DemoMilServiceAfghFrom-2: Military Service
DemoMilServiceAfghTo-2: Military Service
DemoMilServiceAfghMOS-2: Military Service
DemoMilServiceAfghFrom-3: Military Service
DemoMilServiceAfghTo-3: Military Service
DemoMilServiceAfghMOS-3: Military Service
DemoMilService-Other: Military Service
DemoLocationOtherSpecify: Military Service
DemoMilServiceOtherFrom-1: Military Service
DemoMilServiceOtherTo-1: Military Service
DemoMilServiceOtherMOS-1: Military Service
DemoMilServiceOtherFrom-2: Military Service
DemoMilServiceOtherTo-2: Military Service
DemoMilServiceOtherMOS-2: Military Service
DemoMilServiceOtherFrom-3: Military Service
DemoMilServiceOtherTo-3: Military Service
DemoMilServiceOtherMOS-3: Military Service
PCS-1-Dizzy: Feeling dizzy:
PCS-2-Balance: Loss of balance:
PCS-3-Coordination: Poor coordination, clumsy:
PCS-4-Vision: Vision problems, blurring, trouble seeing:
PCS-5-Light: Sensitivity to light:
PCS-6-Taste: Change in taste and/or smell:
PCS-Score1-Dizzy: Score for "Feeling dizzy"
PCS-Score2-Balance: Score for "Loss of balance"
PCS-Score3-Coordination: Score for "Poor coordination, clumsy"
PCS-Score4-Vision: Score for "Vision problems, blurring, trouble
seeing"
PCS-Score5-Light: Score for "Sensitivity to light"
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PCS-Score6-Taste: Score for "Change in taste and/or smell"
PCS-ScoreTotal: Total Score
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